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Ovarian cancer is the leading cause of death from gynaecological malignancies. Late 
diagnosis following metastasis combined with frequent relapse after initial treatment, 
has led to a 5-year survival rate <50%. Thus, new and improved therapeutic strategies 
are urgently required.  
One possible novel therapy involves engaging the adaptive immune system in a 
process of immunogenic cell death (ICD). Apoptotic tumour cell death is usually 
immunologically silent because cells are cleared by phagocytes without the 
involvement of adaptive immunity. However, in ICD apoptotic cells have immunogenic 
properties and immune responses against cancer cell specific antigens or altered self-
antigens can occur. Cells undergoing ICD also have surface expression of damage-
associated molecular pattern molecules (DAMPs) which facilitate recognition and 
engulfment e.g. by dendritic cells, and subsequent activation of a cancer cell specific 
T lymphocyte response. A select group of cancer therapies induce ICD in addition to 
their known cytotoxic effects e.g. the anthracycline doxorubicin and radiotherapy.  
The endoplasmic reticulum (ER) chaperone protein calreticulin (CRT) is a key DAMP. 
CRT translocation from the ER to the cell surface during ICD induced by cytotoxic 
agents that induce ER stress promotes cancer cell immunogenicity. Thus, strategies 
to enhance ovarian cancer cell surface CRT may offer therapeutic options for patients. 
Therefore, the aims of this project were (a) to obtain a purified preparation of CRT (b) 
to determine the conditions that give rise to enhanced surface levels of CRT in ovarian 
cancer cells; specifically externalisation of endogenous CRT or cellular binding of 
exogenously added CRT and (c) to determine if ovarian cancer cells with enhanced 
surface CRT induce dendritic cell activation and subsequent T lymphocyte responses.  
Doxorubicin and the known ER stressor thapsigargin stimulated apoptosis in ovarian 
cancer cells.  This was accompanied by enhanced binding of exogenous CRT, 
enhanced externalisation of endogenous CRT, increased cell expression of CRT and 
increased secretion of the protein.  All of these actions were significantly inhibited by 
the ER stress inhibitor tauroursodeoxycholic acid, confirming the involvement of ER 
stress. Ovarian cancer cells with enhanced surface CRT induced maturation and 
activation of dendritic cells and subsequent activation i.e. proliferation, of cytotoxic T‑




Publication and abstracts arising from this thesis.  
Publications  
1. UM Pandya, C Egbuta, TM Abdullah Norman, CE Chiang, VR Wiersma, RG 
Panchal, E Bremer, P Eggleton, L Gold. (2019). The Biophysical Interaction of the 
Danger-Associated Molecular Pattern (DAMP) Calreticulin with the Pattern-
Associated Molecular Pattern (PAMP) Lipopolysaccharide. Int J Mol Sci, 20;408. 
 
2. VR Wiersma, M Michalak, TM Abdullah, E Bremer & P Eggleton. (2015) 
Mechanisms of translocation of ER chaperones to the cell surface and 




TM Abdullah, JL Whatmore, E Bremer, R Slibinskas, M Michalak. P Eggleton. 
Release and binding of calreticulin from ovarian cancer cells under various states of 
ER stress. 
 
Conference attended  
Oral presentation at Endoplasmic reticulum in health and disease: the 12th 
International Calreticulin Workshop, Delphi, Greece (J Cell Mol Med, 21, 3141-3149). 
Title:  Investigation into the mechanisms of calreticulin binding and release from 















Table of contents                                                                                          Pages  
Acknowledgement   ……………………………………………..………………….…...12 
List of Figures……………………………………………………………..…….….………13 
List of Tables ……………………………………………………………………….......... 19 
Abbreviations …………………………………………………………………..….………20  
Chapter 1:  Introduction………………………………………………………………..…23  
1.1 Ovarian cancer ……………………………………………………………………….23  
1.1.1   Epidemiology ………………………………………………………………...…….23  
1.1.2   Risk factors……………………………………………………………..……....…..23 
1.1.3   Overview of ovarian cancer types……………………………..……….…….…..24  
1.1.4   Staging of ovarian cancer………………………………………………..……..…25  
1.1.5   Chemotherapy in EOC …………………………………………..…………….….27 
 
1.2 An overview of the immune system ………………………………..………....…28 
1.2.1 Innate immune system…………………………………………………..….….….28 
1.2.2 Complement 1q…………………………………………………….…….….….....30 
1.2.3 Adaptive immunity…………………………………………….……...….…….…..31 
1.2.4 Antibody – mediated immunity (humoral)……………..………….……..….…...32 
1.2.5 Cell - mediated immunity................................................................................32 
1.2.6 Antigen presenting cells APCs …………...……………………………..…….…33 
1.2.6.1 Macrophages………………………...……………………………………….….…34 
1.2.6.2 Dendritic cells ………………...…………………………………………………....34 
1.2.7 MHC-1……………………………………………………………………………….35 
1.2.8 T- Cells ………...……………………………………………………………..…….36 
1.3 The immune system and cancer ………………………..………………………..37 
1.4 Cancer immunotherapy ………………………………………………………...….39 
1.5 Immunogenic cell death (ICD) in cancer cells ……………………..…………..40 
1.5.1 ER stress-driven immunogenic cancer cell death…………..………...………..42 





1.6 Apoptosis and necrosis …………………………………………………..............44 
1.6.1 The extrinsic apoptotic pathway………………………………………….……....45 
1.6.2 The intrinsic pathway……………………………………………………………...46 
1.6.3 Morphological changes in apoptosis…………………………………….….…...47 
1.6.4 Necrosis……………………………………………………………………..………47 
1.6.5 Assessment of cell death…………………………………………………….…...49 
1.6.6 Assessment of apoptosis using annexin V…………………………..………….49 
1.6.7 Apoptosis in cancer ………………………………………………………….……51 
 
1.7  Calreticulin ………………………………………………………………............….52 
1.7.1 Calreticulin expression in cancers……………………………………….…...….52 
1.7.2 Structure and function of CRT…………………………………………….……...54 
1.7.3 Calreticulin in the ER……………………………………………………….……...55 
1.7.4 CRT and the innate immune system…………………………………………….55 
1.7.5 CRT in adaptive immunity…………………………………………………….......56 
1.7.6 Role of CRT surface exposure during ICD in cancer treatment……….……...57 
1.7.7 CRT as a therapeutic agent………………………………………………………60 
 
1.8 ER stress inducers …………………………………………………………....…….60 
1.8.1 Doxorubicin…………………………………………………………………...…….61 
1.8.2 Thapsigargin………………………………………………………………...……...62 
1.8.3 Tauroursodeoxycholate (TUDCA) reduces ER stress……………….…..…….63 
 
1.9 Overview of research presented and aims of this  study …………………….64 
 
Chapter 2:  Materials and general methods……………………………………………66 
 
2.1 Suppliers and sources of experimental materials  ………………………….…66 





2.3 Cell culture ……………………………………………………………………………70 
2.3.1 Cell culture conditions.....................................................................................70 
2.3.2 THP-1 cell (human monocytic cell line)………………………………...………..70 
2.3.3 HCMEC/D3 human cerebral microvascular endothelial cells………..…….....71 
2.3.4 Freezing cells……………………………………………………………..………..71 
2.3.5 Thawing cells………………………………………………………………..……..71 
2.3.6 Seeding cells into 6 well plates……………………………………………..……71 
 
2.4 Flow cytometry ………………………………………………………………...…….74 
2.4.1 Gating for live cells…………………………………………………………..…...…74 
2.4.2 Compensation…………………………………………………….………..…….....76 
2.4.3 Flow cytometry to assess cell apoptosis and necrosis………….………...….…78 
 
2.5 ELISAs ……………………………………………………………………..…....….…80 
2.5.1 CRT ELISA…………………………………………………………………..….…...80 
2.5.2 ELISA for IL-12/IL-23p40………………………………………….………..……...82 
 
2.6 Determination of protein concentration ………………….……………....…..…83 
 
2.7 SDS-PAGE (sodium dodecyl sulfate polyacrylamide   
       gel electrophoresis) and western blotting ……..………………..………85 
2.7.1 SDS PAGE to determine protein molecular weight under 
          reducing conditions Western blotting for CRT……………………………….….85 
2.7.2 Western blotting for CRT ……………………………………………………….….85 
 
Chapter 3:  Purification of calreticulin and preparation of monomeric CR……….…87 
3.1 Introduction ………………………………………………………………….………87 





3.3 Methods …………………………………………………………………...………….91 
3.3.1 Source of CRT……………………………………………………………….….…..91 
3.3.2 Ion exchange chromatography (Mono Q)…………………………..…………….91 
3.3.3 MonoQ column cleaning and equilibration………………….…………………....93 
3.3.4 Mono-Q sample application…………………………….………………………….93 
3.3.5 SDS PAGE to determine MW of eluted proteins 
          under reducing conditions……………………….…..……………….….………...94 
3.3.6 Gel Filtration of recombinant CRT………….…………………………..………....94 
3.3.7 Treatment of E -Coli expressed CRT monomeric  
protein fractions (from Mono Q) with  
polymyxin B(PMB)…………………………..……………………………...…..….95 
 
3.4 Results ………...………………………………………………………………………96 
3.4.1 CRT elutes in two separate peaks using anion chromatography……..............96 
3.4.2 SDS PAGE to determine MW under reducing conditions……………...........…98 
3.4.3 Gel filtration of recombinant CRT………………………………………….………98 
 
3.5 Discussion ………………………………………………………………..……..….101 
3.6 Conclusion ……………………………………………………………….........……102 
 
 
Chapter 4:  An investigation into the conditions re quired  
                    for ovarian cancer cell surface  association  
                    with either endogenous or exoge nous CRT calreticulin …………103 
 
Chapter 4a. Examination of the conditions required 







4a.3.1   Conjugation of CRT or HSA with FITC……………………………………….105 
4a.3.2   Culture of cancer cells………………………………………………………….107 
4a.3.3   Exogenous CRT binding to ovarian cancer cells assessed by flow 
cytometry……………………………………………………………………………..……107 
4a.3.4   Staining for cell morphology ……………………………..…….……….……..107 
4a.3.5   immunofluorescent cell staining……………………..………….……..……...107 
4a.3.6   Treatment of cancer cells………………………..……………….….……….. 110 
4a.3.7   Assessment of surface bound CRT on cells  
undergoing apoptosis and necrosis…………………………………..………111 
4a.3.8   Immunocytochemistry……………………………………………….……...… 111 
4a.3.9   Data analysis………………………………………………………….……......113 
 
4a.4. Results………………………………………………………………….…….….…113 
4a.4.1   Binding of CRT to cancer cells under non-stress conditions………..……..113 
4a.4.2   CRT-FITC binds to the surface of cancer cells as assessed by flow 
cytometry……………………………………………………………………….………..113 
4a.4.3   CRT-FITC binds to the surface of cancer cells as assessed by 
immunofluorescence microscopy …………………………………….………118 
4a.4.4   Binding of CRT to cancer cells under stress and ER stress conditions…..118 
4a.4.5   Treatment of both OVcar3 and SKOV3 cells with thapsigargin and 
doxorubicin treatment alone, and combined, increases CRT binding to dying 
cells……….................................................................................................129 
4a.4.6   Inhibition of ER stress reduced binding of exogenous CRT in doxorubicin 
and thapsigargin treated 
cells………………………………………………………………..…………………..….132 
 
Chapter 4b. Examination of the conditions required for surface exposure of 
translocated endogenous calreticulin in ovarian can cer cells ……………….140 
4b.1  Introduction  …………………………………………………………………...…140 
4b.2  Aim ………………………………………………………………………………....141 




4b.3.1  Treatment of cancer cells with doxorubicin…………………………….………141 
4b.3.2  Treatment of cancer cells with thapsigargin…………………………………...141 
4b.3.3  Treatment of cancer cells with TUDCA…………………………………………142 
4b.3.4  Immunocytochemistry…………………………………………………………….142 
4b.3.5  HCMEC/D3……………………………………………………………...………...142 
4b.3.6  CRT ELISA……………………………………………………………………...…142 
4b.3.7  Preparation of cell lysates for western blotting………………………………...142 
4b.3.8  Western blotting…………………………………………………………………..143 
4b.3.9  Assessment of apoptosis and necrosis………………………………………...143 
 
4b.4  Results  ………………………………………………………………………….....144 
4b.4.1  Doxorubicin treatment of cancer cells increased  
release of endogenous CRT…………………………………………….………144 
4b.4.2  The effect of doxorubicin on cell death and CRT externalisation on non- 
cancer cells………………………………………………………,,,,,,,,,,,,,,,…….146 
4b.4.3  Treatment of both OVcar3 and SKOV3 cells with thapsigargin and doxorubicin 
alone and in combination increases surface exposure of endogenous 
CRT……………………………………………………………………………….. 147 
4b.4.4  Inhibition of ER stress by TUDCA reduced externalization of CRT from 
doxorubicin treated ovarian cancer 
cells…………………………………………………………………….…………..154 
4b.4.5  Effect of ER-stressors and inhibitors on CRT expression and release from 
OVcar3 cells……………………………………………………………..………..160 
 
4.1 Discussion ………………………………………………………………..…………162 
4.2 Conclusion ………………………………………………………………...………. 167 
 
Chapter 5:  Investigation into whether exogenous CR T or cancer cells 
expressing surface CRT can induce maturation of DCs  and subsequent 
activation of T- cells ………………………………………….………………………..168 





5.2 Aims …………………………………………………………………………....….…172 
5.3 Methods …………………………………………………………………………...…173 
5.3.1 Cell culture……………………………………………………………………….…173 
5.3.2 Isolation of human blood mononuclear cells (Protocol 1)……………..……....173 
5.3.3 Generation of mDCs from monocytes (Protocol 2) …………………….………175 
5.3.4 Co-culture of imDCs with doxorubicin (DX) pre-treated  
OVcar3 cells or purified CRT (see Figure5.2)…………………………………………176 
5.3.5 ELISA protocol ……………………………………………………………………..178 
5.3.6 Isolation of human T lymphocytes……………………………………………..…178 
5.3.7 Examination of T-cell activation by mDCs (see Figure 5.3)……………….......179 
5.3.8 Treatment of T cells with human T-activator CD3/CD28 Dynabeads………...180 
5.3.9 Activation of human T cells with CD3/CD28 T-activator Dynabeads………....182 
5.3.10 Flow cytometry……………………………………………………………………183 
5.3.11 Statistical analysis…………………………………………………………..……184 
5.4 Results …………………………………………………………………………..…..184 
5.4.1 Generation of imDCs from the human monocytic THP-1 cell line……...........184 
5.4.2 Phenotypic maturation of imDCs derived from  
THP-1 monocytes to mDCs by LPS…………….………………………………188 
5.4.3 The effect of CRT on maturation of THP-1 derived imDCs……………………188 
5.4.4 Monocyte isolation…………………………………………………………………193 
5.4.5 Generation of imDCs from isolated peripheral monocytes…………………….193 
5.4.6 Generation of mDCs from imDCs derived from 
  peripheral blood monocytes……………………………………………………..197 
5.4.7 CRT promotes monocyte derived imDC maturation………………….…………197 
5.4.8 DCs derived from peripheral blood monocytes  
exhibit a dendritic morphology…………………………………….……………..202 
5.4.9 Activation of DC maturation by ovarian  
cancer cells (OVcar3) treated with doxorubicin 
 to induce surface expression of CRT………………….……………………….202 
5.4.10 Doxorubicin-treated ovarian cancer cells 
(OVcar3) induce DC maturation……………..……………………………..……204 
5.4.11 Maturation of dendritic cells derived from  




increased secretion of IL12/IL23…………………..……………………………212 
5.4.12 Maturation of dendritic cells derived from 
 THP-1 cells is also associated with increased  
secretion of IL12/IL23……………………………………………………….……215 
5.4.13 The effect of mDCs on T-cell proliferation………………………………..…….218 
5.4.14 Activation of human T cells by Human  
T-Activator CD3/CD28 Dynabeads®……………………………………....…...220 
5.4.15 Activation of human T cells by mDCs  
induced to mature by various treatments (see Figure 5.30)…………..……..220 
 
5.5 Discussion ……………………………………………………………………..……225 
5.6 Conclusions ……………………………………………………………………..….233 
 
Chapter 6:  Final discussion …………………………………………………….….. 234 
Chapter 7:  Critique of the experimental approaches  used in this thesis ……241 
7.1  Chapter 3. Purification of calreticulin and pr eparation of monomeric 
CRT………………………………………………………………………………………...241 
7.2 Chapter 4a. Examination of the conditions requi red for binding of 
exogenous calreticulin to EOC cells ……………………………………………….242 
7.3 Chapter 4b. Examination of the conditions requi red for surface exposure of 
translocated endogenous calreticulin in ovarian can cer cells …………………251 
7.4 Chapter 5.  Investigation into whether exogenou s CRT or cancer cells 
expressing surface CRT can induce maturation of DCs  and subsequent 















I am extremely grateful to my supervisor Dr Jacqueline Whatmore for her unending 
encouragement, support and continuing to mind me and help me along with my 
project. She willingly lent me her time, resources and expertise without which the 
completion of this thesis would not have been possible. 
Special thanks to my supervisor Dr Paul Eggleton for his support and encouragement 
during this project. At many stages in this research project, I benefited from his advice. 
His positive outlook and confidence in my research inspired me and gave me 
confidence. His careful editing contributed enormously to the production of this thesis. 
A big thank you to my supervisors Dr Edwin Bremer and professor Marek Michalak for 
all the support and encouragement they gave me. 
I would also like to thank Dr Chris Scotton for his help and advice at the start of the 
project. He provided very helpful and encouraging feedback. 
A massive thank you to The Higher Committee for Education Development in Iraq 
(HCED) for funding in this research. 
I want to sincerely thank my three angels for giving me the space and time–out to write 
my thesis and of course I must thank my best friend and my husband, Ahmed for a 
terrific support and great source of encouragement. Thanks also to my parents and 
siblings- from the bottom of my heart. 
Thanks also go to my colleagues all my IBCS colleagues, who expressed an interest 















List of figures 
 
Figure Description                                                                                            pages 
1.1  Overview of the origin of tumours within the ovary…………………………………..25 
1.2  Outline of adaptive immunity …………………………………………………………..33 
1.3  A diagram showing the MHC -1 complex on the cell membrane…………………..36 
1.4  A diagrammatic image showing the main morphological stages 
    of apoptosis……………………………………………………………………………...48 
1.5  Schematic representation of the detection of the apoptotic process using 
fluorescently labelled PI and annexin V to detect changes………………………...50 
1.6  A model of CRT and its domain organisation……………………………………...…54 
1.7  Disruption of the “don’t eat me” signal by CRT………………………………………58 
1.8  Immunogenic cell death and DAMPS…………………………………………………59 
 
2.1  Counting of cells on a haemocytometer………………………………………………72 
2.2  This graph displays two measurement parameters………………………………….75 
2.3  EpCAM-cy5 fluorescence did not overlap with FITC and PE staining……………..77 
2.4  Representative plot of cell viability of ovarian  
   cancer cells assessed by flow cytometry……………………………………...………79 
2.5   CRT ELISA standard curve…………………………………………...……………….81 
2.6   BCA assay standard curve…………………………………………………………….84 
 
3.1  A schematic diagram of calreticulin……………………………………………………89 
3.2  Summary of CRT purification steps……………………………………………………90 
3.3  Mono Q chromatographic analysis of human rCRT from 
 E coli and Pichia pastoris………………………………………………………..……….97 
3.4  Only CRT is detected by SDS PAGE in Mono Q fractions  
of chromatographed E Coli CRT……………………………………………………..…..99 
3.5  Size exclusion chromatography of (A) Pichia expressed and (B) E. coli expressed 
human calreticulin……………………………………………………………...…………100 
 
4a.1  An example of the experimental set up of the CRT binding  




4a.2  Workflow figure showing cells treated with labelled proteins  
and analysed by fluorescence microscopy……………………………………............109 
4a.3  Experimental design of the studies examining CRT binding  
to cancer cells pre-treated with thapsigargin or doxorubicin (DX)…………………..110 
4a.4  Gating of Ovcar3 cancer cells treated with thapsigargin ………………………....112 
4a.5  Sample FPLC traces showing of FITC-conjugation to CRT and HSA ……….…114 
4a.6  Morphological characteristics of the cancer cell lines studies……………………114 
4a.7  Demonstration of FITC-CRT, FITC-HSA and FITC-IgG binding  
to OVcar3 cancer cells by flow cytometry……………………………………...………116 
4a.8  FITC-CRT binds to four cancer cell lines at all concentrations tested…………..117 
4a.9  FITC-CRT and FITC-HSA bind to the surface of cancer cells as  
assessed by fluorescence microscopy………………………………………………..119 
4a.10  Dose response effect of doxorubicin on cancer cell survival……………………120 
4a.11  Doxorubicin treatment of OVcar3 ovarian cancer cells induces cell  
apoptosis (early and late) and necrosis as quantified by flow cytometry  
using Annexin V and PI………………………………………………………………….121 
4a.12  The percentage of living and dying cancer cells pre and post doxorubicin 
treatment……………………………………………………………………………….122 
4a.13  Degree of FITC-CRT binding to A2780 ovarian cancer cells before and after 
treatment with doxorubicin……………………………………………………………125 
4a.14  Mean fluorescence intensity (MFI) of FITC-CRT binding to living and dying cells 
pre and post treatment with doxorubicin……………………………………………126 
4a.15  Doxorubicin treatment of OVcar3 ovarian cancer  
    cells enhances CRT binding………………………………………………………….128 
4a.16  Representative flow cytometry histograms showing  
that exogenous FITC-CRT binding to SKOV3 ovarian cancer 
cells is increased under stress conditions using the ER-stressors 
doxorubicin and thapsigargin……………….............................................................130 
4a.17  Doxorubicin and thapsigargin can induce cell death in ovarian cancer cells and 
exogenous CRT preferentially binds to cancer cells undergoing apoptosis after 
treatment with thapsigargin and doxorubicin………………………………….……131 
4a.18  TUDCA does not induce cell death, and protects against doxorubicin and 




4a.19  TUDCA promoted a decrease in exogenous CRT binding to doxorubicin (DX) 
treated ovarian cancer cells………………………………………………………….136 
4a.20  Treatment with TUDCA reduced the exogenous FITC-CRT  
binding to ovarian cancer cells when compared with cells treated  
with doxorubicin and thapsigargin…………………………………………………..….138 
4a.21  TUDCA reduces binding of exogenous CRT to doxorubicin (DX) treated  
Ovcar3 ovarian cancer cells as assessed by immunofluorescent staining…...……139 
4b.1  Doxorubicin treatment increases surface expression of  
endogenous CRT on non-permeabilised SKOV3 cancer cells………………….…..145 
4b.2  Doxorubicin dose-dependently induces apoptosis and necrosis in  
OVcar3 ovarian cancer cells, but not HCMEC/D3 human endothelial cells………..149 
4b.3  The ER stressors doxorubicin and thapsigargin alone and in  
combination induce CRT exposure in SKov3 and OVcar3  
ovarian cancer cells………………………………………………………………….…..151 
4b.4  Surface expression of endogenous CRT is significantly increased in ovarian 
cancer cells in varying stages of apoptosis and necrosis in cells treated with 
doxorubicin and/or thapsigargin…………………………………………………..…152 
4b.5  Surface exposure of CRT from cancer cells is induced by doxorubicin and 
thapsigargin individually and enhanced by treatment with both together……….153 
4b.6  TUDCA reduces cell death and externalisation of endogenous  
CRT in doxorubicin or thapsigargin treated OVcar3……………………….…………156 
4b.7  TUDCA reduces cell death and externalisation of endogenous  
CRT in doxorubicin or thapsigargin treated SKov3………………………………….158 
4b.8  TUDCA reduced the amount of endogenous CRT externalised  
on the cell surface of OVcar3 ovarian cancer cells treated with the  
ER stressor thapsigargin…………………………………………………………...……159 
4b.9  Effect of Doxorubicin and thapsigargin on secretion and  
expression of CRT in OVcar3 cells……………………………………………………..161 
5.1  Schematic representation of the major signals involved  
in activating T-cell responses…………………………………………………………...170 
5.2  Schematic describing the experimental design of  




5.3  Schematic describing the experimental design of T-cell isolation and 
activation/proliferation as assessed by CFSE staining………………………..…..181 
5.4  Diagram indicting the mechanism by which T cell  
expansion activated using anti-CD3/anti-CD28 coated Dynabeads 
mimics T-cell activation in vivo by antigen presenting cells………………………….182 
5.5  Morphology of THP-1 cells at 0 day…………………………………………….……185 
5.6  THP-1 cells can be induced to express markers of imDCs………………………..187 
5.7  DC maturation status examined using flow cytometry  
analysis of surface markers…………………………………………………………..…189 
5.8  CRT induced maturation of THP-1 derived imDCs to mDCs…………...…………190 
5.9  CRT induced expression of mDC markers in THP-1 derived imDCs………….....192 
5.10  Isolation procedure for purification of monocytes  
from peripheral human blood……………………………………………………………194 
5.11  Characterisation of enriched monocyte population………………………………..184 
5.12  Peripheral monocytes can be differentiated into imDCs………………………….196 
5.13  imDCs derived from peripheral blood monocytes  
can be differentiated into mDC by LPS………………………………………………...198 
5.14  Exogenous CRT can induce maturation of imDCs  
derived from peripheral monocytes…………………………………………………….199 
5.15  CRT induced expression of mDC markers in  
peripheral blood monocyte derived imDCs……………………………………………201 
5.16  The morphology of isolated peripheral blood monocytes  
changes during differentiation to imDCs and maturation to mDCs………………....203 
5.17  EpCAM is expressed on ovarian cancer cells, but DC markers are not………...205 
5.18  Ovcar3 cells express high surface levels of EpCAM  
and low levels of DC markers…………………………………………………………...206 
5.19  mDCs do not express EpCAM……………………………………………………….207 
5.20  Co-incubation of doxorubicin treated OVcar3 cells with  
peripheral blood derived imDCs induced DC maturation…………………………….208 
5.21  Co-incubation of doxorubicin treated OVcar3 cells with peripheral  
monocyte derived imDCs induced DC maturation……………………………………209 
5.22  Co-incubation of doxorubicin treated OVcar3 cells with  




5.23  Co-incubation of doxorubicin treated OVcar3 cells with THP-1  
derived imDCs induced DC maturation………………………………………………...211 
5.24  Peripheral blood monocyte derived DC maturation by CRT is  
associated with secretion of the cytokines IL12 and IL23………………………..…..213 
5.25  Co-incubation of doxorubicin treated OVcar3 cells and peripheral  
monocyte-derived imDCs induces secretion of IL12/IL23………………………..….214 
5.26  THP-1 derived DC maturation is only associated with secretion of the  
cytokines IL12 and IL23 when induced by high concentrations of CRT……….......216 
5.27  OVcar3 cells pre-treated with high concentrations of  
doxorubicin induce secretion of IL12/IL23 from THP-1  
derived DCs during DC maturation………...............................................................217 
5.28  Flow cytometry analysis of a typical CD8 T-cell purification  
using negative selection magnetic bead technology………………………………….219 
5.29  T lymphocyte proliferation induced by human T-activator anti-CD3/CD28 
Dynabeads™ and assessed by CSFE fluorescence………………………………221 
5.30  Schematic showing the experimental plan of studies  
carried out to examine whether DCs induced to mature by  
various treatments could subsequently stimulate T cell proliferation……………….222 
5.31  DCs induced to mature by either exogenous or cancer cell  
surface bound CRT subsequently induce T-cell activation as  
assessed by proliferation………………………………………………………………..224 
5.32  Schematic representation of the experimental procedures  
used in this chapter………………………………………………………………………227 
6.1  Flowchart representing the key finding of this study………………………………237 
6.2  Possible use of EpCAM / CRT bi–specific antibody  
fragments that directly target CRT to tumour cells…………………………………...239 
6.3  Possible future in vivo strategies to test whether enhancing surface  
levels of CRT could be an anti-cancer therapeutic strategy … …………………….240 
7.1  Free FITC does not bind to the surface of OVcar3 ovarian cancer cells …..…243 
7.2  Demonstration of FITC-CRT, FITC-HSA and FITC-IgG binding to OVcar3 cancer 
cells by flow cytometry…………………………………………………………...….245 
7.3  Exogenous FITC-CRT binds to four cancer cell lines at all concentrations 




7.4  Doxorubicin induces externalisation of phosphatidylserine in A2780 ovarian 
cancer cells as assessed by annexin V binding…………………………..…..248 
7.5  No non-specific binding of secondary antibody is observed in cells treated with 
vehicle in place of primary antibody prior to staining with results in Cy5 
secondary antibody ……………………………………………………………..252 
7.6  Mature DCs induce significantly more T-cell proliferation than imDCs ……..254 
7.7  OVcar3 ovarian cancer cells pre-treated with high concentrations of 
doxorubicin induce secretion of IL12/IL23 from THP-1 derived imDCs      




























List of tables 
Table                                                  Description                                               Page 
 
1.1  International Federation of Gynaecology and Obstetrics  
(FIGO) nomenclature staging system for ovarian cancer…………………………….26 
1.2  A table displaying the principle white blood cell types………………………….…..30 
1.3  Expression of level CRT in different cancers……………………………………..….53 
1.4  Characteristics of clinically relevant ER stressors……………………………..……63 
3.1  Preparation of MonoQ buffer A, pH 8…………………………………………...…….92 
3.2  Preparation of MonoQ buffer B, pH 8………………………………………...……….92 
4a.1  Dose-dependent effects of doxorubicin in tumour cells……………………..…….123 
4a.2  Mean fluorescent intensity (MFI) of FITC-CRT binding  
to OVcar3, SKOV3, A2870 and FaDu tumour cells pre- and 
post- doxorubicin treatment……………………………………………………………..127 
4b.1  Doxorubicin induces apoptosis and necrosis in OVcar3  
ovarian cancer cells, but not HCMEC/D3 human endothelial cells…………………150 
5.1  Major cell surface markers on mature DCs…………………………………..……..169 
5.2  Details of the antibodies and the isotype controls used  





















Apaf-1  Apoptotic protease activating factor 1 
APCs  Antigen presenting cells 
ATP                            Adenosine triphosphate 
B- Cell                        B- lymphocytes 
BCA                           Bicinchoninic acid 
BSA Bovine serum albumin 
C1q                            Complement 1q  
CD                             Cluster of differentiation 
CFSE                         Carboxyfluorescein succinimidyl ester 
CRT                           Calreticulin 
CTLs Cytotoxic T lymphocytes 
CV                              Column volume 
DAMP  Damage-associated molecular pattern 
Dapi  4′, 6-Diamidine-2′-phenylindole dihydrochloride 
DCs                            Dendritic cells  
DISC Death-inducing signalling complex 
DMSO Dimethyl sulfoxide 
DPBS Dulbecco's Phosphate Buffered Saline 
DTT Dithiothreitol 
DX  Doxorubicin 
E-coli                         Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EOC                           Epithelial ovarian cancer 
EpCAM        Epithelial cell adhesion molecule 
ER Endoplasmic reticulum 
ERAD                         ER‐associated protein degradation 
FBS Foetal bovine serum 
FDA U.S. Food and Drug Administration 




FITC                          Fluorescein isothiocyanate 
FPLC                         Fast Protein Liquid Chromatography 
FSC Forward scatter 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HCl                            Hydrogen chloride 
HCMEC/D3 Human cerebral microvascular endothelial cell line 
HLA Human leukocyte antigen 
HMGB1 High mobility group box 1 protein 
HSA                           Human serum albumin  
IAP Inhibitors of apoptosis proteins 
ICD Immunogenic cell death 
ICF Guava Instrument Cleaning Fluid 
IFN-γ Interferon- gamma  
IgG  Immunoglobulin G  
IL Interleukins 
imDCs                        Immature denderic cells  
 KDa                           Kilo Daltons 
LAK                            Lymphokine-activated killer cells 
Lith-CRT                    Lithuania calreticulin 
LPS                            lipopolysaccharide  
MAGE                        Melanoma-associated antigen 1 
mDC                          Mature dendritic cells  
MHCs                        Major histocompatibility complexes 
MW                            Molecular weight  
NaCl                          Sodium chloride 
NaOH                        Sodium hydroxide 
NK                             Natural killer 
PAMPs                      Pathogen- associated molecular patterns 
PBMCs         Peripheral blood mononuclear cells 
PBS                           Phosphate Buffered Saline 
PI                               Propidium iodide 
PMB                          Polymyxin B 




PS                        Phosphatidylserine 
rCRT                    Recombinant calreticulin 
ROS                     Reactive oxygen species 
SDS PAGE.         Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SERCA                Sarcoplasmic reticulum/ER Ca+2 ATPase 
SIRP-α                 Signal regulatory protein α 
SSC                     Side scatter 
T cells                  T- lymphocytes 
TBS                     Tris buffered saline 
TCR                     T-cell receptor 
TG                        Thapsigargin  
TLR                      Toll-like receptor 
TNF                      Tumour necrosis factor 
TRAIL                   TNF-related apoptosis inducing ligand 
TSP-1                   Thrombospondin-1 
TUDCA                 Tauroursodeoxycholate 
UPR                      Unfolded protein response 
USA                       United States of America 
WB                         Western blot 
α                           Alpha  
β                            Beta  














Chapter 1 Introduction  
 
1.1 Ovarian cancer 
 Ovarian cancer is one of the most deadly forms of cancer (Siegel et al., 2016). Due 
to the difficulty of early detection, in approximately 80 percent of ovarian cancer cases, 
it is discovered after widespread dissemination throughout the abdomen and other 
areas of the body. Thus ovarian cancer is known as a silent killer with a poor prognosis 
(Coosemans et al., 2016). When diagnosed in the advanced stages, standard 
therapies are surgery, chemotherapy and radiation, and initially, although patients 
respond to these conventional therapies, within 5 years of diagnosis, there is often 
disease recurrence and death due to drug-resistant disease (Drakes and Stiff, 2016). 
A very brief overview of current theories describing the stages of ovarian will be 
discussed later in this chapter. 
 
1.1.1 Epidemiology 
Epithelial ovarian cancer (Binju et al., 2018) is the fifth most common cancer among 
women and the leading cause of death from gynaecological cancer in the UK. Each 
year more than 6,500 women are diagnosed with ovarian cancer in the UK and about 
4,400 women die of the disease (Doufekas and Olaitan, 2014). Latest figures show 
that  ovarian cancer accounts for 4% of all new cancer cases in females in the UK  
(@CR_UK, 2016). Survival following a diagnosis of ovarian cancer has improved in 
England overall since the mid-1980s, from 57% to 73% for one-year survival and from 
33% to 44% for five-year survival. However, there has been little or no improvement 
in both one- and five-year survival rates for the oldest women over the last 20 years 
(Nordin, 2012). 
        
1.1.2 Risk factors 
Although the mortality of ovarian cancer is high, its aetiology is not fully understood 
(Horne, 2018). However, certain factors associated with this cancer have been 
identified (Brinton et al., 2013). The majority of ovarian cancers are sporadic with only 




menopause, the use of hormone replacement therapy and family history of breast and 
ovarian cancer seem to be associated with an elevated risk of ovarian cancer (Berek, 
2003). There also appears to be an association between prior history of pelvic 
inflammatory disease, polycystic ovary syndrome and endometriosis, and an 
increased risk of ovarian cancer (Lin et al., 2011). Conversely, higher parity and the 
use of oral contraceptives have consistently been shown to decrease the risk of 
ovarian cancer (Trevino et al., 2012). In particular, the risk is significantly decreased 
with increased duration of oral contraceptive use; with persistent protection up to 25 
years after the last dose (Brynhildsen, 2014). Interestingly, the majority of studies 
indicate that there is a 16 – 22% reduction in the risk of EOC with each pregnancy 
(Schock et al., 2014), suggesting that fewer ovulations protect against ovarian cancer. 
More recently, this incessant ovulation theory has been questioned by a study where 
women took progesterone-only oral contraceptives. This does not stop ovulation but 
proved to be as effective at reducing ovarian cancer risk as ovulation-inhibiting 
contraceptive pills (Brohet et al., 2007). Additionally, nulligravid women who have not 
been pregnant because of infertility are at 40% higher risk of developing ovarian 
cancer than nulligravid women who did not attempt to become pregnant (Diergaarde 
and Kurta, 2014). 
 
1.1.3 Overview of ovarian cancer types 
Invasive EOCs constitute approximately 90% of all cases of ovarian malignancies 
whereas non-epithelial types are less common; with sex cord-stromal tumours making 
up 6% of all ovarian malignancies, germ cell tumours (3%) and all others only 1% 
collectively (see Figure 1.1) (Boussios et al., 2018). EOCs are divided into five 
histological subtypes: serous, mucinous, endometrioid, clear cell, and transitional, and 
of these, epithelial serous carcinomas represent the majority of all primary ovarian 
carcinomas. Of the EOCs approximately 80% are serous, 10% mucinous and 10% 
endometrioid cancers, with the other types making up only a very small % of the total 




















Figure 1.1 Overview of the anatomy of the ovary and  the histological origin of 
ovarian tumours. Most ovarian tumours (approximately 90%) derive from the 
epithelial layer surrounding the ovary, although tumours can also arise from the germ 




1.1.4 Staging of ovarian cancer  
There is no single universally accepted system for grading ovarian cancers. Over the 
years most of the staging systems for gynaecological cancers (with the exception of 
cervical cancer) have moved from a clinical basis to one of a surgical pathological 
nature. The rationale behind this decision arises in the necessity to evaluate the 
ovarian cancer patient during an initial surgery and the staging is then based on 
localisation and pathological features of a tumour. Further treatment and possible 
outcomes depend on the success of the initial operation and therefore a clear and fast 
staging system had to be created. For ovarian cancer, the International Federation of 
Gynaecology and Obstetrics (FIGO) proposed a staging that is widely used and is 
described in Table 1.1. The FIGO system is a surgical system, which does not 





Stage I - Growth limited to the ovaries  
 
Ia Growth limited to one ovary; no ascites containing malignant cells present; no 
tumour on the external surface; capsules intact. 
 
Ib Growth limited to both ovaries; no ascites containing malignant cells, present;    
no tumour on the external surfaces; capsules intact 
 
Ic Tumour either Stage Ia or Ib, but with: capsule ruptured, or ascites present  
containing malignant cells, or positive peritoneal washings 
 
Stage II  - Growth involving one or both ovaries with pelvic ex tension  
 
 
IIa Extension and/or metastases to the uterus and/or fallopian tubes 
 
 
IIb Extension to other pelvic tissues 
 
 
IIc Tumour either Stage IIa or IIb, but with:  capsule(s) ruptured, or  ascites present 
containing malignant cells,  positive peritoneal washings 
 
Stage III - Tumour involving one or both ovaries with histologi cally 
confirmed peritoneal implants outside the pelvis an d/or positive 
retroperitoneal or inguinal nodes. Superficial live r metastases equals stage 
III. Tumour is limited to the true pelvis, but with  histologically proven 
malignant extension to small bowel or omentum. 
 
 
IIIb Tumour of one or both ovaries with histologically confirmed implants, 
peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 2 cm in 
diameter; nodes are negative. 
 
IIIc Peritoneal metastasis beyond the pelvis >2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes. 
 
Stage IV - Growth involving one or both ovaries with distant m etastases*.   
Parenchymal liver metastasis equals Stage IV. 




Table 1.1. International Federation of Gynaecology and Obstetrics (FIGO) 







1.1.5. Chemotherapy in EOC 
Chemotherapy in treating newly diagnosed advanced EOC (Brohet et al., 2007, 
Harries and Gore, 2002) has been a standard of care for patients (Wright et al., 2016). 
However, there are abundant areas of controversy in treating this disease, including 
the role of cytoreductive surgery, the optimum drug combination regimen, the 
importance of dose intensity in chemotherapy, the effectiveness of intraperitoneal 
therapy, the benefit of abdomen irradiation, and the status of immunotherapy and 
hormones (Hacker, 1989). 
Over the decades, chemotherapy for ovarian cancer has evolved and currently 
involves a combination of intravenous platinum and taxane chemotherapy (Cristea et 
al., 2010). The chemotherapy drugs used to treat ovarian cancer typically combine a 
platinum-based drug such as carboplatin (Paraplatin) or cisplatin, with a taxane such 
as paclitaxel (Taxol) or docetaxel (Taxotere). The number of treatment days varies 
with the drug given (Binju et al., 2018). The most effective treatment for the advanced 
disease involves reducing the tumour burden through surgery followed by 
chemotherapy. 
Two different techniques are used to treat ovarian cancer. One technique, intravenous 
platinum/taxane therapy,  was effective  for ovarian cancer (Cristea et al., 2010).  An 
alternative option is administration of chemotherapy via the intraperitoneal route 
(Armstrong et al., 2006). This enhances drug delivery at the peritoneal surface and 
may improve outcomes by eliminating residual disease more efficiently than 
intravenous administration of chemotherapy (Wright et al., 2016). Interestingly, some 
studies have reported that treatment via the intraperitoneal route gave a significant 
survival advantage compared with intravenous chemotherapy platinum and taxane 
(Ozols et al., 2006, Eoh et al., 2017). Additionally, it has been shown that the effect of 
intraperitoneal chemotherapy extends beyond treatment years (Eoh et al., 2017). 
However, the main disadvantage to intraperitoneal chemotherapy is that the side 
effects can be severe and lead to treatment change to intravenous chemotherapy. 
These issues of poor survival and chemotherapy regimens that reduce patient quality 
of life highlight the urgent need to find improved therapeutic strategies for patients with 
EOC. One alternative chemotherapeutic route might be the development of 
immunotherapy i.e. treatment that stimulates the body’s own immune system to fight 




1.2. An overview of  the immune sysytem  
The immune system utilises a series of  defence mechanisms that help protect cells 
of the body from  pathogens (West et al., 2006). In order for the immune system to be 
effective it must be able to distinguish between  cells of the body and foreign agents 
that can bring harm. Thus, cells have unique molecules on the cell membrane and the 
immune system can recognise these biomolecules to identify ‘self’  cells. Classically, 
the immune system and its defence mechanisms are divided into  non-specific (innate) 
immunity and specific (acquired) immunity (Vivier et al., 2011). The innate and 
acquired immune systems utilise a range of physical and cellular components that play 
a vital role in immune surveillance and immune defence. Therefore, the use of the 
immune system to eradicate cancer is a potential  approach for curing cancer (Wang 
and Wang, 2012). 
1.2.1 Innate immune system   
The innate immune system consists of non-specific defence mechanisms that not only 
act to prevent infection but also act immediately following infection, and is a primary 
line of defence against pathogens. Non-specific defence does not depend on the 
presence of specific antigens, that is, the innate immune system attacks all pathogens 
independently of presented antigens  (Chaplin, 2010). The innate immune system 
functions  not only to prevent physical movement of pathogens into the body but also 
to prevent their spread throughout the body if they do enter.  Thus, the innate immume 
system consists of physical barriers such as skin, non specific defence mechanisms 
such as stomach acid, mucous or tears and general immune reponses such as 
inflammation and non-specific cellular components 
• Physical defenses  There are several antomical structures that act as physical 
barriers to pathogens (Amjadi et al., 2014). 
1. Skin : Skin consists of several layers that create a first line of defence aginst the 
movement of pathagens. Additionally, skin contains glands that secrete a fatty 
acid and this creates a layer in which bacteria cannot grow and survive (Belkaid 
and Hand, 2014). 
2. Tears and salvia : Saliva in the mouth and tears in the eyes contain lysozyme 
which helps break down the cell wall of bacteria (McDermott, 2013). 




and bronchi have specialised cells called goblet cells which secrete a mucus 
which traps pathogens.  Cilia can also be present and move pathogens to the 
outside or to the stomach (Bustamante-Marin and Ostrowski, 2017). 
4. Acidity of stomach acid:  Parietal cells release HCl, which creates a high 
acidity environment that kills of most pathogens that enter the stomach via food 
or via mucus (Sahoo et al., 2017). 
 
• Inflammatory defenses: Following entry of a pathogen into tissue the innate 
immune system intiates the process of inflammation. In this process, blood flow is 
increased to the infected area, enhancing delivery of  key white blood cells 
(leukocytes) – neutrophils, esinophils, basophils and macrophages (Nicholson, 
2016). 
 
• Non-specific cellular components:  
1. Neutrophils: These cells are recruited to the infected area and engulf pathogens 
and harmful agents through release of cytotoxic granules and initiation of the 
oxidative burst.  Each neutrophil is capable  of killing  20 bacteria before dying 
(Selders et al., 2017) (Table 1.2).  
2. Basophils: Basophils release histamine, which causes dilation of blood vessels 
in  the infected area, causing redness. The capillaries in the infected area also 
became more leaky, which causes oedema (Pober and Sessa, 2014). 
3. Eosinophils: These cells  are specialised to fight  certain parasites e.g. the 
eosinophil is a defence against helminth parasites (Klion and Nutman, 2004).  
4. Macrophages: Macrophages are phagocytic cells that can engulf hundreds of 
bacteria before dying (Nix et al., 2007). They also release cytokines that recruit 
additional immune cells. 
5. Mast cells: These are a type of leukocyte normally present in the connective 
tissue. After infection they release histamine and cytokines which cause 
vasodilation and enhanced vascular permeability, resulting in increased blood 
flow and white cell trafficking to infected area (Krystel-Whittemore et al., 2015). 
6. Natural killer (NK) cells:  These are non-specific white blood cells. Although 
these are not involved in the inflammation response directly, they do kill infected 





The innate immune system is not educated,  nor is it selective;  no memory immune 
cells  exist within the innate immune system (Boraschi and Italiani, 2018). 
 
 







Table 1.2: A table displaying the principle white b lood cell types . Non –
granulocytes are lymphocytes and monocytes, these do not have granules. In 
contrast, granulocytes are granulated cells like neutrophils, basophils and eosinophils 
(Nicholson, 2016). 
 
1.2.2 Complement 1q. 
The complement system enhances the ability of antibodies and phagocytic cells to 
clear microbes and damaged cells and plays an essential role in both innate and 
adaptive immunity. The complement system refers to a large group of proteins  
circulating in the blood and tissue fluids that opsonize pathogens and cells and induce 
inflammatory responses to cause cell destruction and fight infection by three main 
mechanisms. Firstly, binding of activated complement proteins to pathogens, leading 
to opsonization and clearance by  phagocytes e.g. macrophages and neutrophils, with 
corresponding complement receptors (classical pathway). Secondly, chemoattraction 
to recruit more phagocytes to the site of complement activation (alternative pathway). 





The classical pathway involves complement components C1, C2 and C4 and is 
triggered by antibody-antigen complexes binding to C1.  Activation of these proteins 
can then create a cascade of events that ultimately destroys that antigen or pathogenic 
agent. The complement component C1 has three subcomponents, C1q, C1s and C1r. 
When activated, the constant region of certain antibodies ( IgM and IgG)  can bind to 
the  C1q molecule of the C1 complex. This, in turn, activates C1r and C1s and the 
pathway forms a  C3 convertase which splits the complement component C3 into two 
fragments. The C3a can activate mast cells, causing the release of vasoactive 
mediators such as histamine. The C3b component can attach to microbial pathogens, 
resulting in opsonisation and lysis.  Opsonisation by the C1 system is driven by 
receptor molecules on macrophages or neutrophils interacting with complement 
components on the cell e.g. C1qRp (CD93) or  calreticulin (Ghebrehiwet and 
Peerschke, 2004). 
 
The complement system also plays a key role in cell homeostasis by contributing to 
the lysis of cells undergoing apoptosis (Trouw et al., 2008). Specifically, extracellular 
plasma membrane changes occurring during apoptosis allow cells to bind complement 
molecules such as C1q. For instance, the ER chaperone protein calreticulin (CRT), 
which is externalised during apoptosis, has been shown to interact with C1q and to 
function as a recognition molecule on the apoptotic cell surface (by mediating 
recognition of phosphatidylserine, a key cellular marker of apoptosis) (Gold et al., 
2010). It is now accepted that some cells and parasites develop mechansisms to avoid 
surveillance by the complement system e.g. by expressing molecules that interfere 
with the host complement system (Shao et al., 2019).  
 
1.2.3. Adaptive immunity  
When infection begins, the innate immune system immediately uses non- specific 
mechanisms (e.g. inflammation) to destroy invading pathogens. The adaptive immune 
system is then activated (Figure 1.2). Adaptive immunity is educated in that it can 
“learn” and it has memory and can recall prior exposure to foreign antigens. It is 




activate the specific defence mechanisms of the adaptive immune system. Adaptive 
immunity can be subdivided into antibody-mediated (humoral) immunity and cell-
mediated immunity (Bonilla and Oettgen, 2010).  
 
1.2.4. Antibody – mediated immunity (humoral) 
Humoral immunity involves leukocytes called B- lymphocytes. B- Lymphocytes are 
produced and mature in the bone marrow and are usually found in the lymph nodes. 
During the innate immune response, macrophages engulf and destroy pathogens. 
However, they process the pathogenic antigens and display them on their cell 
membrane. The B- lymphocytes express B- cell receptor on their membrane that can 
bind to these macrophage-bound antigens (Healey et al., 2005). Once the B- 
lymphocyte binds to a specific antigen, it interacts with T helper cells that initiate further 
differentiation. The B- lymphocyte then undergoes many cycles of mitosis to produce 
plasma cells and memory cells. Plasma cells produce antibodies specific to the original 
antigen exposed to the B- lymphocyte.  Memory cells retain a copy of that antibody in 
case of reinfection. Antibodies are immunoglobulins that only recognise specific 
antigens.  
 
1.2.5. Cell - mediated immunity  
This involves leukocytes called T- lymphocytes (T cells). They are produced in the 
bone marrow but mature in the thymus. Helper T-cells release interleukins (Zhu et al., 
2010) and interferons, which contribute to B- lymphocyte maturation into plasma cells 
and B memory cells. T- Lymphocytes express the membrane T-cell receptor. These 
cells can bind to antigen complexes and, with the help of helper T- cells, differentiate 
into T- cytotoxic cells (killer T-cells). These cytotoxic T- cells migrate to the infected 
area and bind a specific antigen. Once bound, they produce a protein (perforin) that 
can perforate and kill the pathogens. In addition T- lymphocytes can form memory 






1.2.6. Antigen presenting cells APCs 
Antigen presenting cells (APCs) are cells that process and present antigen peptides 
on their cell surface complexed with major histocompatibility complexes (MHCs).  The 
antigens can then be recognised by T- lymphocytes. Antigen presenting cells include 
macrophages, dendritic cells (DCs) and B- lymphocytes. 
 
    
 











Figure 1.2. Outline of adaptive immunity.  This includes humoral and cell-mediated 
immunity. B-lymphocytes release antibodies and are effective against many types of 
pathogens. T-lymphocytes are part of cell-mediated immunity and play an important 
role to activate macrophages to engulf  foreign bodies and produce  chemical factors 







Macrophages have multiple immune functions including detection and phagocytosis 
of pathogens, antigen presentation to T cells and cytokine production. Macrophages 
are derived from circulating monocytes which themselves have negligible immune 
activity (Kiertscher and Roth, 1996). They circulate in the blood, enter the tissue, and 
differentiate to mature macrophages following tissue damage or infection. 
Macrophages engulf pathogens and apoptotic cells, digest them inside vacuoles and 
present the pathogenic molecules on the MHC-class ǁ found on their membrane 
(Berges et al., 2005).  
 
1.2.6.2. Dendritic cells    
DCs are specialised antigen presenting cells found in the tissues, skin, lung and 
gastrointestinal tract. They  essentially function as a bridge between innate immunity 
and adaptive immunity (Shortman and Naik, 2007). DCs are produced in the bone 
marrow and they migrate into the peripheral tissues from the blood stream where they 
initially remain in their immature state (Hansen and Andersen, 2017). Immature DCs 
express various pattern recognition receptors (PRRs). During infection, immature DCs 
recognise common features of many pathogens through these receptors and are thus 
able to bind to, and phagocytose, the pathogens. In this process, they capture and 
process antigens and display them on their MHC class II membrane proteins and 
become mature DCs. This maturation is accompanied by upregulation of co-
stimulatory molecules such as CD40, CD80 and CD86 and increased secretion of 
inflammatory cytokines and chemokines (Savina and Amigorena, 2007) which are able 
to active naïve T-cells. The maturing DCs migrate to the lymph nodes or spleen and 








1.2.7. MHC-1  
The ability of the immune system to recognise its own cells and distinguish those cells 
from foreign pathogens depends on a group of protein markers found on the cell 
membrane called the major histocompatibility complex I (MHC-I) 
(https://www.ncbi.nlm.nih.gov/books/NBK27156/, 2001). These protein complexes are 
found on the surface of most nucleated cells.  This is in contrast to the MHC-II 
complexes mentioned above which are found on APCs.  The MHC-1 complex is 
formed of four peptide domains  alpha 1, alpha 2, alpha 3 and beta 2 (Figure 1.3), with 
the  alpha 3 subunit connected to the cell membrane.  MHC molecules interact with 
peptide fragments derived from pathogens and display them on the cell surface, 
allowing leukocytes to differentiate healthy host cells from infected cells (Wieczorek et 
al., 2017). Healthy cells bind a self-antigen onto the MHC-1 complex allowing 
leukocyte recognition as a healthy cell and preventing immune destruction. In contrast 
in infected cells e.g. a virus, the cells display a non-self-antigen on MHC-I. Leukocytes 
can recognise these foreign antigens, bind to them and initiate a defensive mechanism 

























 Figure 1.3. A schematic diagram showing the MHC -1  complex on the cell 
membrane (©kisspng.com, 2019) . MHC-I is composed of two peptide chains, the 
alpha chain and beta 2 microglobulin with the former folded into three external 
domains; alpha 1, 2 and 3. The alpha chain has a transmembrane domain and a short 
stretch of hydrophilic amino acids which forms the cytoplasmic tail. The alpha chain 3 
domain is invariant and contains the binding site for the T- cell co- receptor CD8. Beta 




1.2.8. T- cells  
T-cells are very important in cell mediated immunity and they are distinguished from 
B-cells and natural killer cells through their surface expression of the T- cell receptor. 
T cells are  categorised into two types, T- helper and T- cytotoxic cells (Vantourout 
and Hayday, 2013). T cells, via their T-cell receptor, identify antigenic peptides bound 
to MHC-I and -II molecules on the surface of host APCs. Initially, naive T-cells are 
triggered by identification of specific antigen/MHC complexes expressed by DCs which 
also present additional potent costimulatory signals for T-cell activation and 




produce T-cell mediated immunity, with activated T-cells damaging antigen-positive 
host cells, e.g., infected cells or tumour cells. Cancer cells can be targets for previously 
activated T-cells through the processing and presentation of relevant peptides 
(Houghton and Guevara-Patino, 2004). 
 
1.3 The immune system and cancer  
It is now accepted that the cells of the immune system constantly monitor the body to 
identify and destroy cancer cells by a process of cancer immune-surveillance (Dunn 
et al., 2002).  Indeed patients who are immunosuppressed have a higher rate of 
malignancy (Engels et al., 2011). This immune-surveillance can be particularly 
effective in the early stages of tumour development because the mutations that lead 
to the formation of a cancer cell can cause cell death or senescence and these 
damaged cells can be recognised and destroyed. NK cells can detect associated 
molecules on damaged cancer cells and DC cells activate cytotoxic T-cells which can 
sense tumour associated antigen via the T-cell receptor and other co-receptors (Vivier 
et al., 2012). Once activated, NK cells and cytotoxic T- cells release perforin and 
granzymes, which damage the surface of tumour cells causing death by apoptosis.  
Helper T-cells support these responses, acting with DCs to activate cytotoxic T-cells, 
producing cytokines such as interferon gamma and recruiting more NK cells (Topham 
and Hewitt, 2009)  
Once tumours become more established immune recognition becomes more difficult 
because many of the tumour antigens that could be recognised by T- cells are self-
related and are thus similar to normal cells (Truscott et al., 2008). There are however, 
several potential mechanisms for cancer cells to be recognised. For instance, there 
are a few antigens that are specifically expressed on cancer cells e.g. HER2 (30% of 
breast cancers are HER2/neu-positive, (Wilson et al., 2002) and RAIDD, Rb p107, Rb 
p130, SRF, and Tyk2 (Song et al., 2008). Additionally, alpha v beta 3/5 integrin has 
been reported to be expressed on glioblastoma and tumour vasculature of the brain 
(Przystal et al., 2019). Another feature of some cancer cells that could enable them to 





For instance, changes in the lipid asymmetry of their plasma membrane which differs 
from normal cells e.g. cancer cells present phosphatidylserine (PS) in the outer leaflet 
of the plasma membrane which could be recognised by macrophages (Fadeel and 
Xue, 2009). Additionally, cytotoxic T- cells can detect the modified surface of cancer 
cells (Maher and Davies, 2004). 
Over the past 20 years, studies have shown that the generation of cancer-specific 
immunity requires three steps.  Firstly, if the tumour cells are recognised as non-self 
by APC then the tumour antigens are processed and presented in interaction with 
human leukocyte antigen (HLA) molecules and MHC molecules to T- cells. The T –
cells can recognise the tumour antigens, but it has been reported that their capacity to 
recognise these antigens is not very strong (James, 2016). Recognition is enhanced 
by a second mechanism i.e. T- cell CD28 binding to CD80 or CD86 on the APCs (DCs 
or macrophages). For optimal -cell activation, both signals 1 and 2 are required  (Mak, 
2006). There are additional multiple agonist and antagonistic pairs of receptor – 
ligands that then interact to regulate T- cells to secrete cytokines i.e. step 3. 
Cancer cells have developed various mechanisms to evade immune-surveillance e.g. 
by minimising expression of MHC molecules (and thus tumour antigens) on the 
surface of tumour cells compared to normal cells (Garrido et al., 2012).  Additionally, 
cancer cells can have reduced expression of receptors and surface molecules that 
activate NK cells, release soluble ligands that compete for NK cell receptors and 
secrete soluble factors such as macrophage migration-inhibitory  factor that create an  
immune-suppressant environment for NK activity reviewed by  (Greppi et al., 2019)  
Tumour-associated DCs are largely disturbed in their functional activity and so 
participate in decreased cancer immunity. During normal antigen processing DCs 
transport tumour antigens to lymph nodes, mature and present the antigens for 
activation of T lymphocytes as previously described. However, it has been reported 
that when DC maturation occurs within tumours, it is often not adequate to induce 
effective immunity, particularly in tumours which actively suppress immunity 
(Shortman and Naik, 2007). Using a novel technique to identify cancer antigens 
recognized by T cells, (Peng et al., 2008) suggested that tumour cell secreted galectin 
3 may inhibit T-cell immune responses, promoting tumour growth in vitro and in vivo 




tumour model and showed that high doses of galectin-3 inhibited tumour-reactive T 
cells and promoted tumour growth in mice receiving tumour-reactive CD8+ T cells. 
Other tumours have high levels of myeloid-derived suppressor cells in the tumour 
microenvironment which block T- cell function, reducing  activation of the immune 
system and leading to poor immune responses (Wang and Wang, 2007).  By-passing 
these suppressive pathways or directly activating relevant immune cells e.g. NK or 
DCs could potentially induce a therapeutic T cell response. 
 
1.4. Cancer immunotherapy  
Cancer immunotherapy requires the activation and development of cancer-specific T 
cells, which kill cancer cells by detection of their presented antigen targets.  In recent 
years immunotherapy has revealed a great potential to eradicate cancer. Cancer 
immunotherapy includes active immunisation as well as nonspecific immune 
stimulation. Some of these strategies have achieved results in cancer clinical trials. 
For instance, the U.S. Food and Drug Administration (FDA) approved immunotherapy 
for the treatment of prostate cancer and metastatic melanoma with the vaccines/drugs 
sipuleucel-T (Provenge® (Kantoff et al., 2010) and ipilimumab (Yervoy®). Sipuleucel-
T, is a personalised immunotherapy involving the reinfusion of patient DCs that have 
been modified to recognize prostatic acid phosphatase.  
Successful immunotherapy in cancer relies mainly on the determination of specific 
cancer antigens for the generation of potent cancer vaccines and antigen-specific T 
cells. MAGE (melanoma-associated antigen 1) was one of the first human cancer 
antigens identified; using in vitro stimulated cancer-specific T cells from melanoma 
(Chaux et al., 1999). MAGE antigens are expressed on the surface of many human 
tumours but not on normal cells and this prompted clinical interest. However, although 
there have been several clinical trials the combined clinical data suggest that the 
methodologies used to date have not had any clinical benefit to cancer sufferers 
(reviewed by (Zajac et al., 2017). An increasing number of cancer antigens have now 
been identified  in different tumour types, with about 403 cancer antigenic peptides in 
the peptide database (Vigneron et al., 2013). These include TRP1, TRP2, NY-ESO-1, 




IL-2 has been shown to have antitumor activity in murine and human tumours and it 
was ultimately approved for use in patients with metastatic cancer who were 
administered with autologous lymphokine-activated killer cells (LAK) and recombinant 
lymphoid interleukin (IL)-2.  Administration of 1.8 - 18.4 x 10 autologous LAK cells and 
up to 90 doses of IL-2 regressed cancer by up to 50 % in 11 of 25 patients and reduced 
the formation of tumours in one patient with metastatic melanoma, an effect that was 
maintained for 10 months after therapy (Rosenberg et al., 1985).  
 
Another potential strategy to advance cancer immunotherapy is the use of engineered 
nanoparticles to passively or actively target the tumour milieu and induce an immune 
response against cancer cells. For instance immunomodulation molecules such as 
receptors, tumour-associated antigens, ligands and antibodies could be encapsulated 
within nanoparticles or absorbed on the surface of nano-carriers. This would allow 
targeted cancer immunotherapy, activating different types of immune cells such as 
macrophages, dendritic cells, T- cells and could ultimately lead to tumour killing. This 
could be achieved by generation of long term memory responses, increased infiltration 
and activation of antigen presenting cells in the tumour milieu and secretion of pro-
inflammatory cytokines which in turn activate T- cell cytotoxic of killing tumour cells 
(Singh and Bhaskar, 2014, Saleh and Shojaosadati, 2016). 
 
 
1.5. Immunogenic cell death (ICD) in cancer cells 
Conventional therapeutic approaches for cancer are mostly aimed at eradicating 
cancer cells by cytostatic and cytotoxic effects. The classical anticancer agents, 
including anthracyclines, antimetabolites, and platinum drugs, were mainly developed 
based on their ability to kill preferentially neoplastic cells (Eccles and Welch, 
2007).Cells can die by two main mechanisms – apoptosis which is programmed cell 
death and is considered to be immunologically silent and necrosis in which cell 
destruction facilitates an immune response (Sachet et al., 2017). 
 
However, recent studies e.g. (Montico et al., 2018) have reported that cancer cells 
respond to some chemotherapeutic agents such doxorubicin and oxaliplatin to 




professional APCs which in turn present tumour-associated antigens, leading to T cell 
activation and proliferation and eventually eradication of the tumour cells by an 
adaptive immune response. For instance, in vitro treatment of cancer cells with the 
anthracycline doxorubicin was able to elicit an effective anti-tumour vaccination 
response that suppressed the growth of inoculated colon carcinoma (Vandenberk et 
al., 2015). It is now accepted that these and other therapies such as radiotherapy and  
photodynamic therapies can trigger this type of cell death termed immunogenic cell 
death (ICD) which facilitates recognition and elimination of tumour cells and primes an 
anticancer immune response (Garg et al., 2010).  
 
Recent findings have shown that immunogenic cancer cell death triggered by certain 
anticancer treatments might actually reset the immune system towards the activation 
of a long-lasting protective anti-tumour response (Wang et al., 2018). Indeed, the 
evidence suggests that the clinical success of conventional chemotherapy may not 
only be due to tumour cell toxicity, but also results from  enhanced immune-
surveillance, which has been largely neglected in the past preclinical and clinical 
research (Wang et al., 2018).  It has been reported that unlike normal apoptosis, which 
does not induce immunogenic responses the immunogenic apoptosis of cancer cells 
can induce an effective antitumor immune response through activation of DCs and 
consequent activation of specific T cell responses (Spisek and Dhodapkar, 2007).  
 
Recent studies suggest that conventional chemotherapeutics inducing ICD are 
capable of modulating tumour infiltrating lymphocytes, leading to a better prognosis 
for cancer patients. For example, in response to anthracyclines or oxaliplatin 
treatment, breast and colorectal cancer patients have increased numbers of 
modulating tumour infiltrating lymphocytes, associated with favourable therapeutic 
response (Wang et al., 2018). A combination of ICD-inducing conventional   
chemotherapy with immunotherapy (anti-tumour immune response) is a promising 
approach for improving the clinical outcomes of cancer patients (Schreiber et al., 
2011).  
 
The key to ICD induction for most of the agents mentioned is the sustained induction 




responses, this is thought to lead to production of reactive oxygen species (ROS), 
which have been reported to activate intracellular signalling pathways that govern ICD 
(Garg et al., 2010).   
In response to ICD-inducing chemotherapeutics, tumour cells expose CRT on the cell 
surface prior to death (Obeid et al., 2007) ,and release other damage-associated 
molecular pattern (DAMP) molecules such as adenosine triphosphate (ATP) during 
apoptosis, or high mobility group box 1 protein (HMGB1) upon secondary necrosis 
(Dumitriu et al., 2005). These DAMPs stimulate the recruitment of DCs into the tumour 
bed, the uptake and processing of tumour cell antigens by DCs, and the optimal 
antigen presentation to T-cells, specifically cytotoxic T lymphocytes (CTLs) triggered 
by mature DCs and T-cells in an IL-1b- and IL-17-dependent manner (Krysko et al., 
2012). Primed CTLs then elicit a direct cytotoxic response to kill remaining tumour 
cells through the generation of interferon (IFN)-γ from the T-cytotoxic cells and 
perforin-1 (Tau et al., 2001). Therefore, the hallmarks of ICD include CRT plasma-
membrane translocation, extracellular ATP and/or HMGB1 release, and stimulation of 
type I IFN responses.  
The ICD hypothesis suggests that the tumour cell can also become more susceptible 
to ICD as a consequence of chemotherapy through additional mechanisms (Kroemer 
et al., 2013). For instance, several experimental models suggest that these therapies 
actually elicit a multistep process in dying cancer cells.  This includes the release of 
“find-me” signals that attract phagocytes or DCs, exposure of “eat-me” signals (such 
as PS and CRT) on the surface of apoptotic cells and release of DAMPs that facilitate 
recognition by phagocytes or DCs.  An additional factor that is involved in the success 
of the immunogenic chemotherapy may result from the activation  of caspases to 
cleave  and release apoptotic cell associated antigenic fragments, thus facilitating their 
processing and cross-presentation by DCs (“digest-me” signals) (Rawson et al., 2007) 
 
1.5.1. ER stress-driven immunogenic cancer cell dea th 
Many of the agents inducing ICD target the ER. The ER is a major site of protein 
synthesis and transport, intracellular protein folding, lipid and steroid synthesis, 
carbohydrate metabolism and calcium storage (Araki and Nagata, 2011). Newly 




they are folded and assembled before being delivered to intra- and extracellular 
destinations according to their function. This process is mediated by chaperone 
proteins resident in the ER lumen which prevent accumulation of misfolded or unfolded 
products in the cell. Unfolded proteins are recognised and targeted to the proteasome 
in a process called ER‐associated protein degradation or ERAD which involves retro-
translocation across the ER membrane to the cytosol. Malfunctioning of ERAD 
machinery or accumulation of defective proteins in the ER is associated with various 
human conditions ranging from neurodegenerative disorders, hypoxia, glucose 
deprivation, oxidative stress, and cancer (Hetz et al., 2013). High levels of ER stress 
e.g. caused by overexpression of proteins entering the secretory pathway, may 
eventually lead to cell death or release of intracellular proteins including the 
chaperones. Indeed it has been reported that a sign of increased malignancy may be 
the overexpression of chaperones, with CRT in particular, being over-expressed in 
numerous tumour tissues, possibly to cope with increased ER stress due to protein 
production errors. In tumour or malignancy, changed vascularization in the blood 
network into the tissue can lead to hypoxia and oxidative stress, causing reduced 
amino acid delivery, possibly altering the protein synthesis necessary for normal cell 
growth. This could ultimately lead to ER stress and an unfolded protein response in 
tumour cells (Wiersma et al., 2015). While increased chaperone expression could 
simply be a biomarker of increased ER stress due to malignancy, some studies have 
suggested that chaperones are also engaged directly in the spread of tumours by 
promoting cell proliferation (Chen et al., 2009).  
 
1.5.2. The role of intracellular chaperones as DAMPs 
Many intracellular host and “self” proteins that are not normally presented to the 
immune system act as DAMPs or “alarmins” upon their release from (dying) cells. One 
of the most prominent is the HMGB1 DNA binding protein. HMGB1 normally resides 
in the nucleus of cells, loosely bound to chromatin, but is released into the extracellular 
space during necrosis. This is in contrast to apoptosis, where the interaction between 
HMGB1 and chromatin is strengthened, thus preventing the release of HMGB1 
(Wiersma et al., 2015). A second  major DAMP is the chaperone CRT which is thought 




CRT is exposed on the surface of cells undergoing ER stress and as a DAMP it 
enhances cell immunogenicity, allowing cells to be  recognised by immature DCs 
which then triggers DC maturation and T-cell responses (Palucka et al., 2011).  
It has been shown that treatment with anthracycline antibiotics such as doxorubicin, 
which commonly induce ER stress, leads to externalisation of CRT (Obeid et al., 
2007). Functionally, this chaperone has been reported to bind to various receptors on 
immune cells, such as  CD91 and certain scavenger receptors (Kroemer et al., 2013). 
Pre-apoptotic CRT surface exposure seems to be an important mediator of ICD 
immunogenicity, by acting as a potent pre-apoptotic ‘eat me’ signal that assists in 
phagocytic uptake of  a dying cancer cell (Park and Kim, 2017). Moreover, CRT has 
been shown to enhance DC maturation and MHC I-based antigen presentation, 
particularly to CD8+ cytotoxic T lymphocytes (CTL) (Obeid et al., 2007).  
It may be possible to exploit the potential physiology of CRT to enhance the immune 
ability to detect cancer cells by using strategies that increase cell surface exposure of 
CRT to make cancer cells more “visible”. 
 
1.6. Apoptosis and necrosis 
Apoptosis is a pathway of cell death induced by a tightly regulated intracellular 
program (Kerr et al., 1972). The cell effectively commits suicide and this eventually 
results in the clearance of the dying cell from the tissue in a process referred to as 
programmed cell death. Briefly, apoptosis results from activation of certain enzymes 
which cause the destruction of DNA and cytoplasmic proteins with the cell membrane 
remaining intact (Elmore, 2007). Apoptosis occurs in physiological and pathological 
conditions. For example, during embryogenesis apoptosis occurs throughout the  
implantation and organogenesis  stages of development  as  cells that are no longer 
needed  die via apoptosis in a programmed manner (Boehm, 2006). Additionally, 
destruction of hormone dependent tissue such as during menopause and weaning, 
loss of cells in proliferating cell populations and removal of self-reactive lymphocytes 
all occur via apoptosis.  




radiation and cytotoxic drugs which damage DNA and the cell cannot repair this 
(Hassan et al., 2014). When tumour cells are regressing due to some treatments, 
many cells  die via apoptosis (Agostini et al., 2011). Misfolded protein accumulation 
can lead to the build-up of these proteins inducing the apoptotic pathway (Rao and 
Bredesen, 2004). Apoptosis can also be seen in a cell which is infected with virus. In 
this case  the cytotoxic T-cell kills the virus-infected cell by apoptosis (Kaminskyy and 
Zhivotovsky, 2010).  
Apoptosis can broadly be divided into three steps-initiation, execution and 
phagocytosis. Initiation may be initiated by two different mechanisms depending on 
whether the initiating signal comes from inside or outside the cell i.e. the extrinsic or 
death receptor pathway and the intrinsic or mitochondrial pathway (Wong, 2011). 
However, there is now evidence that the two pathways are linked and that molecules 
in one pathway can affect the other (Igney and Krammer, 2002). The execution phase 
involves activation of caspases,  followed by the execution pathway which is basically 
nuclear breakdown by endonuclease activation and breakdown of the cytoskeleton 
(Elmore, 2007). This cleavage  results in cells showing  morphological features of 
apoptosis (Saraste and Pulkki, 2000). 
1.6.1. The extrinsic apoptotic pathway  
The extrinsic pathway involves single molecules originating outside the cell that 
stimulate apoptosis. Healthy cells contain integral membrane proteins (death 
receptors) that can bind complementary molecules called death activators (Wajant, 
2002). This binding process stimulates the internal pathway  that activates caspase-8 
(Fulda and Debatin, 2006), initiating a cascade that leads to the destruction of the cell.  
The extrinsic pathway is divided into paths based on the signalling molecules and 
receptors involved. The first pathway is via the extracellular molecule tumour necrosis 
factor (TNF) alpha, a cell signalling cytokine produced by activated macrophages, 
natural killer cells and CD4 positive cells  (Putcha et al., 2002). A second pathway is 
via Fas, a transmembrane protein receptor on the cell membrane (Li et al., 2002). In 
this pathway the Fas- ligand protein, an extracellular signalling molecule belonging to 
TNF family, and expressed on cytotoxic T-cells and NK cells,  binds to the Fas receptor 
ultimately leading to formation of a death-inducing signalling complex (DISC) and 




1.6.2. The intrinsic pathway   
The intrinsic pathway is known as mitochondrial apoptosis because of the origin of this 
pathway within the cytosol. Healthy cells have a protein called Bcl-2 on their 
mitochondrial membrane, which normally inhibits apoptosis. When the cell is 
damaged, it stimulates the cytosolic protein Bax to move onto the outer membrane of 
mitochondria and associate with the Bcl-2 protein on the outer membrane of 
mitochondria, suppressing its normal anti-apoptotic function. During apoptosis, Bax 
punctures holes in the outer membrane of mitochondria, leading to leakage of 
cytochrome C from the inner membrane of mitochondria to the cytoplasm (Radogna 
et al., 2007). Cytochrome C then attaches to Apaf-1 (apoptotic protease activating 
factor 1) causing the aggregation of a protein complex called the apotosome in the 
cytoplasm which binds to, and activates, the caspase 9 complex. The caspase 9 
proteins cleave and break down DNA and other internal structures within the cells,  
eventually leading to cell death (Inoue et al., 2009).  
This process is commonly blocked in tumour cells, and restoring the intrinsic apoptotic 
pathway after it is been activated may promote cell death (Saelens et al., 2004). It 
appears that certain other caspases are necessary for apoptosis. For instance, mouse 
embryonic fibroblasts with a deficiency in caspases 3 and 7 and 9 and treated with 
thapsigargin to induce ER stress-induced apoptosis, tunicamycin, the calcium 
ionophore A23187, or brefeldin A failed to display apoptosis. This suggests that 
caspases 3 and 9 have an important role in the intrinsic pathway in apoptosis (Masud 
et al., 2007). As mentioned previously, apoptosis is considered to be an 










1.6.3. Morphological changes in apoptosis 
Morphological features of apoptotic cell death that concern both the nucleus and the 
cytoplasm are remarkably similar across cell types and species (Saraste and Pulkki, 
2000). The first notable feature in the morphology of apoptosis is cell shrinking as a 
result of the cytoplasm becoming denser. The second feature is chromatin 
condensation in the nucleus and nuclear fragmentation (Wlodkowic et al., 2011), 
termed pyknosis. The nucleus becomes dark as the DNA becomes condensed and 
eventually the cells form membrane blebs, although the membrane is still intact. The 
cell eventually fragments into individual apoptotic bodies which can be engulfed by 
phagocytes (Brauchle et al., 2014) (Figure 1.4).  
1.6.4. Necrosis 
Cells can also die by the process of necrosis. Necrosis is a pathological process of 
irreversible cell injury which is caused when a cell is exposed to extreme conditions 
that are very different from the normal living conditions, leading to damage to the 
internal cellular environment and tissue damage (Galluzzi et al., 2018). The basic 
ability of the cell to maintain homeostasis when exposed to these conditions is lost, 
leading to complete discord in the cellular function and eventually death. A key 
difference between apoptosis and necrosis is a loss of the integrity of the cell 
membrane  which leads  to swollen cell contents as well as the disintegration of the  
body of the cell (Proskuryakov and Gabai, 2010). The intracellular components leak 
out and elicit an inflammatory response. There are several agents which have reported 
to trigger necrosis such as hypoxia, physical damage  chemical damage, bacteria and 
immunological agents (Adigun and Bhimji, 2018). Two common characteristic features 
of cell injury and necrosis are denaturation of proteins and cell degradation, with 
changes happening with nuclear material, cellular structure and function. Cell damage 
causes lysosome rupture with release of destructive enzymes which leads to 
proteolysis and ingestion of cellular components (Proskuryakov et al., 2003). This 
initiates more morphological changes. The necrotic cells attract inflammatory cells 
such as neutrophils and macrophages, which migrate to the  injured area and release 
destructive enzymes to  further digest and ultimately phagocytose the dying cell (Rock 
and Kono, 2008). Thus, unlike apoptosis, necrosis does elicit an immunogenic 




















Figure 1.4. A diagrammatic image showing the main m orphological stages of 
apoptosis. Cells undergoing apoptosis go through several stages that are 
characterised by distinct changes in cell morphology. There is initial chromatin 
condensation, nuclear collapse and cell shrinkage. The DNA then condenses more 
tightly and the cells break apart with the formation of nuclear blebs and cell membrane 
fragments. These form apoptotic bodies, the DNA is broken down by DNase and the 







1.6.5. Assessment of cell death 
For many cell based studies it is important to be able to quantify both total levels of 
cell death and type of cell death i.e. apoptosis or necrosis.  
Assessment of total cell death can be achieved using staining to distinguish membrane 
integrity. Specifically fluorescent or coloured dyes which can  penetrate cells with a 
compromised cell membrane to stain nucleic acids, but don’t across the membrane of 
live cells, can be used to quantify dead cells in a population (Coleman et al., 2001). 
Fluorescent cell stains are available with a variety of excitation and emission spectra, 
allowing cell viability to be assessed in combination with many fluorophores. One of 
the most common dyes is propidium iodide (PI) (Wallberg et al., 2016) which simply 
enters the cell when membrane integrity is lost, staining  the nucleus (Atale et al., 
2014). 
1.6.6. Assessment of apoptosis using annexin V 
Annexin V staining is the most widely used technique to detect apoptosis in the cell. It 
is a Ca2+ dependent phospholipid-binding protein with a high affinity for PS. normally, 
cells have the phospholipid PS presented on the inner leaflet of the cell membrane. 
When cells enter the apoptotic pathway then the cell membrane is changed and the 
PS flips from the cytosolic portion to the outer section of the cell membrane. 
Fluorescence-conjugated annexin V can be used to detect and quantify this 
externalised PS (Schutte et al., 1998, Demchenko, 2013).  
Fluorescent annexin V and PI (with different fluorophores) (Figure 1.5) can be used 
together to distinguish between cells undergoing apoptosis and dead cells.   If cells 
are mixed with fluorescence conjugated annexin V and PI there is no fluorescent in 
viable cells because PS is presented inside the cell and annexin V cannot bind and PI 
cannot enter the cells. Once these cells start entering apoptosis, the PS is flipped out 
and annexin V can bind to  give a  fluorescence signal (van Genderen et al., 2008), 
but the membrane is still intact so the PI cannot enter. In dead cells with advanced 
apoptosis PI enters and binds to DNA and annexin V is also bound so the cells have 
dual staining. It is possible to analyse the cells by flow cytometry to detect the 
fluorescence.  In a population undergoing cell death four major cell populations can 




positive and PI negative = cells undergoing  apoptosis with an intact plasma 
membrane (c)  double positive for annexin V and PI = late apoptosis where membrane 
integrity is lost (d) in necrosis PI can stain the nucleus, but PS is not exposed 











Figure 1.5. Schematic representation of the detecti on of the apoptotic process 
using fluorescently labelled PI and annexin V to de tect changes . Annexin V is a 
protein that has the ability to bind to PS. It cannot bind to PS when it is in the inner 
plasma membrane leaflet, but during apoptosis, PS flips from inside the cell to the 
outer cell surface and annexin V can bind it. To allow visual detection annexin V is 
bound to a green fluorescent dye. PI is used to detect cell death. Since it cannot 
penetrate through intact cell membranes, it can only stain cells with disrupted 
membranes or dead cells where the membrane is completely damaged, allowing PI to 
penetrate. In the necrotic condition PS is not flipped out to the outer leaflet but PI can 







1.6.7. Apoptosis in cancer  
Apoptosis is one of the mechanisms by which an organism limits the growth and 
replication of cells. If apoptosis did not occur, there would be no way to control cell 
growth and tissue homeostasis would be lost. In fact, this is a key mechanism in cancer 
growth where genetic alterations or environmental factors in the cancer cell lead to 
increased cellular proliferation and growth, and loss of apoptosis i.e. there is too much 
cell growth, and too little cell death in malignant tissue. In some malignant cells, there 
is resistance to apoptosis due to overexpression of anti-apoptotic proteins, for example 
survivin is an anti-apoptotic protein found in many cancers.  Increased expression of 
survivin has been found in myeloid leukaemic cells and it was found to block cytokine 
stimulated apoptotic pathways and caspase-3 activation (Carter et al., 2001). 
Bcl-2, while generally anti-apoptotic has also been implicated in loss of control in 
cancer if dysregulated simultaneously with other key molecules e.g. oncogenes.  This 
has been observed in leukaemias where alterations in the balance of pro-apoptotic 
and anti-apoptotic proteins results in uncontrolled growth of malignant cells (Pandey 
et al., 2016). Conversely, deactivation mutations of pro-apoptotic molecules such as  
Bax  is seen in some gastrointestinal tumours (Gao and Wang, 2009) and leukaemias 
(Moazami-Goudarzi et al., 2016). Activation of transcription factors can also lead to 
apoptotic resistance. This occurs when nuclear factor Kappa B (NF-kB) or transcription 
factors are overexpressed in tumours which leads to increased transcription of anti-
apoptotic members of the inhibitors of apoptosis proteins (IAP) and Bcl-2 families 
(Hoesel and Schmid, 2013) 
As a result some anti-cancer agents have been developed which target anti –apoptotic 
molecules,  for instance short segments of DNA complementary to RNA of Bcl-2 or 
antisense oligonucleotides have been designed to reduce translation of anti-apoptotic 
proteins (BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1/A1) (Kirkin et al., 2004). Additionally, 
Borterzomib is a 26S proteasome inhibitor that is thought to prevent degradation of 
anti-apoptotic proteins and is used in the treatment of multiple myeloma (Shahshahan 







1.7. Calreticulin  
As previously described CRT is an intracellular protein that can be translocated to the 
external surface of the cell during ICD.  CRT is a highly conserved ER chaperone 
protein that also displays extracellular multifunctional properties in various cellular 
processes (Wiersma et al., 2015). It was first identified as a Ca2+-binding protein in 
1974 (Ostwald and MacLennan, 1974). Later, the gene coding for this protein was 
cloned and the product was named “calreticulin”, reflecting its ability to bind calcium 
and its primary localization to the ER (Smith and Koch, 1989). Accumulated evidence 
indicates that CRT impacts on the development of different cancers and the effect of 
CRT on tumour formation and progression may depend on cell type and clinical 
stages.  
 
1.7.1. Calreticulin expression in cancers 
The correlation between CRT expression levels and tumorigenesis has been 
extensively studied in various cancers and most reports have indicated that CRT is 
aberrantly overexpressed in tumour tissues compared with normal tissues (Zamanian 
et al., 2013), summarised in Table 1.3. Studies have shown correlation between CRT 
expression levels and clinical stages and lymph node metastasis in gastric cancer 
(Chen et al., 2009) and breast cancer (Lwin et al., 2010). In addition, patients with 
higher CRT levels had a lower survival rate in pancreatic cancer and oesophageal 
squamous cell carcinoma (Du et al., 2007). Other studies also detected high 
expression levels of CRT in oral cancer (Chiang et al., 2013), breast ductal carcinoma 
(Song et al., 2012), prostate cancer (Alaiya et al., 2000) and vaginal carcinoma 
(Hellman et al., 2004). Furthermore, CRT levels not only increased in bladder cancer 
tissues, but urinary CRT has been shown to be a biomarker for bladder urothelial 
cancer detection (Kageyama et al., 2004). These results suggest that increased CRT 
expression might play an important role during development of cancer. However, the 
effect of CRT on tumour formation and development may depend on different tumour 





Cancer CRT levels* Clinical outcomes 
Oral Increased  
oesophagus Increased ↓survival (Chen et al.) 
Breast Increased ↑Metastasis,↑ invasion 
Pancreas Increased ↑Lymph node metastasis 
Gastric Increased ↑Lymph node metastasis ,↑invasion 
Colon Increased  
Bladder Increased 
↑Urinary CRT ,↑histological grade 
,↑pathological T stage 
Prostate Increased  
Vagina Increased  
#Ovarian Increased Better response to chemotherapy 
#Neuroblastoma  Increased ↑Differentiated, ↑survival 
 
Table 1.3: Expression of level CRT in different can cers (Lu et al., 2015).   
↑: increased; ↓: decreased. 
*CRT levels in tumour tissue except ovarian carcinoma in effusion fluids. 





1.7.2. Structure and function of CRT 
CRT is a ubiquitous Ca2+-binding protein, found in a wide range of species and in all 
nucleated cell types, and has a variety of important biological functions. These include 
protein folding in newly-synthesized proteins (Gelebart et al., 2005) and maintaining 
Ca2+ homeostasis in the ER lumen. Both functions are critical for many cellular 
processes and, when impaired, may lead to pathology (Arruda and Hotamisligil, 2015) 
e.g. CRT mutations have been found in patients suffering from myeloperoxidase 
deficiency (Theocharides et al., 2016).  
The biophysical analysis of CRT indicates it has three structural and functional 
domains. Nine exons encode the N-domain (including the N-terminal signal 
sequence), the proline-rich P-domain, and the C domain of CRT respectively (Figure 
1.6). The protein contains an N-terminal amino acid signal sequence and a C-terminal 
KDEL (Lys-Asp-Glu-Leu) ER retrieval signal. CRT possesses 3 cysteine residues and 
a single disulfide bridge in the N domain (Michalak et al., 1999). The N and C segments 
form an N-C globular head domain, while the proline-rich domain forms an elongated 








Figure 1.6. A model of CRT and its domain organisat ion.  (A) The x-ray 
crystallography structure of CRT. (B) Domain structure of CRT which comprises of an 
N-C domain of approximately 290 amino acids in length, together with a P domain of 





1.7.3. Calreticulin in the ER 
Calreticulin has many cellular functions both, intracellular and extracellular. In addition 
to its intracellular roles in Ca2+ homeostasis and glycoprotein folding in the ER, 
extracellular CRT has been identified on the cell surface of apoptotic and necrotic cells 
and is involved in wound healing. CRT is an essential protein for life, for instance, 
studies have also revealed that CRT deficient mice embryos die from heart failure at 
day 14 due to the loss of the normal role of CRT as a calcium buffer in the ER (Mesaeli 
et al., 1999).   
 
Intracellularly, native proteins synthesized in ribosomes on the rough ER translocate 
into the ER lumen where some, via interaction with CRT, are identified as “misfolded” 
and directed to the ERAD pathway (Benham, 2012). Thus, together with other 
chaperones, CRT effectively marks misfolded proteins and ensures that only correctly 
folded proteins exit the ER. Additionally, as an ER chaperone, calreticulin is important 
for the normal trafficking of many cell surface proteins (Wiersma et al., 2015). CRT 
binds transiently to most glycoproteins that pass through the ER, slowing the folding 
rate but increasing folding efficiency; largely by preventing aggregation. It also 
promotes correct disulfide bond formation in bound substrates by recruitment of 
ERp57 chaperone. CRT therefore participates in quality control, monitoring 
glycoprotein folding status and retaining folding intermediates of terminally misfolded 
glycoproteins in the ER. It may also participate in targeting misfolded proteins for 
degradation (Ferris et al., 2014) 
 
1.7.4. CRT and the innate immune system   
Early studies showed that calreticulin was found on the surface of many mammalian 
cells (Arosa et al., 1999). CRT is translocated from within cells by unknown 
mechanisms under stress conditions such as treatment of cells with anthracyclines, 
oxaliplatin, ultraviolet C and γ-radiation (Tarr et al., 2010b). It has an important function 
at the cell surface by mediating phagocytosis of apoptotic or dying tumour cells. CRT 
was first found to function on phagocytic cells as a receptor for complement I of the 




unregulated exposure of ER contents during cell death, but a pre-apoptotic event that 
appears to be highly regulated. Cancer chemotherapy such as anthracyclines induce 
CRT exposure in cancer cells within one hour, preceding the apoptosis-associated PS 
exposure. This CRT translocation is important for the immunogenicity of dying tumour   
cells, which is key to the success of chemotherapy (Obeid et al., 2007). 
 
Surface bound CRT has been reported serve as an “eat me” signal on the surface of 
apoptotic cells and to have several binding partners that may positively impact on 
innate immunity, most notably complement C1q (Osman et al., 2017, Stuart et al., 
1997) Through these binding partners CRT can enhance the innate immunity 
responses, especially phagocyte removal of cells. CRT was initially characterized as 
a receptor for the C1q binding to apoptotic cells where CRT binding to apoptotic cells 
coated with C1q enhanced the phagocyte-mediated removal of cells by macrophages 
(Ogden et al., 2001). Extracellular CRT binds to C1q on the surface of apoptotic cells 
and acts as a bridging molecule by binding to CD91 on macrophages (also called LDL-
receptor related protein) allowing macrophages to engulf the C1q opsonised cells 
(Gardai et al., 2005, Verneret et al., 2014).  
It is believed that CRT also acts as an 'eat-me' signalling molecule by blocking the 
ability of the cellular CD47 ('don't-eat-me' signal) to bind to its ligand on the 
macrophage i.e. signal regulatory protein α (SIRP-α) (Chao et al., 2010). SIRP-α is a 
heavily glycosylated transmembrane protein on the engulfing cell which facilitates 
uptake of target cells. Disruption of this CD47-SIRP-α axis can be important in cancer. 
Indeed, in apoptotic breast cancer cells, CD47 was altered and/or lost and no longer 
activated SIRPα on macrophages or DCs, preventing clearance  (Lv et al., 2015).Thus, 
in the presence of CRT an apoptotic cell “don’t eat me” signal could instead be 
recognised as “eat me”; signalling cells for removal (Chao et al., 2010) (see Figure 
1.6).  
 
1.7.5. CRT in adaptive immunity  
CRT also has multiple functions in adaptive immunity.  Intracellularly, CRT can 
promote folding and assembly of glycoproteins including major histocompatibility 




class I antigen presentation pathway which is called cross-presentation (Raghavan, 
2010). MHC I presentation of these antigenic peptides at the cell surface plays a vital 
role in distinguishing healthy cells from infected cells and mediates interactions 
between immune cells. CRT also stabilises this MHC-1 complex (Peaper and 
Cresswell, 2008).  
 
1.7.6. Role of CRT surface exposure during ICD in c ancer treatment  
 As mentioned previously the immunogenic characteristics of ICD are mediated mainly 
by molecules called DAMPs, most of which are recognised by pattern recognition 
motifs called Toll-like receptor (TLR) system on macrophages and DC (Piccinini and 
Midwood, 2010). Some DAMPs are actively released by cells undergoing ICD (e.g. 
CRT and ATP) whereas others are released passively (e.g. HMGB1). Recent studies 
have shown that these three DAMPs play a crucial role in anti-cancer therapy by 
interacting with the immune system (Figure 1.7) (Krysko et al., 2012). In addition, the 
ER releases other ER chaperones which would normally not be considered to be 
immunogenic, but many reports have now highlighted their role as DAMPs in the 
extracellular space such as BiP, and gp96. However, some studies have suggested 
that CRT has the major role in ICD (Wiersma et al., 2015). Importantly, in cancer 
treatment, anthracyclines triggered the translocation of CRT to the cell surface of 
apoptotic tumour cells, which is dependent on the induction of an ER-stress response 
(Garg et al., 2012, Martins et al., 2011). 
CRT expressed on the cell surface of dying cancer cells then clears the dead cells by 
enhancing maturation of DCs.  This is accompanied by release of intracellular DAMP 
molecules such as ATP and HMGB1 from late apoptotic cells which further enhance 
DC maturation and subsequent clonal expansion of cytotoxic CD8+ T-cells (Apetoh et 
al., 2007) (Figure 1.8). ICD has been discussed in a preclinical setting for an ever-
expanding set of cytotoxic therapies, including many chemotherapeutics, radiation 
therapy, and photodynamic therapy. Interestingly, treatment of cancer cells with a 
recombinant form of the TNF-related apoptosis inducing ligand (TRAIL) -a death 
receptor ligand was reported to induce CRT cell surface exposure and ICD 















Figure 1.7.  Disruption of the “don’t eat me” signal by CRT.  Cells express a high 
amount of CD47 “don’t eat me” signalling molecule which binds SIRPα on phagocytes. 
During apoptosis PS translocates from inside the cell to the outer section of the cell 
membrane, and with the CRT on the cell surface, works as a bridge molecule between 
C1q and CD91 on phagocytes. In immunogenic cancer cell death, cells treated with 
certain chemotherapeutic drugs and ER stress-inducing drugs have up-regulation of 
surface exposed CRT, which enhances phagocytic uptake by DCs via a mechanism 
that is at least partially CRT-dependent. Non-immunogenic cells have a high amount 













Figure 1.8. Immunogenic cell death and DAMPS. In tumour cells, CRT normally 
resides in the lumen of the ER. However, upon induction of immunogenic cell death 
(ICD), CRT translocases to the surface of pre-apoptotic cells, whereupon these 
apoptotic cells are taken up by dendritic cells (DCs).  Immature DC (iDC) maturation 
to mature DCs (mDC) and clonal T-cell expansion are enhanced by additional DAMP 
signals such as HMGB1, ATP and HSP70. DAMPs are derived from different 
compartments of the cells. For example, they can come from mitochondria (ATP), 
nucleus (HMGB1, high mobility group box 1 protein; HMGN1), ER (CRT and ATP) and 















1.7.7. CRT as a therapeutic agent  
The accumulated evidence  has suggested  that manipulation of CRT levels may have 
important therapeutic potential through its pro-immunogenic role in ICD (Zitvogel et 
al., 2010). Chemotherapy such as anthracycline and irradiation could be planned to 
enhance CRT translocation to the cell surface of pre- apoptotic cells allowing them to 
be recognised and removed by phagocytosis and enhancing the elimination of tumour 
cells (Eggleton et al., 2016).   
 
Additionally, CRT has shown potential as a wound-healing therapeutic and this is only 
just starting to be explored. Dr Leslie Gold and her team in New York, have identified 
that CRT accelerates and enhances wound healing in both porcine (heals like 
humans) and diabetic murine experimental models of skin injury (Gold et al., 
2010).Indeed when applied topically, CRT repaired the wound of porcine skin far better 
than Regranex which is the only current treatment used for diabetic foot ulcers (Gold 
et al., 2010). When applied topically CRT enhances epithelial migration and 
granulation tissue formation and, importantly increases number of phagocytic cells in 
the wound, such as macrophages, thus aiding removal of dead cells (Gold et al., 
2006).  It has also been reported that CRT aids wound healing by reducing bacterial 
infection and these multifunctional effects have suggested a potential therapeutic role 
for exogenous CRT in patients such as those with diabetic ulcers who have with 
delayed wound healing (Gold et al., 2006). 
 
1.8. ER stress inducers 
It is clear from the previous discussion that inducing ER stress in cancer cells is a 
possible strategy for enhancing surface exposure of cellular CRT and triggering 
subsequent cell removal by macrophages and/or by ICD mechanisms. A number of 
drugs have been reported to induce cell surface CRT expression and the resulting 
immunological consequences (Michalak et al., 2009). In this thesis ER stress is 
induced by doxorubicin and thapsigargin to examine mechanisms of CRT 
translocation in ovarian cancer cell ICD. Thus, this section briefly describes the 




resulting in increased cellular CRT production and surface translocation (also see 
Table 1.4). 
1.8.1. Doxorubicin 
Doxorubicin is a cytotoxic drug that is used to treat many different types of cancer, 
including solid tumors, leukemia, lymphomas and breast cancer (Holmgren et al., 
2015). It is an antibiotic, a secondary metabolite of Streptomyces peucetius var. 
Caesius, and along with daunorubicin, epirubicin, and idarubicin, it belongs to the 
family of anthracyclines (Yu et al., 2018).  
Doxorubicin and other anthracycline drugs have been intensively examined during the 
last several decades. Doxorubicin has been reported to exert its anti-neoplastic effect 
by intercalation into DNA, inhibition of the enzyme topoisomerase II, and formation of 
ROS (Tewey et al., 1984, Renu et al., 2018). All of these have a harmful effect on DNA 
synthesis and DNA repair mechanisms and lead to mutagenesis and chromosomal 
aberrations (Momparler et al., 1976, Malla et al., 2009). At the molecular level, 
doxorubicin is incorporated in-between two nitric bases of the double DNA helix, thus 
causing the inhibition of DNA dependent DNA and RNA polymerases (Zunina et al., 
1975). The successful use of doxorubicin has been hampered by toxicities such as 
hematopoietic suppression, nausea, vomiting, extravasation, and alopecia, yet the 
most feared side-effect is cardiotoxicity (Fu et al., 2016).  
The ability of doxorubicin to induce the pre-apoptotic surface exposure of CRT which 
is required for ICD is very specific i.e. it is not observed in all chemotherapeutic agents 
(Obeid et al., 2007).  Doxorubicin has been suggested to induce ER stress by 
interfering with (via its topoisomerase inhibition) the unfolded protein response (UPR) 
at the level of transcription of key components such as ATF4 transcription (sulfate, 
Kim et al., 2006).  The cell responds to doxorubicin by initial activation of the ER 
membrane protein kinase RNA-like endoplasmic reticulum kinase (PERK) which 
phosphorylates eukaryotic initiation factor 2 (eIF2α). This is a normal UPR and usually 
protects cells from ER stress by attenuating protein synthesis and reducing ER protein 
load. However, in the presence of doxorubicin these initial events occur in conjunction 




which ultimately results in changes in ER membrane Ca2+ fluxes and exocytosis of 
CRT via Golgi apparatus-derived vesicles (Panaretakis et al., 2009) .  
As mentioned previously a major side effect of doxorubicin is cardiac toxicity, at least 
partly due to mitochondrial damage as a result of generation of mitochondrial ROS 
(Oliveira, 2016).  If doxorubicin could be used to induce ICD at lower dosages than 
required for its conventional cytotoxic effects then it may show improved therapeutic 
benefit, but with lower toxicity. 
1.8.2. Thapsigargin  
Thapsigargin is a naturally occurring tumour promoter derived from the plant Thapsia 
garganica. It affects cells by emptying the intracellular calcium stores, which leads to 
a chain of events that causes apoptosis.  
In basic research, thapsigargin is the most widely used inhibitor of the ubiquitous 
sarcoplasmic reticulum/ER Ca+2 ATPase (SERCA). SERCA pumps calcium ions from 
the cytoplasm into the lumen of the ER and thapsigargin, by preventing this, causes a 
decrease in calcium in the ER while depleting ER stores. This, in turn, decreases the 
activity of Ca2+ dependent chaperones, leading to an increase in unfolded proteins and 
the corresponding induction of UPR signalling (Janssen et al., 2006). 
Thapsigargin also interferes with mechanisms of autophagy by inhibiting fusion of auto 
phagosomes to lysosomes. Thus, increased calcium level along with dysregulated 
autophagy leads to ER stress, which ultimately progresses to apoptosis and cell death 




















Table 1.4 Characteristics of clinically relevant ER  stressors (info.emea@bio-
techne.com, 2108) . (UPR) unfolded protein response, (ATPase) adenosine 
triphosphates’, (DAMPs) damage -associated molecular pattern, (HSP70) heat shock 
protein, (HMGB1) high mobility group box 1 protein) and (INF) interferon.  
 
1.8.3. Tauroursodeoxycholate (TUDCA) reduces ER str ess 
In recent studies, several small molecules commonly referred to as “chemical 
chaperones” (e.g., 4-phenylbutyric acid or 4-PBA, a modified fatty acid or TUDCA, a 
bile acid) have been identified that function to attenuate cellular stress and enhance 
protein processing (Vega et al., 2016). TUDCA is an amphiphilic bile acid that has 
been shown to control the growth of a variety of epithelial cells, including 
cholangiocytes (Alpini et al., 2001). TUDCA has been used effectively for the treatment 
of cholestatic liver diseases and its efficacy has been attributed to its cytoprotective 
effects on hepatocytes by increasing bile flow, biliary acid secretion, and 




TUDCA is effective in protecting hepatocytes and restoring glucose homeostasis by 
reduction of ER stress (Gentile et al., 2011). Thus, there is evidence indicating that 
TUDCA can modulate signalling of the UPR coping response by promoting protein 
folding and, by activating transcription programs leading to increased expression of 
chaperone genes, which may increase the activity of molecular chaperones or folding 
enzymes in the ER, thereby increasing ER folding capacity (Ozcan et al., 2006). 
TUDCA reduces BiP upregulation, protein kinase R-like ER kinase and JNK 
phosphorylation, expression of the ER stress protein CHOP, caspase 3 activation and 
apoptosis in following cholecystokinin treatment (Malo et al., 2010).  
  
1.9. Overview of research presented and aims of thi s study 
Ovarian cancer is the fifth most common cancer among women worldwide and the 
most common cause of death due to a gynaecological malignancy, causing ~125,000 
deaths worldwide/year (Carolina Vera Castillo, 2016). Conventional treatment of EOC 
is radical surgery, typically followed by chemo/radiotherapy. Unfortunately, late stage 
of diagnosis and intrinsic/acquired resistance to therapy leads to a limited 5-year 
survival rate of only 45%. This survival rate needs to be improved. Immunotherapy, 
designed to boost the body’s natural defences against cancer, appears to be a 
promising option against ovarian cancer. Extracellular cell surface associated CRT 
promotes the immunogenicity of early apoptotic cancer cells and boosts adaptive 
immunity, a finding that has set CRT at a centre stage for cancer immunology in recent 
years. Elucidation of mechanisms by which ovarian cancer cell surface levels of CRT 
can be enhanced to encourage cell phagocytosis and induction of ICD is important in 
developing novel CRT-based therapeutics for this disease. Therefore, this thesis 
examines strategies to increase CRT surface levels in ovarian cancer cells, either from 
endogenous stores (by inducing cellular ER stress) or by adding exogenous CRT. The 
ability of cells treated in this way to enhance immune responses, specifically DC 
maturation and T-cell activation, are then examined. The data indicate that exogenous 
and endogenously translocated CRT bind to cancer cells and that the latter cells with 
externalised CRT were then able to induce DC maturation and subsequently T-cell 





The overall aim of this thesis was to examine the hypothesis that enhancement of CRT 
on the surface of EOC could induce immunogenic responses, potentially leading to 
targeted cancer cell death and immunotherapy. 
 
Specific aims:   
• Purification of both bacterial (Escherichia. coli) and yeast (Pichia pastoris) 
expressed human full length CRT (Chapter 3). 
• Fluorescent labelling of purified CRT to enable CRT-binding studies in EOC 
cells (Chapter 4a)  
• To determine whether exogenous CRT binds to the surface of EOC under 
resting or stressed conditions (Chapter 4a).  
• To examine the conditions of ER stress that give rise to endogenous cell 
surface expression of CRT on cancer cells (Chapter 4b).  
• To examine whether CRT alone or surface bound can activate immune 

















Chapter 2.  Materials and general methods 
2.1. Suppliers and sources of experimental material s 
Abcam, Cambridge, UK:  Goat anti-rabbit IgG H&L (Alexa Fluor® 488), Anti-EpCAM 
antibody. 
Alpha laboratories Limited, Hampshire, UK: LW1154 Tip 0.1-10µl universal micro 
ultrafine tip, graduated, loose non sterile 32mm in length, APV000100 single channel 
pipettes 0.5-10 µl; APV002000 single channel pipettes 20-200 µl, APV010000 single 
channel pipettes 100-1000 µl. 
 
BD Biosciences, Oxford, UK: Syringe luer 1ml. 
 
Cambridge Bioscience, Cambridge, UK:  PluriStrainers 30µm. 
 
Bio Legend, Cambridge, UK:   Alexa Fluor® 647 annexin V;  annexin V binding buffer; 
PE anti-human CD16 antibody;  Alexa Fluor® 488 anti-human CD14 antibody; PE anti-
human CD11c antibody; PE anti-human CD80 antibody; PE anti-human CD83 
antibody; PE anti-human CD86 antibody; PE anti-human HLA-DR antibody; IL-12/23 
(p40) ELISA MAX™ Deluxe; mouse IgG1; anti-CD3-PerCP-Cyanine5.5; anti- human 
CD3. 
 
Bio-Rad Laboratories, Hemel Hempstead, UK:  10% Mini-PROTEAN® TGX™ precast 
protein gels; 10-well;  precision plus protein all blue standard; Bio-Safe Coomassie 
Stain;  4x Laemmlli sample buffer, 8-16% 15 well mini protean TGX precast gels. 
Fisher Scientific, Loughborough, UK:  ProLong® Diamond antifade mountant; P36931 
ProLong® Gold antifade mountant with DAPI;  microscope slide super frost plus 
adhesion, glass grounded edges with white marking area 25mm x 75mm x 1mm;  
Cover slip best borosilicate glass 22mm x 22mm 0.13mm to 0.17mm thick;  gloves, 
latex; syringe filter, diameter (Metric 25mm, pore size 0.45µm); DPBS (Dulbecco's 
Phosphate Buffered Saline) 1x without calcium, magnesium; microscope slide box 




0.05%(w/v) EDTA, Tris base;  test tube DNA LoBind 1.5mL;  Nalgene™ 25mm syringe 
filters (CA; 0.8µm pore);  calreticulin antibody (PA3-900);  DMSO (dimethyl sulfoxide), 
Penicillin-Streptomycin solution liquid, clinical waste bins; Cryovial 1 degree freezing 
container;   protease inhibitor tablets  EDTA-free; syringe hypodermic with needle 1mL; 
pipette tip, blue; racked, to fit Gilson P1000; Dynabeads™ Human T-Activator 
CD3/CD28 for T Cell expansion and activation. 
Greiner Bio-One Ltd, Gloucestershire, UK: Cryovial, 2.0ml, skirted, internal thread, 
natural cap, sterile; aspiration pipette, 2ml, sterile, individually wrapped; 15ml 
centrifuge tube, graduated, bagged, sterile;  50ml centrifuge tube, conical base, 
bagged, sterile;  6 well tissue culture  treated plate with lid, sterile; serological pipette 
10ml; serological pipette, 5ml; cryovial, 2.0ml, skirted, internal thread; aspiration 
pipette 2ml; 15ml centrifuge tube; 50ml centrifuge tube;  pipette tip, yellow, racked, to 
fit Gilson P20/P200; pipette tip, to fit Gilson P2/P10, racked, sterile. 
 
Invitrogen, Paisley, UK:  CFSE (Carboxyfluorescein succinimidyl ester); cell proliferation 
kit.  
 
LI-COR Biosciences, Cambridge, UK:  800CW goat anti-rabbit IgG, 680RD goat anti-
mouse IgG. 
Lonza, Wokingham, UK:  RPMI 1640 without L-glutamine; gentamycin sulfate L-
glutamine solution, 200 mM suitable for cell culture. 
 
Miltenyi Biotech, Bisley, UK:  Pan monocyte isolation kit, human; midi MACS separator, 
LS+ positive selection column; CD8+ T Cell isolation kit human. 
 
PeproTech, London, UK: Recombinant human GM-CSF; recombinant Human IL-4. 
 
Sartorius, Epsom, UK: 75cm2 cell culture flasks;  serological pipette 5ml, 10 ml, 25 ml 






Sigma Aldrich, Gillingham, UK:  Paque plus GE17-1440-02; Roche Dapi (4′, 6-
Diamidine-2′-phenylindole dihydrochloride);  monoclonal anti-actin antibody produced 
in mouse, Doxorubicin; thapsigargin; sodium tauroursodeoxycholate (TUDCA); Tris 
buffered saline (TBS);  propidium iodide; Guava Instrument Cleaning Fluid (ICF); 
Fluorescein isothiocyanate (FITC);  BSA (bovine serum albumin). 
  
Promo Cell, Heidelberg, Germany: Endothelial cell basal medium MV-2. 
 
VH Bio, Gateshead, England:  hCMEC/D3 (human cerebral microvascular endothelial 
cell line) 
 
2.2. Buffers and Solutions 
 
 Tris buffered saline + CaCl2 (CRT binding buffer) pH=7.6  
Cacl2                        5 mM 
Tris buffered saline    100 ml  
 
RPMI complete medium for OVcar3, SKOV3, A2780, FaDu cells 
RPMI                         500 ml  
FBS                          10% v/v 
L-glutamine               2mM 
Gentamicin               50µg/ml 
 
Freezing solution for OVcar3, SKOV3, A2780, FaDu cells  
 
Growth medium                               20% (v/v) 
FBS                                                 70% (v/v) 
DMSO                                              10% (v/v) 
 
Complete medium for hCMEC/D3 (human cerebral microvascular endothelial 
cell line) 
 




FBS (heat inactivated)                          5% v/v 
Endothelial cell growth MV-2 bullet kit 
                                                                                 
Collagen solution (for coating flask). 
 
Collagen solution, type I from rat tail        4mg/ml 




PBS                                                          100 ml 
BSA                                                           0.5 g  
EDTA                                                        2 mM (0.744g)  
 
Staining buffer (for use in immunofluorescent staining protocols of cells in 
suspension) 
 
PBS                                                          
FBS                                                         1 % (v/v) 
NaN3                                                       0.09 % (w/v)  
 
10x sodium carbonate buffer for CRT ELISA 
Use 6ml of ddH2O initially to dissolve powder in tube 
Na2CO3                                              0.1575g  
NaHCO3                                            0.294g 
pH solution to 9.6 using HCl 
Make up final volume to 10ml 
 
0.1% (v/v) PBST -Tween 20 for ELISA 
 
500µl Tween-20 
500ml PBS  
 
5% (w/v) BSA blocking buffer 
Bovine serum albumin                            1g 







2.3. Cell culture 
2.3.1. Cell culture conditions  
SKOV3, A2780, OVcar3, FaDu cancer cells 
For all experiments cancer cells were maintained at 37oC in a humidified incubator 
with 5% CO2. Cancer cells were cultured in media as follows (unless otherwise 
specified).  
SKOV3, A2780, OVcar3, FaDu cells provided by collaborators/supervisors (Dr 
Jacqueline Whatmore, Exeter University & Dr Edwin Bremer; University of Groningen) 
were grown in RPMI medium supplemented with 10% (v/v) FBS and gentamicin 
(50µg/ml)  
Ovarian cancer cells were passaged by trypsinisation when they reached confluency 
in the tissue culture flasks/dishes. The medium was removed and the cells were 
washed once with warmed PBS followed by addition of 2 ml trypsin solution (0.05%) 
(w/v). The cells were placed in the incubator at 37oC for 3-5 minutes. Detachment was 
monitored by microscope until cells could be seen floating in the trypsin solution. 
Trypsin was then neutralized by the addition of 8 ml of growth medium (containing 
10% (v/v) FBS) and the cell suspension was transferred to a tube and centrifuged at 
1500rpm for 5 minutes. The supernatant was removed and the cells were 
resuspended in complete growth medium. Required number of cells was transferred 
into tissue culture flask (25cm [T25] or 75cm [T75]) and the total volume of medium 
was filled up to 10ml for T75 or 4ml for T25. 
 
2.3.2. THP-1 cell (human monocytic cell line) 
THP-1 cells were a kind gift from Dr Chris Scotton.  
Cells were cultured in RPMI 1640 supplemented with 10% (v/v) FBS and 2-
mercaptoethanol to a final concentration of 50µM. Cells grow in suspension and were 
sub-cultured when cell concentration reached approximately 1 x106 cells/ml by 
centrifugation and resuspension at 2-4 X 104 cells/ml. Media was changed every 2 to 




2.3.3. HCMEC/D3 human cerebral microvascular endoth elial cells 
Primary HCMEC/D3 cells were maintained at 37°C in 5% CO2 in culture media 
(Endothelial Cell complete Media MV 2). For progressive passages, cells were 
trypsinised as in (2.3.1) with 0.05% (w/v) trypsin-EDTA and these cells were seeded 
in collagen type I (100µg/ml) coated tissue culture flasks and cultured in supplemented 
MV-2 endothelial growth medium. Cells were passaged at a ratio of 1:3 and fed every 
2-3 days.  After removing the culture medium, cells were washed twice with PBS and 
trypsinised.  To collagen coat the flasks diluted collagen solution (3ml) was evenly 
distributed across the bottom of a T75 tissue culture flask and incubated at 37oC for 
at least 1 hour. Any remaining collagen was aspirated and the flask was washed twice 
with PBS prior to adding the HCMEC/D3 cell suspension. 
 
2.3.4. Freezing cells 
Cells were trypsinised (2.3.1), centrifuged and resuspended (~2x106 cells) in 1ml 
freezing medium (as described for each cell type in 2.2.1). The cell suspension was 
transferred into sterile labelled vials, which were then placed in a cryo-container 
containing isopropanol and stored at -80oC overnight for slow cooling. Frozen vials 
were ultimately transferred into liquid nitrogen for long term storage. 
2.3.5. Thawing cells 
The frozen cells in cryovials were rapidly thawed by placing in a 37oC water bath. 
Thereafter, the cells were slowly diluted in 10mls of pre-warmed growth medium and 
plated in T75 flasks (collagen coated for HCMEC/D3). The medium was replaced after 
cell attachment (usually 24hrs) in order to remove the DMSO used during freezing.4. 
2.3.6. Seeding cells into 6 well plates. 
Flasks that were fully confluent were sub-cultured into 6-well plates. The method for 
sub-culturing was followed as described in section in 2.3.1. For cell counting the cell 
pellet was re-suspended in 1 ml cell complete medium pre-warmed to 37oC. Equal 
volume of 0.4% (w/v) trypan blue dye was added to the cell suspension (example: 10 
µl of cells to 10 µl of trypan blue) and the suspension mixed by pipetting up and down. 
10 µl of the cell-suspension was removed and placed in a haemocytometer (Figure 































 Figure 2.1 Counting of cells on a haemocytometer ( LLC, 2018) 
 
Trypan blue, made up in phosphate buffered saline (PBS), was used as the vital dye 
stain because of its ability to cross the plasma membrane and be retained within non-
viable cells. A haemocytometer was used to count the number of live cells. All viable 
cells in the four corner squares were counted. If the cells were on the border outlining 
each square, only the cells on the top and left border of the square were included. This 
value represented the number of cells/ µl fluid. Based on the average number of cells, 







For example, an average of 150 cells in all four corner-squares of the haemocytometer 
constituted 1.5 x106 cells/ ml in 10 ml complete media. For the cancer cells, 0.5 x106 
cells were seeded in each well of a 6 well plate. To obtain the correct seeding density, 




1  1=2  2 
Whereby: 
C1 = number of cells x106/ ml; 
V1 = initial volume of complete medium added to cells to create cell suspension; 
C2 = desired number of cells/ ml in final cell suspension; 
V2 = final volume of complete medium used to resuspend cells. 
Example: 
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 media) 
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2.4. Flow cytometry  
Flow cytometry is a method that allows the measurement of the properties individual 
cells, and their in-depth analysis by specific software programmes, as they flow in a 
fluid stream through a beam of light. The properties measured include a particle’s 
relative size, relative granularity or internal complexity, and relative fluorescence 
intensity after specific staining. These characteristics are determined using an optical-
to-electronic coupling system that records how the cell or particle scatters incident 
laser light and emits fluorescence.  
A flow cytometer is made up of three main systems: fluidics, optics, and electronics: 
a) The fluidics system transports particles in a stream to the laser beam for 
interrogation. 
b) The optics system consists of lasers to illuminate the particles in the sample 
stream and optical filters to direct the resulting light signals to the appropriate 
detectors. 
c)  The electronics system converts the detected light signals into electronic 
signals that can be processed by the computer.  
2.4.1 Gating for live cells 
After preparation cells in suspension are passed through the narrowing channel. Each 
cell passes the laser beam, allowing individual analysis. The laser beam scatters in 
multiple directions and the flow cytometer detects light scatter as forward scatter and 
side scatter. Forward scatter (FSC) is proportional to cell-surface area or size. It is a 
measurement of mostly diffracted light and is detected just off the axis of the incident 
laser beam in the forward direction by a photodiode. The other detector measures 
scatter at a ninety degree angle relative to the laser. This parameter is called side 
scatter (SSC) and is a measure of the granularity of a cell. When measured together, 
these allow for differentiation in a heterogeneous cell population (Figure 2.2). This 
allows a gating strategy to eliminate cell debris from further analysis because it has 
lower forward scatter levels, FSC and SSC can also be used to assess cell death, 








Figure 2.2.  This graph displays two measurement parameters . Cell size on the x-
axis (FSC) and granularity on the y-axis (SSC) and the events are shown as a density 
(or dot) plot. The gating strategy eliminates cell debris because it has lower forward 
scatter levels. Gated cells are often found at the bottom left corner of the FSC vs SSC 
density plot. The plot shows typical side scatter (SSC) and forward scatter (FSC) 









2.4.2. Compensation  
Where more than one fluorophore is used there is a possibility of overlap between the 
emission spectra that may influence the data and require correction through data 
processing i.e. compensation. The Guava flow cytometer and associated software 
used here automatically calculates accurate compensation values for each 
fluorochrome combination and so it is not necessary to do this manually. However, for 
confirmatory purposes this was checked for the fluorophore combinations used in 
Chapter 5 i.e.Cy-5 (far red excitation/emission approximately 650/670), PE (yellow, 
excitation/emission approximately 496 nm/578 nm) or FITC (green, excitation/ 
emission approximately 495 nm/519 nm). 
 
Briefly, cells were stained with pairs of antibodies with different fluorophore 
combinations analysed by flow cytometry.  Figure 2.3 Indicates that positively stained 
cells labelled with the fluorophore identified on the x axis of each image do not show 
any overlap with the fluorophore identified on the y axis.  These data confirm that no 



























Figure 2.3.  EpCAM-cy5 fluorescence did not overlap  with FITC or PE staining. 
iDCs and mDCs derived from THP-1 cells (as described in the Materials and Methods) 
were stained with pairs of antibodies as indicated i.e. CD11c-PE +  EpCam-cy5 or 
CD14-FITC (upper panel) or CD14-FITC +  CD11c-PE or EpCan-cy5 (lower panel), 
and then assessed for the relevant fluorophore by flow cytometry to examine any 











2.4.3. Flow cytometry to assess cell apoptosis and necrosis   
Annexin V and PI propidium iodide can be used to detect cell death as described in 
the Introduction. PI is a nuclear stain which does not stain live and early apoptotic cells 
due to the presence of an intact of plasma membrane but in late apoptosis and 
necrosis the plasma integrity decreases and PI can enter the cell.   PI is therefore only 
incorporated into the DNA of dying and dead cells. These cells are described as ‘PI 
positive cells’. The results can provide information regarding cell viability (i.e. the 
percentage of dead and live cells). As PI cannot enter live cells, flow cytometry can 
only indirectly detect these cells. Such cells are referred to as ‘PI negative cells.  In 
contrast, annexin V is a marker to detect apoptosis.  It specifically recognises PS that 
is exposed on the cells during apoptosis.  
Cell apoptosis and necrosis were examined using the annexin V and PI staining and 
flow cytometry. Flow cytometry was performed using a Guava flow cytometer 
instrument (Millipore, Hertfordshire, UK). The data was analysed using Guava 3.1.1 
software. The criteria for early and late apoptotic cells were annexin V-positive, PI-
negative and annexin V-positive, and PI-positive, respectively. Signals were detected 
using Alexa Fluor® 647 which is a bright, far-red–fluorescent dye with excitation ideally  
suited for the  excited at 633nm / 635nm; maximum emission of 668 nm. PI is yellow-
fluorescent dye with excitation ideally suited to the excitation 540 nm; emission 
608 nm laser line.  
 
Sample preparation 
Cells were trypsinised as in section (2.3.1), washed 1 x by centrifugation in annexin V 
binding buffer and resuspended at 1x105 cells  in  100-µl of annexin V binding buffer 
in a 1.5-ml Eppendorf tube.  5 µl Alexa Fluor® 647-annexin V and 10 µl PI were added 
and cells were incubated for 15 min in the dark at room temperature. Finally, the 
volume was adjusted to 500 µl with 1x binding buffer and analysed by flow cytometry 



















Figure 2.4. Representative plot of cell viability o f SKov3 ovarian cancer cells 
assessed by flow cytometry following dual staining with annexin V (Ann V) and 
propidium iodide (PI).  Cells were trypsinised, washed 1 x by centrifugation in annexin 
V binding buffer and resuspended at 1x105 cells in 100-µl of annexin V binding buffer 
in a 1.5-ml Eppendorf tube.  5 µl Alexa Fluor® 647-annexin V and 10 µl PI were added 
and cells were incubated for 15 min in the dark at room temperature and analysed by 
flow cytometry immediately. Data are presented as percentage of the cell population 
and interpreted showing the possible combinations of positive and negative staining 
for two different dyes as follows: annexin V-ve/PI-ve cells (lower left quadrant) are 
considered healthy cells, AnnV+ve/PI-ve cells (lower right quadrant) are considered 
early apoptosis, AnnV+ve/PI+ve (upper right quadrant) are considered late apoptosis, 






In some experiments extracellular CRT was also assessed. Cells were treated as 
above to label annexin V and PI, resuspended in 1 ml PBS containing 0.5% w/v BSA 
and immediately incubated with rabbit anti-human-CRT Ab (1:200) for 1 h, followed by 
further washing x 3 and then stained with a 1:2000 dilution of a secondary antibody - 
goat anti-rabbit IgG in the dark for 30 minutes at room temperature. Finally, the volume 
was adjusted to 500 µl with 1x binding buffer and analysed by flow cytometry 




2.5.1. CRT ELISA  
An enzyme-linked immunosorbent assay (ELISA) was used to quantity the CRT 
protein in cell culture media (Donnelly et al., 2006). Briefly, 153 µl of cell-free 
supernatant fraction was placed into wells of a 96-well ELISA plate with 17 µl of 10x 
carbonate buffer, pH 9.6 (section 2.2.). The protein was left to bind at 4°C overnight. 
The plates were then washed four times with PBS containing 0.1% v/v Tween 20 
(PBST). Remaining binding sites were blocked with 5% (w/v) BSA in PBST at 37oC for 
30 minutes. Wells were washed a further four times with PBST. Next 100µl of 1:2000 
dilution of rabbit anti-human CRT antibody (PA3-900) diluted in PBST was added to 
each well for 2 hours in 37°C. The wells were washed again as described above, and 
a 100 µl of 1:2000 dilution of secondary anti-rabbit HRP-conjugated antibody was 
added to the wells and the plate incubated for 1 hour at 37°C. The reaction was 
developed for 15 minutes at room temperature in the dark and was terminated by 
adding 50 µl 2N H2SO4 to each well. The optical density at 450 nm (OD45nm) of each 
sample was measure on a BMG Labtech FLUROstar™ plate reader and protein 
concentration estimated from a standard. A standard curve of known concentration of 
CRT yeast (Pichia pastoris) was constructed each time the ELISA was performed. A 






Figure 2.5. CRT ELISA standard curve.  Standards of CRT at a known concentration 
(0.05 µg/ml -3.2 µg/ml) generated from a 2.5 µg/ml CRT stock serially diluted with 
binding buffer were assessed by ELISA (see Methods – section 2.5.1) and the data 
plotted as concentration vs OD450nm to provide a reference for calculation of CRT 












2.5.2. ELISA for IL-12/IL-23p40 
IL-12/IL-23p40, levels were determined in cell culture supernatants using enzyme-
linked immunosorbent assay (ELISA) kits according to the manufacturer’s instructions. 
IL-12 is secreted by activated B lymphocytes and macrophages as a 70 kD 
heterodimeric glycoprotein comprised of disulfide-bonded 35 kD and 40 kD subunits. 
IL-23 is a heterodimeric cytokine composed of two disulfide-linked subunits, a p19 
subunit that is unique to IL-23, and a p40 subunit that is shared with IL-12. IL-23 is 
secreted by activated macrophages and dendritic cells. The antibodies in the Human 
IL-12/IL-23 (p40) ELISA MAXTM set react with the p40 subunit of human IL-12 and 
IL-23, as monomer and homodimer. 
An anti-human IL-12/IL-23 p40 capture antibody was added to wells of a 96-well plate. 
The plate was sealed and incubated overnight (16-18 hrs) at 4°C. The plate was 
washed 4 times with at least 300 µL wash buffer per well and the residual buffer was 
removed by firmly tapping the plate upside down on absorbent paper. Assay volume 
diluent was added to each well to block non-specific binding, the plate sealed and 
incubated at room temperature for 1 hour with shaking at 200 rpm on a plate shaker.  
The plate was washed plate 4 times as above and 100 µL/well of standards or samples 
added to the appropriate wells, the plate sealed and incubated at room temperature 
for 2 hours with shaking. After washing 4 times as above, 100 µL of diluted biotinylated 
detection antibody solution was added to each well, the plate was sealed and 
incubated at room temperature for 1 hour with shaking.  100 µL of diluted avidin-HRP 
solution was added to each well, the plate sealed and incubated at room temperature 
for 30 minutes with shaking. The avidin-HRP solution was removed during a wash 
step, and 100 µL of freshly mixed TMB substrate solution was added and incubated 
in the dark for 15 minutes and 100 µL of stop solution added. Absorbance was read at 











2.6. Determination of protein concentration  
The bicinchoninic acid (BCA) assay (Thermo Fisher, Cramlington, UK) was used to 
determine protein concentration in a solution. The working range of the assay is 25-
2000 µg/mL. The BCA assay uses the Biuret reaction (reduction of copper (II) to 
copper oxide (I), in alkali conditions, by the peptide bond), which is then followed by 
the formation of a complex between copper oxide (I) and BCA which has  an 
absorbance maximum at 562 nm (Smith et al., 1985). BSA was used to make a 6 point 
standard curve with a range of 25-2000 µg/mL. Clear, flat bottom, 96-well microtiter 
plates were used and 25 µl of the sample/standard was mixed with 200 µl of BCA 
reagent. Each sample standard was measured in triplicate. The plate was covered 
and incubated at 37°C for 30 minutes before measuring the absorbance on a Fluostar 
Optima plate reader (BMG Labtech, Ortenberg, Germany), with a 550 excitation filter. 
Calculated concentrations (from the standard curve) were then multiplied by the 
relevant dilution factor to give a final concentration. A typical standard curve from this 





































                                    
Figure 2.6. BCA assay standard curve. Standards of bovine serum albumin (BSA) 
at a range of 25 – 2500 µg/ml of known concentrations were assessed using the BCA 
protein assay and the data plotted as concentration vs OD550 nm to provide a 
reference for calculation of protein levels in tested samples. 25 µl of the protein 
standards (diluted in H2O) was incubated with 200 µl BCA reagent at 37°C for 30 
minutes before measuring the absorbance on a Fluostar Optima plate reader, with a 










2.7. SDS-PAGE (sodium dodecyl sulfate polyacrylamid e gel electrophoresis) 
and western blotting.  
SDS-PAGE can be used to separate proteins in a sample by mass. Protein samples 
were denatured by addition of Laemmli buffer and heating. Laemmli buffer contains 
SDS and a reducing agent. SDS is both denaturing and an ionic detergent that binds 
evenly to proteins in a mixture giving them all an equivalent negative charge and 
allowing separation by mass only in the gel. DTT was used as a reducing agent; 
breaking the disulphide bonds so that proteins were no longer in their tertiary or 
quaternary structures. Samples then underwent electrophoresis; this process uses a 
positive charge to draw the proteins through the pores in the polyacrylamide gel. A 
12% acrylamide gel was used as this has a small pore size.  
 
2.7.1. SDS PAGE to determine protein molecular weig ht under reducing 
conditions. 
7.5µl of 3x Laemmli buffer (with DTT to give a final concentration of 350 mM) was 
added to 15 µL of each protein sample, boiled for 5 min at 95oC and resolved by SDS-
PAGE using a 12 %, 15µl/well gradient gel immersed in running buffer (25 mM Tris, 
192 mM Glycine pH 8.3). Samples were electrophoresed at constant voltage of 75 V 
for 20 min and 100 V for 45 minutes.  The gel was then removed and washed twice 
with ddH2O and stained with Bio-safe Coomassie Blue G-250 stain on a low speed 
orbital shaker for about an hour. The gel was then washed with ddH2O water then left 
to de-stain in ddH2O overnight.   
 
2.7.2 Western blotting for CRT 
Western blotting is a widely used method to identify the presence and relevant 
abundance of a specific protein (using specific antibodies) in a sample following the 
transfer of proteins from the SDS-PAGE gel to a membrane. This technique was 
described and named by (Burnette, 1981) and the main principles of the procedure 






Transfer from the SDS-PAGE gel to a nitrocellulose (0.45 µm) membrane was 
performed using the ‘wet’ tank electro transfer method. The gel was carefully removed 
from the running operation. After trimming off the top and bottom the gel was then 
placed on the top of membrane in a Trans-blot® Turbo™blotting system (Bio-Rad). A 
roller was used to remove bubbles and enhance transfer. The transfer was completed 
in seven minutes, and the membrane processed to identify the proteins.    
 
 
Blocking the membrane  
The nitrocellulose membrane has a high affinity for protein and therefore would bind 
the antibodies non-specifically if not ‘blocked’ first. Pierce protein free blocking buffer 
was used, rather than the common BSA blocking solution, as nitrated tyrosine could 
be expected to be present in albumin. This step was performed for one hour at 4°C 
with gentle rocking. 
 
Antibody incubation.  
After blocking the membranes were probed with primary antibodies as indicated, 
washed and incubated at room temperature in the dark for 1 h with secondary 
antibodies conjugated to fluorophores that emit in near-infrared, wavelengths (680 and 
800 nm). These fluorophores produce a signal directly proportional to the antigen and 
are stable over time. 2.9.3.4. Protein bands were imaged using the LiCor Odyssey CLx 
system (LI-COR Biosciences UK Ltd Cambridge, UK), this platform has an infrared 
laser for excitation. The Image Studio Lite (LI-COR Biosciences UK Ltd Cambridge, 
UK) software was then used to analyse the images. This software allows for the image 
to be edited (e.g. cropped, flipped, brightened) without changing the actual signal 











In recent years knowledge of  the functional complexity of CRT has expanded, 
resulting in CRT being implicated in many aspects of normal physiological and 
pathological cell function, including important roles in health, disease, and the 
regulation of cell death (Eggleton and Michalak, 2013). As previously mentioned CRT 
is a 46 KDa protein with   three defined regions; the amino and carboxy regions make 
up the N-C globular domain and the middle segment is the comprised of the proline-
rich P-domain rich. The N-C globular domain of CRT contains eight antiparallel β-
strands (Michalak et al., 2002). It interacts with α-integrins (Rojiani et al., 1991) and 
the DNA-binding site of the steroid receptor. Cysteine residues form the disulfide bond 
in the N-domain and the N-and P-domains are reported to have an important role in 
the chaperone function of CRT (Figure 3.1) (Krause and Michalak, 1997, Martin et al., 
2006).  The P-domain has three repetitive regions (Krause and Michalak, 1997) with  
repeated amino acid sequences and is thought to contribute to the protein-protein 
binding functions of CRT. The P-domain of CRT also has two Ca2+-binding sites (high-
affinity, low-capacity) (Tjoelker et al., 1994) and acts as a bridge to the co-receptor on 
phagocytic cells (Chouquet et al., 2011). The Carboxy terminal region of CRT contains 
a highly acidic, negatively charged segment which is important for Ca2+- buffering 
functions (Nakamura et al., 2001). This region  interacts with other chaperone proteins 
in the ER (Michalak et al., 1999).  Additionally, there is considerable evidence indicated 
that the Carboxyl region of CRT has a critical role in re-translocation of CRT from the 
ER lumen to the cytosol, a process that can be  triggered by ER Ca2+  becoming 
depleted (Labriola et al., 2010). The globular -domain of CRT interacts with PS on the 
cell surface of apoptotic cells (Chouquet et al., 2011).   
 
The increasing recognition of CRT as a multifunctional protein has led to a requirement 
for purified CRT for experimental purposes.  Thus, recombinant human CRT (rCRT) 
preparations have now been produced using a wide range of expression systems 
including bacteria and yeasts (Pandya et al., 2019). The CRT obtained can then be 
further purified using  techniques, such as FPLC, which separate the protein from 




negatively charged. However, it has emerged that CRT purified in this way from 
bacterial expression systems can be complexed with lipopolysaccharides (LPS or 
endotoxin) (Pockley et al., 2008).   LPS is the most predominant lipid on the outer layer 
of Gram-negative bacteria, such as E.coli, and it is capable of triggering cellular 
immune responses including phagocytosis and cytokine release (Kelley et al., 2013). 
LPS is composed of three major portions; a lipid A portion which is responsible for its 
virulence and two polysaccharide components O and R  (Todar, 2018).  It has been 
reported that LPS-free CRT induced the expression of cell surface maturation markers 
and cytokine release by dendritic cells via NFkB signalling (Bajor et al., 2011). In 
contrast, LPS-free CRT in other studies was shown to prevent upregulation of dendritic 
cell surface activation markers, such as MHCII and CD86, and pro-inflammatory 
cytokine production (Bak et al., 2008). These contrasting results may be due to 
incomplete removal of LPS from the CRT preparations used, highlighting that it is 
sometimes difficult to distinguish the cellular effects of the CRT from the LPS.  Thus, 
it is clearly important to ensure that the CRT preparations used for experimentation 
are LPS free. However, this is technically very difficult to achieve completely.  
 
This chapter describes the preparation of purified full length human rCRT expressed 
in both the bacterium E. coli and the yeast Pichia pastoris (as previously described; 
(Andrin et al., 2000, Baksh and Michalak, 1991) CRT from both sources was received 
from collaborators or commercial sources and subsequently further purified to remove 
any impurities) by FPLC using anion exchange (Mono Q) chromatography (Tarr et al., 
2010a). Since recombinant forms of CRT at high concentrations in solution can form 
monomers, dimers and multimers which might influence the ability of CRT to bind to 
cells, monomeric CRT was subsequently purified using size exclusion 
chromatography. Additionally the CRT preparation from E Coli was treated using the 
antibiotic polymyxin B to neutralise LPS activity (Domingues et al., 2012).  Since the 
CRT from Pichia pastoris was expressed in yeast this preparation was not treated with 








3.2. Aims of this chapter:  
 
• To purify monomeric CRT expressed in both E. coli and Pichia pastoris using 
anion exchange chromatography followed by size exclusion chromatography 
(Figure 3.2). 
• To investigate the purity, size and complexity of rCRT in terms of aggregates. 



















Figure 3.1. A schematic diagram of calreticulin;  (A) The N-domain of CRT has a 
signal sequence peptide that is cleaved off to allow the protein to be retained in the 
endoplasmic reticulum; the C-terminal has a KDEL ER retrieval signal, calcium storage 
(buffering) domain and is highly acidic and negatively charged. This region interacts 
with other chaperons in the ER, and it has an important role in re-translocation of CRT 
from ER to the cytosol and interacts with PS on the apoptotic cells. The P–terminal is 
the ERp57 binding region. (B) A schematic of the 3D structure of CRT N, P and C 


























Figure 3.2. Summary of CRT purification steps. B oth bacterial (Esherichia. coli) 
and yeast (Pichia pastoris) pellets expressing human full-length CRT were lysed and 
the soluble lysates containing CRT were further purified using FPLC (fast protein liquid 
chromatography).   As CRT is highly negatively charged (pI 4.6) at pH 8.0, initial 
purification used an anion exchange Mono Q column.  All eluted fractions were 
examined for purity on SDS-PAGE under reducing conditions. MonoQ fractions 
containing CRT were collected and subjected to size exclusion chromatography to 
estimate the molecular weight of CRT and the complexity of the purified protein in 
terms of aggregates of recombinant CRT. A Superdex200™ gel filtration column was 
used with molecular weight standards to calibrate the column (range 2 million Daltons 






3.3.1. Source of CRT  
Human full length CRT was obtained from the following sources: (i) expressed in 
Pichia pastoris and a gift from Dr Evaldas Ciplys and Dr Rimantas Slibinskas (Vilnius 
University, Lithuania) (Ciplys et al., 2015) (Nagata et al., 2016) cloned into the pBAD 
plasmid vector, expressed, and purified from E. coli BL21 (DE3), as previously 
described (Baksh et al., 1992) and purchased from Intas Pharmaceuticals Ltd. 
(Ahmedabad, India) . All CRT was prepared and stored in CRT buffer (0.01 M Tris, 3 
mM Ca, pH 7.6). Further purification of CRT was carried out as described (Pandya et 
al., 2019)  
 
3.3.2. Ion exchange chromatography (Mono Q) 
 
Both recombinant CRT preparations were further purified using anion exchange 
chromatography which depends upon the reversible adsorption of negatively charged 
solute molecules to an immobilised group of opposite charge. Briefly, 100 µg human 
rCRT was suspended in 400 µl of Buffer A (50 mM Tris-HCl, 50 mM NaCl, 0.005M K-
EDTA) and injected onto an  AKTA MonoQ (Q-Sepharose) HR 5/5 anion exchange 
column and the sample was subjected to gradient elution with Buffer A and Buffer B 
(50 mM Tris-HCl, 1.0 M NaCl, 0.005M K-EDTA). The experiments were performed in 















Table 3.1. Preparation of MonoQ buffer A, pH 8  
Reagent Quantity (1 l) 

















Table 3.2. Preparation of MonoQ  buffer B, pH 8  
 
Reagent Quantity (1 l) 
50 mM Tris-HCl  7.88 g  




5 mM K·EDTA 
2.02 g 
 








3.3.3. MonoQ column cleaning and equilibration  
To ensure the anion exchange column was clean and sterile, it was routinely flushed 
with filter sterilized water and ethanol. In addition the column was run in the reverse 
direction of flow during column cleaning so that any contaminants accumulating near 
the top of the column do not pass through the entire length of the column. 
Flow: 0.5 ml/min at room temperature 
1. Column was washed with: 2 column volumes (CV) of 2 M NaCl; 4 CV of 1 M NaOH; 
at least 2 CV of 2 M NaCl. 
2. The column was then rinsed with at least 2 CV of distilled water until the eluent pH 
was stable and then washed with at least 4 CV of start buffer or storage buffer until pH 
and conductivity values reached stability. Routinely the column was clean with 70% 
ethanol and stored in 20% ethanol prepared in sterile filtered H20. 
 
3.3.4. Mono-Q sample application  
Aliquots of 100 µl of 1 mg/ml CRT was taken and mixed with 400 µl of buffer A.  The 
500 µl sample was then injected (using a 10 ml injection loop onto the AKTA FPLC 
loaded with a MonoQ HR 5/5 anion exchange column, using a pre-written Programme 
'MonoQ2015'. This procedure ran for approximately 38 min and 0.5 ml fractions were 
collected from the eluted proteins peaks from 25-50 mls.  
Unbound sample was eluted over 3 CV, then a linear gradient of Buffer B (0-1 M NaCl) 
was introduced (prepared using Buffer A and Buffer B in the AKTA pumps A and B 
respectively) and the protein fractions collected. The column was then washed with 
100 % buffer B then re-equilibrated in buffer A. Fractions were monitored for protein 
concentration by optical density at 280 nm and for salt concentration using 
conductivity. Fractions containing protein which eluted from the column at a salt 
gradient of 150 – 400 mM as this was the conductivity that we had previously shown 
was optimum for CRT elution (ref - Purification, isolation and characterization of 





3.3.5. SDS PAGE to determine MW of eluted proteins under reducing conditions 
SDS-PAGE was performed as described in Chapter 2 section (2.10.1).  
 
3.3.6. Gel Filtration of recombinant CRT 
To ensure preparation of high quality calreticulin relevant fractions were further purified 
by size exclusion chromatography to determine the size of the protein aggregations 
and to obtain monomeric CRT. The multimeric status and molecular weight of both the 
E.coli-and Pichia pastoris- expressed CRT were examined using size exclusion 
chromatography to assess aggregates of recombinant CRT (using a Superdex200™ 
gel filtration column).  
Commercial molecular weight standards (Sigma were individually applied (200 µl via 
the injection loop) to calibrate the column and allow accurate determination of the 
precise molecular weight of CRT. 
Specifically; 
I. Carbonic Anhydrase (bovine erythrocytes) MW = 29 kDa 
II.        Albumin (bovine serum) MW= 66 kDa 
II. Alcohol Dehydrogenase (yeast) MW= 150 kDa 
III. Beta-amylase (sweet potato) MW=200 kDa 
IV. Apoferrin (horse spleen) MW=443 kDa 
V. Blue dextran MW= 2000 kDa 
50 µl of CRT plus 250 µl of PBS was then chromatographed by size exclusion using 
a Superdex-200 pre-packed commercial column 10/300 GL at a flow rate of 1 ml/min 
on an AKTA FPLC system (separation capacity between 600 kDa to 10 kDa). 0.2ml 
fractions were collected and the progress of the protein through the column was 





3.3.7. Treatment of E -Coli expressed CRT monomeric protein fractions (from 
Mono Q) with polymyxin B (PMB) 
1.  PMB stock was prepared at 1mg/ml in sterile endotoxin-free PBS and 
subsequently diluted 1/100 in Tris buffered saline (2.2.1.). 
2. 4 volumes of PBS was added to the combined fractions containing the E Coli CRT 
protein peak collected at lower salt concentrations  (monomeric CRT). 
3. A buffer exchange procedure was performed on the CRT by spinning the protein 
though a 50,000 KDa cut off centrifugal separation unit (Amicon) spun at 3000 x g 
for 30 minutes at 4oC.    
4.  The waste buffer in the lower reservoir was discarded and the protein 
resuspended in PMB in TBS prepared as in 1 above.  
5. The treated protein sample was then washed using the steps described in 3 with 4 
times with fresh TBS. 
6. The final protein was resuspended in TBS and  
7. 5 µl was removed to determine the protein concentration using NanoDrop 






















3.4.1. CRT elutes in two separate peaks using anion  chromatography  
CRT has an isolectric point (pI)  of ~4.6  with a net negative charge at pH 8.0, so an 
anion exchange Mono Q column was initially used to separate it from any impurities 
(Eggleton et al., 2016). A pure single peak of rCRT eluted from the column at 240 mM 
NaCl in proteinexpressed in both E Coli and Pichia pastoris. A second minor protein 
peak eluting at a higher salt concentrations (>300 mM NaCl) was observed in E. coli 
CRT preparations, but this was less pronounced in Pichia pastoris rCRT (Figure 3.3). 
All fractions containing protein from these two major peaks were collected and 























Figure 3.3. Mono Q chromatographic analysis of huma n rCRT from E coli and 
Pichia pastoris.  A) E -Coli expressed human rCRT was routinely separated by anion 
exchange chromatography and eluted from the column with a 0-1 M NaCl buffer 
gradient rCRT consistently eluted with 240 mM NaCl (as depicted by arrow) as 
expected.  A second protein peak eluted with at >300 mM NaCl. The red line shows 
the conductivity (concentration of NaCl) and the blue line shows the optical density 
(OD280 nm, concentration of protein). B) Pichia pastoris expressed human rCRT also 
eluted as one major protein peak in the presence of 240 mM NaCl (as assessed 
monitored at OD280nm). C) Comparison of the Mono Q chromatograph for human 
CRT isolated from Pichia pastoris and E-coli expression systems. Note the extra 
higher negatively charged protein contaminants eluting from the E. coli expressed 
system. A and B show representative chromatograms from a single FPLC run; C 




3.4.2. SDS PAGE to determine MW under reducing cond itions   
Mono Q fractions containing both CRT protein peaks from E Coli were examined for 
protein purity using SDS PAGE and Coomassie blue staining. It can be seen from 
(Figure 3.4) that a single protein band at a molecular weight of approx. 55-58 KDa was 
observed in all fractions tested. This corresponded to the reported relative molecular 
weight of CRT on SDS PAGE (Figure 3.4). 
 
3.4.3. Gel filtration of recombinant CRT   
Figure 4 clearly shows that the only protein detected in all fractions collected was CRT. 
It has been demonstrated that recombinant forms of CRT can form monomers, dimers 
and multimers (Pandya et al., 2019). This raised the possibility that these complexes 
may be responsible for the additional CRT peak that eluted at higher salt 
concentrations (Andrin et al., 2000).   CRT aggregates with greater overall negative 
charge might require a greater salt concentration to elute from the anion exchange 
column.   CRT does have the propensity to form complexes that might influence the 
ability of CRT to bind to cells (Andrin et al., 2000) and so the CRT was further purified 
by size exclusion chromatography to both confirm this hypothesis and to obtain pure 
monomeric CRT. 
 
Size exclusion chromatography was performed using a Sephadex 200 column 
following calibration of the column using a number of proteins of known molecular 
weight between 20 to >2million KDa. Their approximate elution positions are shown in 
Figure 3.5. It can be seen that E Coli CRT shows two protein peaks on gel filtration, 
one at ~ 120 kDa and another  at a very high molecular weight (<669 KDa (Figure 3.5 
B) which is many times the reported molecular mass of CRT (approx. 48 KDa), 
suggesting the presence of protein aggregates.  In comparison, Pichia pastoris CRT 
(‘Lith-CRT’) ran on gel filtration showed a single peak with a molecular weight of 
approximately 120 kDa (Figure 3.5 A). CRT is comprised of a globular head and 
elongated hair-pinned looped P-domain. It is known to characteristically run as a 120 
kDa specieis due to retardation in its migration through gel filtration columns in 
solution, due to its comma shaped appearance ( ref as a above:((Young et al., 2006)) 



















Figure 3.4. E Coli CRT detected by SDS PAGE in fractions collected fo llowing 
Mono Q chromatography (both panels).   Protein fractions from both protein peaks 
were collected, concentrated were mixed with sample buffer, heated and analysed 
using a 12% SDS-PAGE gel under reducing conditions.  Separated proteins were 
stained with Coomassie Brilliant Blue. A single protein band of similar relative 
























Figure 3.5. Size exclusion chromatography of (A) Pi chia expressed and (B) E.coli 
expressed human calreticulin.  Gel filtration of CRT-containing fractions (collected 
following anion exchange and eluted with 240 mM NaCl) was performed using a 
Superdex 200 column to determine the precise molecular weight of CRT. Calibration 
of the column was performed with number of molecular weight species from >2million 
Daltons to 20 KDa their approximate position is shown. Pichia expressed CRT (A, 
dotted lines) eluted as a single peak whereas E-Coli CRT (B, dotted line) eluted in 
multiple peaks suggesting  the E.coli purified protein was comprised of a number of a 





3.5. Discussion  
In this study human rCRT was received from two sources and expressed in either E 
coli or Pichia pastoris.  Since CRT is highly negatively charged (pI 4.6) to ensure a 
pure preparation for future studies CRT was initially purified from any impurities by 
FPLC using a Mono Q HR 5/5 anion exchange column as previously described (Tarr 
et al., 2010a). For rCRT expressed in E coli two clear peaks of protein eluting at 
approximately at 240 mM NaCl and 300 mM NaCl salt concentration were observed.  
These data agree with those published in the literature (Pandya et al., 2019) and it has 
been hypothesised that the peak eluting at the high salt concentrations is CRT present 
in the form of multimers. Indeed recombinant forms of CRT can form monomers, 
dimers and multimers (Andrin et al., 2000). This was supported here by the 
observation that SDS-PAGE confirmed the presence of only one protein, with a 
molecular weight equivalent to that reported for CRT (approx. 55 KDa) in all fractions 
collected (Baksh et al., 1992). In contrast to the E coli expressed CRT, anion exchange 
analysis of Pichia pastoris showed only one peak (at 240 mM NaCl salt), suggesting 
that CRT expressed in this system was less prone to  forming multimers.  
Therefore, for all further studies Pichia pastoris expressed CRT was used.  The 
observation that it did not form multimers a) suggests that it is folded correctly and 
does not form aggregates and b) as a monomer it is easier to interpret binding 
interactions with cells as it is not a complex of unknown size. Additionally, since it is 
not expressed in a bacterium LPS contamination was not considered to be an issue.  
Finally, Pichia pastoris CRT was shown to be stable in a 20 mM Tris base and 5mM 
Na-EDTA over 24 hours (Figure 5A). 
Since this work was carried out further investigation suggested that even the Pichia 
pastoris CRT preparation contained very low levels of LPS, perhaps due to 










In this study, purification of rCRT expressed in E coli and Pichia pastoris was 
performed by anion exchange and gel filtration chromatography. Due to its non-
bacterial source and the observation that it did not form multimers Pichia pastoris was 
used for all further experiments in this thesis. The E coli rCRT was sent to collaborators 







Chapter 4.  An investigation into the conditions re quired for ovarian cancer cell 
surface association with either endogenous or exoge nous CRT calreticulin  
Although CRT is mainly an ER chaperone protein, as discussed in the Introduction, 
cell surface-associated CRT is now recognized as an important DAMP molecule, 
identifying distressed cells to local immune cells. As such CRT promotes the 
immunogenicity of early apoptotic cancer cells and boosts adaptive immunity in the 
process of ICD. Cell surface CRT acts as an “eat-me” signal, enhancing phagocytic 
uptake of cancer cells (Gardai et al., 2005) by blocking the ability of the CD47 ('don't-
eat-me' signal) to bind to its ligand SIRP-α (Krysko et al., 2018). Additionally, CRT has 
binding partners on immune cells that trigger innate immunity such as complement 
C1q (Donnelly et al., 2006, Verneret et al., 2014).  In this case cell surface exposed 
CRT enhances complement-mediated phagocytosis of cells. These functional 
characteristics have increased the interest in surface expressed CRT in cancer 
immunology in recent years and it has been observed to have an anti-tumour role 
(Martins et al., 2010). Cell associated levels of CRT can be increased by either adding 
exogenous CRT or by inducing translocation of intracellular CRT to the cell surface.  
This chapter describes studies which examined strategies to increase ovarian cancer 
cell surface CRT from both sources.  
 
 
Chapter 4a. Examination of the conditions required for binding of exogenous 
calreticulin to ovarian cancer cells.  
4a.1. Introduction .  
Recent studies at the messenger RNA level suggest that lack of CRT expression 
correlated with lower cytotoxic T cell infiltration into tumour sites in ovarian cancer 
patients, negatively impacting their survival (Stoll et al., 2016). This highlights the 
requirement for cancer cells to express surface CRT to maintain immune surveillance. 
It is possible that surface CRT levels could be enhanced by exogenous CRT.  
Extracellular CRT was first reported over a decade ago when it was detected in human 
plasma although its origins and function were unclear (Gardai et al., 2005, Sueyoshi 
et al., 1991). It has since been reported that exogenously added CRT can enhance 




photodynamic therapy in a mouse squamous cell carcinoma  model (Korbelik et al., 
2015) and cytotoxic T-lymphocyte lysis of various irradiated human carcinoma cells 
(Bernstein et al., 2014). However, there is no available data on whether exogenous 
CRT interacts with ovarian cancer cells either under resting conditions or in cells 
treated with cytotoxic therapies. Determination of this would allow an insight into 
whether exogenous CRT could be used therapeutically to enhance immune mediated 
death of ovarian cancer cells induced by these traditional therapies. 
 
As previously discussed in the Introduction, doxorubicin is an anthracycline 
chemotherapy widely used to treat ovarian cancer.  Doxorubicin is known to induce 
ER stress and early apoptosis initiate ICD in some cell types (Panaretakis et al., 2009).  
However, doxorubicin is relatively toxic and is known to cause DNA damage, oxidative 
stress and cell death (Thorn et al., 2011). If the immunogenicity of cancer cells treated 
with doxorubicin could be enhanced by binding of exogenous CRT this may increase 
the efficiency of lower doses of doxorubicin to induce ICD, reducing off target toxicity.   
Thapsigargin can be used experimentally to induce ER stress by inhibiting SERCA1 
which in turn decreases ER calcium levels. This form of ER-stress leads to changes 
in the activity of chaperones, including CRT and accumulation of unfolded proteins 
(Peters and Raghavan, 2011), resulting in CRT translocation to the cell surface.  Both 
doxorubicin and thapsigargin were used here to induce ER stress in ovarian cancer 
cells. Additionally the impact of co-treatment with TUDCA, a chemical chaperone that 
inhibits ER stress, reducing the unfolded protein response (Ozcan et al., 2006) was 
studied. 
Chapter 3 demonstrated the purification of monomeric CRT from Pichia pastoris. This 
CRT preparation was used here to examine the binding of exogenous CRT to OVcar3 
SKOV3, A2780 and FaDu cancer cells in both untreated conditions and conditions of 
ER stress and cell death induced by doxorubicin and thapsigargin. The impact of 
preventing ER stress with TUDCA was also examined to further understand the 






4a.2. Aim  
The aims of this chapter were to determine whether extracellular CRT binds directly 
to ovarian cancer cells, potentially identifying these cells for immune-mediated 
eradication. 
The specific objectives were: 
1. To examine whether extracellular CRT was able to bind to ovarian cancer cells 
under normal and stress conditions induced by doxorubicin and thapsigargin. 
2. To examine whether exogenous CRT preferentially bound to ovarian cancer 
cells in certain stages of cell death 
3. To examine whether TUDCA was able to inhibit doxorubicin and/or thapsigargin 
induced extracellular CRT binding to ovarian cancer cells. 
 
4a.3. Methods 
The ability of fluorescently labelled extracellular CRT, human serum albumin  (Positive 
control) (Nakamura et al., 2001), and IgG (negative control) to bind cancer cells under 
resting and drug-treatment conditions was analysed in a panel of ovarian cancer cell 
lines (SKov3/OVcar3/A2780) and a1 pharyngeal cancer cell line for comparison 
(FaDu).  Cells were treated with different concentrations of the above proteins and 
analysed by flow cytometry and immunofluorescence microscopy. FITC and HSA were 
conjugated to fluorescein isothiocyanate (FITC) for detection. Commercially 
purchased IgG−FITC from human serum was used as a negative control.  
 
4a.3.1. Conjugation of CRT or HSA with FITC. 
CRT and HSA were conjugated to FITC according to the manufacturer’s instructions. 
Briefly, a 54 µM solution of CRT or HSA in 200 µl of conjugation buffer (0.1 M sodium 
carbonate buffer - pH 9.0) was incubated with 50 µl of 0.5 mg/ml (128 µM) FITC 
solution in conjugation buffer for 2 hours at room temperature in the dark. The resulting 
FITC-protein was separated from free FITC and buffer exchanged into PBS (pH 7.4) 




purifier (GE Healthcare). Elution of the FITC-conjugated protein was followed by 
measuring absorbance at 280nm (https://www.thermofisher.com/uk/en/home/life-
science/protein-biology/protein-assays-analysis/immunoprecipitation/magnets-
immunoprecipitation-co-ip-pull-down.html) and 495nm (FITC). 0.2 ml fractions were 
collected and fractions containing the conjugated protein (approx. 2 – 6) were collected 
and pooled.  Protein concentration was determined by Nano-drop spectroscopy and 
adjusted to 0.5 mg /ml. 










C is a constant value given for a particular protein 
MW is the molecular weight of the protein HSA = 66500  
MW is the molecular weight of the protein CRT= 46000 
389 is the molecular weight of FITC 
195 is the absorption E0.1% of bound FITC at 490 nm at pH 13.0 
(0.35 X A495) is the correction factor due to the absorbance of FITC at 280 nm 
E0.1% is the absorption at 280 nm of a protein HSA at 1.0 mg/ml. 
E0.1% is the absorption at 280 nm of a protein CRT at 1.0 mg/ml. 
 
The prepared FITC-CRT had a F/P ratio of 2.1  






4a.3.2. Culture of cancer cells 
OVcar3, SKov3, A2780 cells and FaDu cells (all adherent cell lines) were cultured as 
described in Chapter 2. Binding of FITC labelled proteins was assessed by flow 
cytometry or immunocytochemistry as described.  
 
4a.3.3. Exogenous CRT binding to ovarian cancer cel ls assessed by flow 
cytometry. 
Cells were trypsinised, resuspended in 1ml growth media and counted in a 
haemocytometer. 4 x 106 cells/ml were resuspended in 500µl of Tris buffered saline 
with 5mM CaCl2.  Different concentrations from 1-8µg/ml of FITC labelled protein were 
added to different tubes i.e. CRT-FITC, HSA-FITC and IgG –FITC. All treatments were 
incubated for 30 minutes in the dark at room temperature and analysed by flow 
cytometry to determine binding of FITC proteins to the cell surface (Figure 4a.1).   
  
 
4a.3.4. Staining for cell morphology  
100 µl of 4x106 cell suspension was prepared on a slide using a cytospin. The slides 
were then fixed with 4% (w/v) paraformaldehyde for 10 minutes followed by a Diffquik 
stain i.e. the slide was fixed  was fixed in methanol for 10 seconds, stained with eosin 
G for 10 seconds, followed by staining with methylene blue dye for 10 seconds. The 
slides were washed and then imaged via light microscopy. 
 
 
4a.3.5. immunofluorescent cell staining  
The FITC labelled cell population was also examined by fluorescence microscopy. 
Cells were prepared as above using a cytospin and fixed with fixed with 4% (w/v) 
paraformaldehyde for 10 minutes. Cells were mounted in gold anti-fade reagent 
containing the nuclear stain DAPI and imaged using a LEICA DM4000 fluorescent 















Figure 4a.1. An example of the experimental set up of the CRT binding (in this 
case to OVcar3 cells).   Ovarian cancer cells were resuspended in 1 ml media and 
counted in a haemocytometer.  4 X 106 cells were mixed with increasing 
concentrations (from 1-8µg/ml) of FITC labelled protein i.e. CRT-FITC, HSA-FITC and 
IgG–FITC. All treatments were incubated for 30 minutes in the dark at room 
temperature and analysed by flow cytometry to determine binding of FITC proteins to 

























Figure 4a.2. Workflow figure showing methodology fo llowed for cells treated 
with labelled proteins and analysed by fluorescence  microscopy.  100 µl of 4 x 
106 cell suspension mixed with either FITC-CRT, HSA-FITC or IgG-FITC was 
subsequently plated onto a microscope slide using a cytospin centrifuge. Cell were 
fixed with 100 µl 4% (w/v) paraformaldehyde, washed, mounted in gold anti-fade 
reagent containing the nuclear stain DAPI and imaged using a LEICA DM4000 












4a.3.6. Treatment of cancer cells  
Doxorubicin was supplied as a lyophilized powder. Working concentrations and length 
of treatments varied depending on the desired effect.  Briefly, 1 × 105 cancer cells 
were seeded onto chamber slides (for microscopy) or into each well of a 6-well plate 
(for flow cytometry) and grown to 80% confluence in complete media. Cells were then  
treated with: 0.25, 6.3, 12.5 and 25 µM; 0.2, 0.5 µM thapsigargin ± 2.5 µM doxorubicin 
or 200, 400µM TUDCA ± 2.5µM doxorubicin or 0.2 µM thapsigargin as indicated. After 
16 h cells were stained for analysis using immunocytochemistry or flow cytometry as 
indicated.  A typical experimental scheme is shown in Figure 4a.3. 
 
 
Figure 4a.3. Experimental design of the studies exa mining CRT binding to 
cancer cells pre-treated with thapsigargin or doxor ubicin (DX).  Cancer cells were 
plated into each well of a 6-well plate and treated with varying concentrations of 
thapsigargin (0.2, 0.5 µM) in the absence or presence of 2.5 µM doxorubicin before 
being exposed to FITC-CRT for 30 minutes in the dark. The cells were then washed 
three times in PBS, trypsinised, placed in 1 ml annexin V binding buffer and co-stained 
with 5 µl Alexa Fluor® 647 Annexin V to monitor apoptosis and 10 µl propidium iodide-
Yellow  to assess necrosis. Finally, the volume was adjusted to 500 ul with 1x binding 




4a.3.7. Assessment of surface bound CRT on cells un dergoing apoptosis and 
necrosis. 
Cells were triple stained with FITC labelled protein and Alexa Fluor® 647 annexin V 
and PI to distinguish apoptotic and necrotic cells respectively.  
1. After treatment as above cells were harvested by EDTA-trypsin, pelleted by 
centrifugation at 1500 rpm for 5 minutes and resuspended in 1 ml of PBS.  
2. After counting by haemocytometer cells were double labelled with annexin V and 
PI. Specifically, 100-µl of cell suspension (containing 1x105 cells in total) was mixed 
with 5 µl annexin V-FITC and 10 µl PI.  
3. The cells were incubated for 15 min in the dark at room temperature. 400-µl 1x 
binding buffer was added and they were analysed by flow cytometry as described 
in the general methods section with FITC-conjugated protein F1 (green), ALEXA 
Fluorescent 647 annexin V (apoptosis) F2 (red), propidium iodide (necrosis) F3 
(yellow).   
4. The cells were initially gated using FSC-A and SSC-A to gate out any cell debris.  
5. Cells were then gated on the dot plot by their PI and annexin V staining to give four 
populations: annexin V-ve/PI-ve (lower left quadrant) were considered as living 
cells, annexin V+ve/PI-ve (lower right quadrant) were early apoptotic cells, annexin 
V+ve/PI+ve (upper right quadrant) were late apoptotic cells, and annexin 
V−ve/PI+ve (upper left quadrant) were necrotic cells. FITC signal e.g. bound FTC-
CRT was assessed on each of the four cell populations and could be expressed 
as mean fluorescence intensity (MFI). A high signal of the FITC fluorophore 
indicated high binding of CRT to cells (Figure 4a.4. Shows an example). 
 
4a.3.8. Immunocytochemistry  
Cells were plated onto coverslips and treated with doxorubicin, thapsigargin and 
TUDCA as indicated and then fixed with 4% (w/v) PFA in PBS for 30 minutes. Cells 
were then washed twice in PBS, and blocked in 2% (w/v) BSA for 20 minutes. Cells 
were exposed to FITC-CRT (2µg/ml) for 30 min at 37°C in the dark. Subsequently, 
cells were washed with PBS and liquid was removed from the coverslip by touching 
the corner on a paper towel. The slide was inverted on a drop of anti-fade Gold 
mounting media with the use of forceps. Cover slips were left for 20 min to dry and 




captured either on a Leica DM4000 B LED fluorescent microscope or Leica DMi8 TCS 





Figure 4a.4. Gating of Ovcar3 cancer cells treated with thapsigargin . OVcar3 cells 
were triple stained with FITC-conjugated protein F1 (green), ALEXA Fluorescent 647 
annexin V (apoptosis) F2 (red), propidium iodide (necrosis) F3 (yellow). The dot plots 
represent the gating out of cell debris using forward and side scatter and the 
percentage of the cell population detected as living cells, early apoptotic cells, late 
apoptotic cells, and necrotic cells. The histogram represents the mean fluorescence 
intensity of FITC-CRT binding to pre-apoptotic, apoptotic and necrotic OVcar3 cells 







4a.3.9. Data analysis 
 
The data sets obtained from individual experiments were averaged and their mean 
values were statistically analysed using the non-parametric Mann Whitney test or one-




Identification of CRT and cell surface association of extracellular CRT is almost 
exclusively performed by fluorescent-based assays such as flow cytometry or 
immunofluorescence staining of cells (Goicoechea et al., 2000). Therefore, CRT and 
a positive control protein HSA were conjugated to FITC and purified and concentrated 
by FLPC employing a Hi-trap desalting column.  The fractions containing the eluted 
FITC-conjugated protein were determined by monitoring at OD280nm and OD495nm 
and pooled for future use (Figure 4a.5). 
 
4a.4.1. Binding of CRT to cancer cells under non-st ress conditions. 
In order to examine variations in the ability of exogenous CRT to bind to various human 
cancer cells, a number of epithelial cancer cell lines were obtained from the 
supervisory team.  These were three ovarian cell lines (SKov3, OVcar3 and A2780) 
and a pharyngeal cancer cell line (FaDu), which was included for comparison. The 
morphological features of these cultured cells are shown in Figure 4a.6. 
4a.4.2. CRT-FITC binds to the surface of cancer cel ls as assessed by flow 
cytometry 
Initial studies were carried out to examine whether exogenous CRT could bind to the 
cell surface of otherwise untreated cancer cells. Cells were treated with different 
concentrations (1-µg - 8µg/ml) of FITC-CRT, the positive control FITC-HSA and the 













Figure 4a.5. Sample FPLC traces showing FITC-conjug ation to CRT and HSA.  
(A) FITC bound to calreticulin. (B) FITC bound to albumin. CRT and human serum 
albumin (HSA) were conjugated to fluorescein isothiocyanate (FITC) and purified and 
concentrated using FLPC employing a Hi-trap desalting column.  The eluted fractions 
were monitoring for FITC at OD495nm and protein at OD280nm. Note: the fractions 
containing the highest absorbance at 495 nm should overlap with a similar peak of 








Figure 4a.6. Morphological characteristics of the c ancer cell lines studies.  
Cultured cells were stained Diff-Quick and observed by light microscopy at 10x 
magnification (lower panels) and 40 x magnifications (upper panels). (A) OVcar3, (B) 




Incubation of OVcar3 cells with all concentrations of FITC-CRT studied resulted in 
significant  binding of exogenous CRT to the cells.  For instance at 1µg/ml the MFI of 
bound FITC-CRT increased from controls levels of 19.5 ± 6.403 to 96.75 ± 17.93 
(Figure 4a.8(b)). The level of binding was concentration dependent i.e. MFI of FITC-
CRT treated cells  was 136.8 ± 17.56 at 2µg/ml treatment and 162.5 ± 5.745 and  
233.5+52 at 4 µg/ml and 8µg/ml respectively after 30-minutes exposure (Figure 4a.8). 
A similar binding pattern was observed for HSA which was included as a positive 
control. In contrast MFI of FITC-IgG (negative control) binding was significantly lower 
than both the CRT and HSA binding at all concentrations tested above 1 µg/ml (Figure 
4a.8). These data indicate that exogenous CRT bound to the surface of OVcar3 
ovarian cancer cells.  
Similar data was found for all three ovarian cancer lines (Figure 4a.8) i.e. CRT-FITC 
bound to cells at all concentrations tested, but FITC-IgG binding was low. Interestingly, 
MFI of bound FITC-CRT was higher for SKov3 cells than all of the other cancer cell 
lines tested at all concentrations of CRT tested, suggesting that these cells bind more 
CRT. For instance, in cells treated with 1µg/ml FITC-CRT, there was a 4-fold increase 
in the MFI compared with control cells i.e. from 25.75 ± 5.058 to 201.3 ± 93.82  
(p<0.025).  A significant dose dependent increase of CRT binding was observed at 
higher CRT concentrations with an MFI of 215.8 ± 60.98 2µg/ml, 242.5 at ± 76.57 at 
4µg/ml and 348 ±70.39 at 8µg/ml (p<0.05 for all vs control).    
Since OVcar3, A2780 and SKov3  cells all significantly bound exogneous CRT, FaDu 
pharyngeal  tumour cells were also examined to determine whether this effect is limited 
to ovarian cancer cells.  Again, incubation with increasing FITC-CRT resulted in a 
dramatic increase surface bound CRT at all concentrations tested. For instance, the 
two highest concentrations of FITC-CRT, 4 and 8µg/ml significantly enhanced CRT 
binding by 3.1- and 3.6-fold (to 192.8 ± 24.62 MFI and 245.3 ± 41.31MFI) (***p<0.001) 
(Figure 4a.8 (d,e)) respectively in comparison to the control. Experiments were also 
performed to determine whether unconjugated FITC alone bound to cells to i.e. to 
ensure that the CRT-FITC was binding via CRT and not FITC.  No background staining 


















Figure 4a.7. Demonstration of FITC-CRT, FITC-HSA an d FITC-IgG binding to 
OVcar3 cancer cells by flow cytometry . OVcar3 cells were treated with different 
concentrations (1-µg - 8µg/ml) of FITC protein or untreated (0, auto-fluorescence 
control) and analysed by flow cytometry (A)  Typical dot plot of the cells showing their 
size (forward scatter-FSC) and granularity (side scatter-SS). (B) CRT (C) HSA 
(positive control) (D) IgG (negative control). Representative graphs from at least three 





















Figure 4a.8. FITC-CRT binds to four cancer cell lin es at all concentrations tested.  
Cancer cells were incubated with increasing concentrations (0-8 µg/ml) of FITC-CRT,   
FITC-HSA (positive control) or FITC-IgG (negative control) for 30 min at 37°C in the 
dark. After incubation the amount of FITC-conjugated protein bound to cells was 
assessed by flow cytometry. (A), (B), (C), (D) and (E) cells treated with 0 (buffer alone), 
1, 2, 4, 8 µg/ml FITC-CRT, HSA-FITC and IgG-FITC, respectively. Data are mean ± 
SD) and analysed by one-way ANOVA and Tukey’s multiple comparison test *** 
p<0.001, n=6. Significance is between HSA and IgG where indicated and between 
CRT and IgG where not specified. Note the difference in the range of the y axis on (A) 




4a.4.3. CRT-FITC binds to the surface of cancer cel ls as assessed by 
immunofluorescence microscopy.  
To further test the ability of extracellular CRT, IgG and HSA to bind to cancer cells 
under resting conditions, cells were also analysed by immunofluorescence 
microscopy. Both FITC-CRT and FITC-HSA bound to cancer cells, but there was 
negligible staining with FITC-IgG (Figure 4a.9). All of the data above confirm that 
exogenously added CRT binds to the surface of cancer cells under resting conditions 
i.e. standard cell culture.   
4a.4.4. Binding of CRT to cancer cells under stress  and ER stress conditions.  
A series of experiments were then carried out to examine whether extracellular binding 
of exogenous CRT could be enhanced in cells subjected to cellular stress.  Initial 
studies were carried out to examine the effect of doxorubicin on cell viability. OVcar3, 
SKov3, A2780 and FaDu cells were treated with increasing concentrations of 
doxorubicin (2.5µM, 6.3µM, and 12.5µM, 25µM, based on values obtained from the 
literature) (Inoue et al., 2014). After incubation, cell viability was assessed by staining 
with annexin V and PI and flow cytometry analysis. 
Doxorubicin significantly induced cell death in all four cancer cell types at all 
concentrations compared with vehicle only treated cells. For instance, in OVCar3 cells 
viability decreased from 85.41+ 9.17 % in control cells to 21.55 ± 11.37%, 13.72 ± 
0.737%, 15.66 ± 9.455% and 11.82 ± 7.271% in cells treated with 2.5, 6.3, 12.5 and 
25 µM respectively (Figure 4a.10(a)).  
Figure 4a.11. Shows a typical flow cytometry dot plot for doxorubicin treated OVCar3 
showing analysis of living, early apoptotic, late apoptotic or necrotic cells based on 
annexin V or PI staining. Similar analyses were carried for SKOV3, A2780 and FaDu 
cells. Interestingly, although doxorubicin significantly reduced cell viability in all cell 
lines tested the proportion of cells in the different phases of cell death differed between 
the cell lines. For instance, in SKov3 early apoptotic cells formed the largest cell 
population at all concentrations of doxorubicin tested, whereas in OVcar3 cells late 




and FaDu cells virtually no early apoptotic cells were observed.  Most cells were either 









Figure 4a.9. FITC-CRT and FITC-HSA bind to the surf ace of cancer cells as 
assessed by fluorescence microscopy.  Cancer cells were incubated with FITC 
labelled proteins and the nuclear stain DAPI and fixed and imaged by fluorescence 
microscopy. Images show FITC-CRT binding (upper panel), FITC-HSA (positive 
control, middle panel) and FITC-IgG (negative control, lower panel). (A) OVcar3, (B) 
SKov3, (C) A2780 and (D) FaDu cells. Green labelling represents CRT, HSA or IgG 
individually binding to cancer cells; blue labelling represents DAPI stain of cell nuclei. 
10x magnification images shown. Representative images of experiments carried out 







Figure 4a.10. Dose response effect of doxorubicin o n cancer cell survival. 
Various cancer cells were treated with doxorubicin and the percentage of living cells 
(annexin V –ve/PI-ve) were assessed. (A) OVcar3 cells (B) SKov3 cells, (C) A2780 cells, 
(D) FaDu. Data show the mean + SD. Experiments were repeated three times. Mann-
Whitney analysis, *p= 0.0286 vs control. All concentrations of doxorubicin used 






Figure 4a.11. Doxorubicin  treatment of OVcar3 ovarian cancer cells induces ce ll 
apoptosis (early and late) and necrosis as quantifi ed by flow cytometry using 
Annexin V and PI. OVcar3 cells were treated with increasing concentrations (0, 2.5, 
6.3, 12.5, 25 µM) of doxorubicin (DX) and then harvested by trypsinisation.  To 
discriminate between early and late apoptosis and necrosis, the cells were 
simultaneously stained with annexin V and PI and analysed by flow cytometry using 
guava 3.1.1 software. At least 5000 cells were counted in each sample. Experiments 
were performed and interpreted as follows: cells that were annexin (Ann) V-ve/PI-ve 
(lower left quadrant) were considered as living cells, AnnV+ve/PI-ve cells (lower right 
quadrant) as early apoptotic cells, AnnV+ve/PI+ve (upper right quadrant) cells as late 
apoptotic cells, and AnnV−ve/PI+ve (upper left quadrant) as necrotic cells. A 





Figure 4a.12. The percentage of living and dying ca ncer cells pre and post 
doxorubicin treatment.  Cells were treated with increasing concentrations of 
doxorubicin as indicated. To discriminate between early and late apoptosis and 
necrosis, the cells were simultaneously stained with annexin V and PI and analysed 
by flow cytometry. (A) OVcar3 cells (B) SKov3 cells, (C) A2780 cells, (D) FaDu cells. 






Table 4a.1. Dose-dependent effects of doxorubicin i n tumour cells . Cells were 
treated for 16 hours with doxorubicin. To discriminate between early and late apoptosis 
and necrosis, the cells were simultaneously stained with annexin V and PI and 
analysed by flow cytometry. Pooled data from 3 different experiments, were 








Experiments were then carried out to examine whether CRT bound to the surface of 
these dying cells. Initially, A2780 tumour cells were treated with 2.5 and 25 µM 
doxorubicin.  It was evident that increasing doses of doxorubicin increased the binding 
of exogenous FITC-CRT to apoptotic and necrotic cells (Figure 4a.13.).   Based on 
this result all four cancer cell lines were treated with increasing concentrations of 
doxorubicin (0, 2.5, 6.3, 12.5 and 25 µM) followed by exposure to FITC-CRT. The MFI 
of FITC-CRT binding to apoptotic and necrotic cells (gated by co-staining with annexin 
V and PI) was analysed by flow cytometry.   
From (Figure 4a.14. and Table 4a.2), it can be seen that CRT binding (assessed by 
MFI) was lowest in the living cell population for all four cancer cell types.  Interestingly, 
this was observed in the remaining living cells even in doxorubicin treated populations, 
suggesting that the presence of doxorubicin alone is not sufficient to enhance CRT 
binding i.e. cell death is required.  Highly enhanced CRT binding was observed in cells 
at all stages of cell death examined i.e. early apoptosis, late apoptosis and necrosis in 
all cell types. However, these increases did not consistently seem to be dependent on 
the dose of doxorubicin used in early or late apoptotic cells suggesting that even the 
lowest concentration i.e. 2.5 µM was enough to induce maximum CRT binding in these 
stages of cell death. For instance MFI of CRT binding to early apoptotic SKov3 cells 
was 731 ± 870, 424 ± 98, 846 ± 995 and 857 ± 1254 f or cells treated with 2.5, 6.3, 
12.5 and 25 µM doxorubicin respectively.  MFI of CRT binding to late apoptotic SKov3 
cells was 793 ± 858, 1422 ± 1731, 920 ± 956 and 1044 ± 1152 following treatment 
with 2.5, 6.3, 12.5 and 25 µM doxorubicin respectively (Table 4a.2), MFI of CRT 
binding to necrotic cells did show a dose dependent effect in all cells except A2780. It 
can also be observed that in SKov3 and FaDu cells CRT binding was greatest in 
necrotic cells, whereas in A2780 CRT binding was greatest in late apoptotic cells.   
These effects were investigated further on OVcar3 cells treated in the same way and 
examined for cell morphology and FITC-CRT binding by microscopy. The images 
shown in Figure 4a.15 support the flow cytometry data that doxorubicin treatment 















Figure 4a.13. Degree of FITC-CRT binding to A2780 o varian cancer cells before 
and after treatment with doxorubicin .  A2780 cells were initially treated with 0, 2.5 
or 25 µM doxorubicin (DX) and then incubated with FITC-CRT at 2µg/ml.  The MFI of 
FITC-CRT on apoptotic and necrotic gated cells (determined by co-staining with Alexa 
Fluor® 647 annexin V and PI) was assessed by flow cytometry. CRT fluorescence 
intensity (at the indicated stages of cell death) is plotted on the x axis. CRT-FITC 
























Figure 4a.14. Mean fluorescence intensity (MFI) of FITC-CRT binding to living 
and dying cells pre and post treatment with doxorub icin . Cancer cells were treated 
with increasing concentrations of doxorubicin (0, 2.5, 6.3, 12.5 and 25 µM) and then 
with FITC-CRT at 2µg/ml. The MFI of FITC-CRT on early and late apoptotic and 
necrotic cells (gated by co-staining with annexin V and PI) was analysed by flow 
cytometry.  (A) OVcar3 cells (B) SKov3 cells, (C) A2780 cells, (D) FaDu cells. Data 







Table 4a.2.  Mean fluorescent intensity (MFI) of FI TC-CRT binding to OVcar3, 
SKov3, A2870 and FaDu tumour cells pre- and post- d oxorubicin treatment. 
Cancer cells were treated with increasing concentrations of doxorubicin (0, 2.5, 6.3, 
12.5 and 25 µM) and then incubated with FITC-CRT at 2µg/ml. The MFI of FITC-CRT 
binding to early and late apoptotic and necrotic cells (gated by co-staining with annexin 
V and PI) was analysed by flow cytometry. Pooled data from 4 different experiments 
were statistically analysed using the Mann Whitney test (n≥12, mean ± S.D, 







Figure 4a.15. Doxorubicin treatment of OVcar3 ovari an cancer cells enhances 
CRT binding. Upper row - cells were treated with different concentrations of 
doxorubicin (0, 2.5, 6.3, 12.5 and 25µM; I, III, V, VII, IX respectively), fixed, stained 
with FITC-CRT (green, 2µg/ml) and DAPI (blue, nuclear stain) and observed under 
fluorescence microscopy. Lower row - cells treated as for upper row and imaged with 
phase contrast microscopy (PC), (0, 2.5, 6.3, 12.5 and 25µM doxorubicin = I, III, V, 
VII, IX respectively) Scale bar = 50 µm. Representative images from three similar data 





4a.4.5. Treatment of both OVcar3 and SKov3 cells wi th thapsigargin and 
doxorubicin treatment alone, and combined, increase s CRT binding to dying 
cells. 
It is evident from the previous experiments that inducing cancer cell stress with 
doxorubicin enhances their exogenous CRT binding. It was hypothesised that 
subjecting cells to additional stress induced by an ER stressor might enhance CRT 
binding further, which could be therapeutically beneficial i.e. further enhance CRT-
mediated ICD. Additionally, examining the impact of another ER stressor could provide 
mechanistic data on the effects of doxorubicin. 
OVcar3 and SKov3 cells were treated with doxorubicin alone (0, 2.5, 6.3, 12.5, 25 µM) 
or thapsigargin (0.2, 0.5µM) alone, or in combination with 2.5µM doxorubicin, and cell 
death was monitored by annexin V and PI staining and CRT binding was monitored 
by FITC-CRT binding. The highest concentration of 0.5 µM thapsigargin was chosen 
based on previous studies where this concentration was employed (Mlynarczyk and 
Fahraeus, 2014). Both doses of thapsigargin used (0.2, 0.5 µM) significantly reduced 
cell viability in both OVcar3 and SKov3 to similar levels observed with doxorubicin 
alone (Figure 4a.16.). Combined treatment with thapsigargin and doxorubicin did not 
induce further cell death. Interestingly, both treatments induced a high proportion of 
late apoptotic cells in OVcar3 cells whereas in SKov3 necrotic cells were the largest 
cell population (Figure 4a.17 (a, b)). 
 
Exogenous FITC-CRT binding to cancer cells was increased under stress conditions 
induced by doxorubicin and thapsigargin, similar to the previous data on doxorubicin 
(Figure 4a.17(c, d)). The amount of CRT on the external surface of all apoptotic (early 
and late) and necrotic cells was statistically significantly greater in treated cells 
compared with living cells (AnnV-ve/PI-ve) treated under the same conditions. For 
instance, (Figure 4a.17(d)) MFI of CRT binding to SKov3 cells treated with 0.5 µM 
thapsigargin was 17.41 ± 2.314 for living cells but increased to 317.8 ± 28.6, 701.1 ±  
58.6 and 309 ± 203.2 in cells undergoing early apoptosis, late apoptosis and necrosis 
respectively  (p=<0.05 for all, n=3).  Cells treated with thapsigargin and doxorubicin 
alone showed increased cell surface CRT on early apoptotic (annexin V+ve / PI-ve), 













Figure 4a.16. Representative flow cytometry histogr ams showing that 
exogenous FITC-CRT binding to SKov3 ovarian cancer cells is increased under 
stress conditions using the ER-stressors doxorubici n and thapsigargin.   SKov3 
cells were treated with 0, 2.5, 6.3, 12.5, 25 µM doxorubicin or 0.2 or 0.5 µM 
thapsigargin ± 2.5µM doxorubicin and then incubated with FITC-CRT at 2µg/ml. The 
fluorescence intensity of FITC-CRT binding was analysed by flow cytometry. (a) Flow 
cytometry histogram of fluorescence of FITC-CRT binding after treatment with 
doxorubicin. (B) Flow cytometry histogram of fluorescence of FITC-CRT binding after 
treatment with doxorubicin and thapsigargin. Representative histograms of one of at 




















Figure 4a.17. Doxorubicin and thapsigargin can indu ce cell death in ovarian 
cancer cells and exogenous CRT preferentially binds  to cancer cells undergoing 
apoptosis after treatment with thapsigargin and dox orubicin. Cancer cells were 
treated with 0.2 and 0.5 µM thapsigargin ± 2.5 µM doxorubicin (DX) and then with 
FITC-CRT at 2µg/ml. The early and late apoptotic and necrotic cells (gated by co-
staining with annexin V and PI) were analysed by flow cytometry.  (a, b) The 
percentage of OVcar3 and SKov3 cells in each phase of cell death; (c, d) Mean 
fluorescence intensity (MFI) of FITC-CRT binding to OVcar3, SKov3 cancer cells pre 
and post-doxorubicin treatment. Data show the mean + SD.  *p<0.5. Experiments were 




Combined treatment of cancer cells with thapsigargin and doxorubicin did not lead to 
the greater surface binding of CRT on apoptotic (early and late) or necrotic cells in 
either OVcar3 or SKov3. Indeed no significant difference in FITC-CRT binding was 
observed between thapsigargin alone and thapsigargin at the same dose plus 
doxorubicin for any stage of cell death in either cell type. 
 
4a.4.6. Inhibition of ER stress reduced binding of exogenous CRT in doxorubicin 
and thapsigargin treated cells. 
To clarify whether the ER stress-inducing properties of doxorubicin and thapsigargin 
were related to their induction of cell death and enhanced exogenous CRT binding, 
the effect of tauroursodeoxycholic acid (TUDCA) on doxorubicin and thapsigargin 
treated cells was examined. TUDCA is known to reduce ER stress, prevent the 
dysfunction caused by UFP response, and stabilise mitochondria (Vang et al., 2014).  
SKov3 and OVcar3 cells were pre-treated with 200 µM or 400 µM TUDCA.  Cells were 
then incubated in the absence or presence of doxorubicin or thapsigargin to examine 
the impact of TUDCA on cell death by these two agents (as assessed by annexin V 
and PI staining) induced (Figure 4a.18.). TUDCA alone did not reduce cell viability at 
either concentration used in either cell type. However, toxicity of both ER stressors, 
as assessed by percentage of live cells, was partially, but significantly reduced by pre-
treatment with TUDCA. In SKov3 cells there did not appear to be any dose effect of 
the concentration of TUDCA used, whereas in OVcar3 cells 400 µM was slightly more 
effective, although this difference did not reach significance. 
Further analysis of PI and annexin V status indicated that TUDCA reduced 
doxorubicin-mediated apoptosis and necrosis in both OVcar3 (Figure 4a.18), and 
SKOV3 cells. This did not always reach significance, but was highly significant in both 
cells types for doxorubicin induction of late apoptosis. TUDCA significantly reduced 
thapsigargin-mediated induction of CRT in early and late apoptotic and necrotic cells 
in OVcar3, but interestingly this reduction failed to reach significance in SKov3 cells.  
These data indicate that thapsigargin is able to partially protect against cell death 




Examination of the effect of TUDCA on doxorubicin and thapsigargin mediated binding 
of exogenous CRT showed a similar trend (Figures 4a.19 and 4a.20).  Figure 4a.20 
shows the effect of TUDCA pre-treatment on the MFI of FITC-CRT binding to OVcar3 
and SKov3 undergoing different stages of cell death induced by doxorubicin or 
thapsigargin. TUDCA significantly inhibited exogenous CRT binding facilitated by ER 
stressors. Doxorubicin and thapsigargin -mediated late apoptotic and necrotic OVcar3 
and SKov3 cells had significantly reduced cell surface CRT in the presence of TUDCA.  
These findings indicated that treatment with TUDCA attenuated exogenous CRT 
binding to dying cells under ER-stress conditions. For instance, MFI of late apoptotic 
OVcar3 cells treated with 2.5 µM doxorubicin + 400 µM TUDCA was 481.9 ± 25.94 
compared with 697.9 ± 72 in doxorubicin treatment alone (n=3; p=<0.05, Figure 4a.20 
(a)) and MFI of exogenous CRT in necrotic cells was 185.5 ± 8.6 vs 1383 ± 39.21) 
with the same treatments. 
Similarly, in SKov3 cells treated with TUDCA (200 µM) and thapsigargin (0.5 µM) the 
data revealed that there was a significant reduction in MFI of exogenous FITC-CRT 
on necrotic cells from 269.6 ± 50.01with thapsigargin alone compared with 103.5 
±10.12 in cells treated with both, (Figure 4a.20. (d)). These flow cytometry data were 
supported by direct immunofluorescence visualisation of FITC-CRT bound to treated 
cells (figure 4a.21). 
These combined data suggest that ER stress on ovarian cancer cells is associated 
with induction of apoptotic and necrotic cell death and enhanced binding of exogenous 




















































Figure 4a.18. TUDCA does not induce cell death, and  protects against 
doxorubicin and thapsigargin induced toxicity, in o varian cancer cells. SKov3 
and OVcar3 cancer cells were treated with TUDCA (200 µM or 400 µM), doxorubicin 
(DX, 2.5 µM) or thapsigargin (TG, 0.2 µM) or in combination as indicated, and stained 
with annexin V and PI to assess apoptosis and necrosis by flow cytometry. Data show 
% of cells in different stages of cell death. (a) OVcar3 treated with TUDCA ± DX or DX 
alone, (b) OVcar3 treated with TUDCA ± TG or TG alone, (c), SKov3 treated with 
TUDCA ± DX or DX alone, (d) SKOV3 treated with TUDCA ± TG or TG alone. Data 
show the mean + SD. Experiments were repeated three times. * =0 µM vs. 2.5 µM DX, 
200 µM TUDCA and 400 µM TUDCA) (a & c), * =0 µM vs. 0.2 µM TG, 200 µM TUDCA 
and 400 µM TUDCA (b & d). # = 2.5 µM DX vs. 2.5 µM DX + 200, 400 µM TUDCA (a 




















Figure 4a.19. TUDCA promoted a decrease in exogenou s CRT binding to 
doxorubicin (DX) treated ovarian cancer cells. SKov3 cancer cells were treated 
with doxorubicin (2.5 µM), TUDCA (200 µM or 400 µM) or a combination of both for 
16 hours followed by exposure to FITC-CRT (2µg/ml) and staining with annexin V/PI 
to assess apoptosis and necrosis. (A) Fluorescence intensity of exogenous FITC-CRT 
binding to SKov3 cancer cells undergoing different stages of cell death (gated by 
annexin and PI staining). (B) Representative flow cytometry dot plot illustrating 
percentage of cells undergoing apoptosis and necrosis with the different treatments. 
Lower right quadrant (annexin V +ve / PI -ve) represents early apoptosis; upper right 
quadrant (annexin V +ve / PI +ve) represents late-apoptosis; upper left quadrant  
annexin V –ve / PI +ve) represents necrosis. Representative data are shown from 


















































Figure 4a.20. Treatment with TUDCA reduced the exog enous FITC-CRT binding 
to ovarian cancer cells when compared with cells tr eated with doxorubicin and 
thapsigargin. SKov3 and OVcar3 cancer cells were treated with TUDCA (200 µM or 
400 µM), doxorubicin (DX, 2.5 µM) or thapsigargin (TG, 0.2 µM) or in combination as 
indicated.  Cells were then incubated with FITC-CRT and stained with annexin V and 
PI to assess apoptosis and necrosis by flow cytometry. Data show mean fluorescence 
intensity (MFI) of FITC-CRT binding to cells undergoing different stages of cell death 
as gated by annexin V and PI staining. (a) OVcar3 treated with TUDCA ± DX or DX 
alone, (b) OVcar3 treated with TUDCA ± TG or TG alone, (c), SKov3 treated with 
TUDCA ± DX or DX alone, (d) SKOV3 treated with TUDCA ± TG or TG alone. Data 
show the mean + SD. Experiments were repeated three times. * =0 µM vs. 2.5 µM DX, 
200 µM TUDCA and 400 µM TUDCA) (a & c), * =0 µM vs. 0.2 µM TG, 200 µM TUDCA 
and 400 µM TUDCA (b & d). # = 2.5 DX vs. 2.5 µM DX + 200, 400 µM TUDCA (a & c), 


























Figure 4a.21. TUDCA reduces binding of exogenous CR T to doxorubicin (DX) 
treated OVcar3 ovarian cancer cells as assessed by immunofluorescent 
staining. OVcar3 cells were treated with TUDCA (200 µM or 400 µM) ± doxorubicin 
(2.5 µM) or doxorubicin alone (2.5 µM).  Cells were fixed in 4% (w/v) 
paraformaldehyde, stained with ± FITC-CRT (2µg/ml) and DAPI and observed under 
confocal microscopy.  FITC-CRT = green labelling, blue labelling represents DAPI 
stain of cell nuclei. Scale bar equals 25 µm. Representative images are shown from 






Chapter 4b.  Examination of the conditions required  for surface exposure of 
translocated endogenous calreticulin in ovarian can cer cells.  
 
4b.1 Introduction  
Chapter 4a described studies that demonstrated that exogenous CRT could bind to 
the surface of ovarian cancer cells and that this binding was increased in cells 
undergoing cell death induced by ER stressors such as doxorubicin. It is now known 
that chemotherapies such as doxorubicin also induce translocation of CRT to the cell 
surface of some tumour cells (Obeid et al., 2007) The possibility that this CRT 
enhances the immunogenicity of early apoptotic cancer cells by triggering ICD has set 
CRT at centre stage for aiding our understanding of cancer immunology in recent 
years (Panaretakis et al., 2009).  Translocation of endogenous CRT to the cell surface 
of dying tumour cells is now thought to enhance their recognition and engulfment by 
DC (Raghavan et al., 2013). Although not fully established, the importance of this 
mechanism operating in ovarian cancer is supported by recent studies at the 
messenger RNA level that suggest that lack of CRT message correlated negatively 
with cytotoxic T cell infiltration into tumour sites in ovarian cancer patients influencing 
survival (Stoll et al., 2016).  
The aims of this section were to determine the conditions that give rise to endogenous 
CRT cell surface expression under stress conditions in ovarian cancer. Elucidation of 
the conditions required may aid targeted immunotherapy for immune-mediated 
eradication of ovarian cancer. Briefly, cancer cells were treated with the ER stressors 
doxorubicin and thapsigargin in the presence or absence of TUDCA which has been 
reported to protect against ER damage.  Cells were analysed for externalised CRT by 
staining with specific antibodies followed by flow cytometry and immunofluorescence.  










The aims of this section were to determine whether intracellular CRT becomes 
externalised in ovarian cancer cells, potentially identifying these cells for immune-
mediated eradication.  
The specific objectives were: 
1.To examine whether endogenous CRT was translocated to the surface of ovarian 
cancer cells and/or secreted under stress conditions induced by doxorubicin and 
thapsigargin. 
2.To examine whether endogenous CRT preferentially became externalised in ovarian 
cancer cells in certain stages of cell death 
3.To examine whether TUDCA was able to inhibit doxorubicin and/or thapsigargin 
induced translocation and secretion of intracellular CRT in ovarian cancer cells. 
 
4b.3 Methods 
4b.3.1. Treatment of cancer cells with doxorubicin.   
Ovarian cancer cells were cultured as described in Chapter 2 (Materials and Methods). 
1 × 105 cells/well were plated in 6-well plates and cultured to 80% confluence 
(approximated 48 hours) in complete media.  Cells were treated with 2.5 µM 
doxorubicin for (0, 2, 4, 6, 8, 16, 24 h), harvested prepared for using flow cytometry.  
Externalised CRT was quantified using a rabbit anti-human-CRT primary antibody 
(1:200, 1 hour) followed by washing and incubation with a goat anti-rabbit IgG H&L 
secondary antibody (Alexa Fluor® 488) (green  color)  (1/2000, 30 minutes).   
 
4b.3.2. Treatment of cancer cells with thapsigargin   
Ovarian cancer cells 1 × 105 cells/well were plated in 6-well plates and cultured to 80% 
confluence (approximated 48 hours) in complete media.  Cells were then treated with 
varying concentrations of thapsigargin (0.2, 0.5 µM) in the absence or presence of 2.5 
µM doxorubicin. After washing twice in PBS, cells were harvested, stained for 
externalised CRT as above and with annexin V and PI as previously described in 




in each sample and analysed by flow cytometer then the fluorescent intensity of 
stained cells was gated on propidium iodide (PI), annexin V by flow cytometry. 
 
4b.3.3. Treatment of cancer cells with TUDCA  
1 × 105 ovarian cancer cells, SKov3 and OVcar3, were plated in each well of a 6-well 
plate and treated with different concentrations (200 µM, 400µM) of TUDCA, 2.5uM 
doxorubicin and thapsigargin for 16 h. After washing twice in PBS, cells were stained 
for externalised CRT and annexin V and PI as above. Cells were harvested, 
resuspended in 100 µl of binding buffer and analysed by flow cytometry with the 




Immunocytochemistry was carried out as described in section 4a.3.7. 
 
4b.3.5. HCMEC/D3 
HCMEC/D3 cells were cultured as described in Chapter 2 section (2.3.3). Cells were 
treated, stained for externalised CRT and prepared for flow cytometry and as in section 
4a.3.6. 
 
4b.3.6. CRT ELISA  
Secreted CRT was quantified by ELISA as described in chapter 2 (2.5.1). 
 
4b.3.7. Preparation of cell lysates for western blo tting 
Following treatment cells were immediately solubilized in 200 µl of ice-cold lysis buffer 
containing 1% (w/v) SDS, 1% (v/v) triton X 100, 50 mM Tris (pH 7.5), 150 mM NaCl, 
and 1 protease inhibitor tablet. After lysis on ice for 30 minutes samples were 
centrifuged at 340g at 4°C for 20 minutes and the supernatant collected. Protein 
content of the lysates was determined by BCA assay. Samples were then assessed 
for their CRT content by western blotting according to the method of Osman (Osman 




4b.3.8. Western blotting 
Changes in CRT protein levels were examined by western blotting as described in 
Chapter 2 (2.7). Membranes were incubated with 1:1000 dilution of a 1 µg/ml rabbit 
anti–human-CRT (A3-900) in PBS-0.2% (v/v) Tween-20 on a rocker overnight at 4oC. 
After washing the membranes were incubated at room temperature in the dark for 1 h 
with a 1:15000 dilution of IRDye 800CW goat anti-rabbit IgG. Blots were washed twice 
in PBS-0.2% (v/v) Tween-20 and once in PBS alone and were analysed on an 
Odyssey CLx Imager. 
 
4b.3.9. Assessment of apoptosis and necrosis 























4b.4.1 Doxorubicin treatment of cancer cells increased rel ease of endogenous 
CRT. 
Initial experiments were carried out to examine whether doxorubicin treatment could 
induce externalisation of CRT on ovarian cancer cells. To test this, SKov3 cells were 
treated with 2.5µM doxorubicin for a maximum of 24 hours and cell surface CRT and 
cell apoptosis and necrosis were assessed by immunocytochemistry and flow 
cytometry. Doxorubicin induced a robust expression of CRT on the cell surface as 
assessed immunocytochemistry (Figure 4b.1). This was accompanied by induction of 
cell death (Figure 4b.1 (b, c)). Doxorubicin treatment led to a rapid decrease in live 
cells and a steady increase in late apoptotic cells and a transient increase in  early 
apoptotic and necrotic cells over 24 hour treatment Notably, late apoptotic cells 
increased from 0.3% to 56% of the cell population after 24 hours doxorubicin 
treatment. When CRT exposure on the different cell populations was examined it was 
observed that cells undergoing early and late apoptosis, as well as necrosis had a 
marked increase in cell surface CRT expression compared with living cells (Figure 
4b.1 (d)).  For instance MFI of externalised CRT after 2 hours of treatment was   12.25 
± 0.96 in living cells; 94.25 ± 0.96 in cells undergoing early apoptosis; 188.8 ± 25.51 
in cells in late apoptosis and 151.3 ± 10.11 in necrotic cells, (p=<0.05 for all, n=3).  At 
later time points necrotic cells had the highest MFI of CRT staining suggesting that 




























Figure 4b.1.  Doxorubicin treatment increases surface expression of 
endogenous CRT on non-permeabilised SKov3 cancer ce lls.  SKOV3 cells were 
treated with 2.5 µM doxorubicin for times as indicated. Extracellular CRT was 
assessed by immunocytochemistry and flow cytometry (after staining with fluorescent 
anti-CRT antibody) and apoptosis and necrosis were assessed using annexin V and 
PI. MFI of externalised CRT in live, apoptotic and necrotic cells was measured after 
gating cell population based on their PI and annexin V staining.  (a) Representative 
image showing expression of surface CRT detected by immunofluorescence on 
untreated and 2.5 µM doxorubicin treated SKOV3  post-16 h treatment (x20 
magnification). (b) Representative flow cytometry histograms of SVOV3 cells treated 
with 2.5 µM doxorubicin for 0-24 hours and assessed for cell death. (c) Percentage of 
living, apoptotic and necrotic cells pre and post doxorubicin treatment. (d) MFI of 
surface CRT on SKov3 cell population’s pre and post- 2.5 µM doxorubicin. Figures a-




4b.4.2.The effect of doxorubicin on cell death and CRT externalisation on non- 
cancer cells.  
The data in section 4b.4.1.  Indicate that ovarian cancer cells treated with doxorubicin 
externalise CRT. To examine whether this observation is only seen in cancer cells or 
is a wide spread effect, similar experiments were carried out on human endothelial 
cells (HCMEC/D3) and a different ovarian cancer cell line, OVcar3. Additionally the 
dose response to doxorubicin was tested. HCMEC/D3 and OVcar3 cells were treated 
with increasing concentrations of doxorubicin (0, 0.125, 0.25, 0.5, 1, 2.5 µM) for 16 
hours and apoptosis and necrosis and MFI of externalised CRT were examined 
(Figure 4b.2 and Table 4b.1). As shown in (Figure 4b.2. (a)) treatment with doxorubicin 
for 16 hours markedly reduced cell viability in OVcar3 cell compared with untreated 
cells (p<0.05 all concentrations tested), but only minimally altered cell viability in 
HCMEC/D3 (Figure 4b.2 (b)), suggesting that doxorubicin is preferentially toxic to 
cancer cells. 
OVcar3 cancer cells undergoing doxorubicin-induced cell death had significantly 
increased surface CRT at all stages of cell death (Figure 4b.2 (c)). After 16 hours of 
treatment CRT MFI was 31.5 ± 8.963 in living cells;  261.5 ± 30.65 in early apoptotic 
cells; 255.5 ± 16.11 in late apoptotic cells and 109.5 ± 3 in necrotic cells (p=<0.05 vs 
untreated for all, n=3).  In contrast there was virtually no change in MFI of CRT with 
time across the different stages of cell death in the HCMEC/D3 cells (Figure 4b.2 (d)). 
These data indicate that doxorubicin does not induce CRT exposure in these cells.  It 
also appears that doxorubicin induced externalisation of CRT is associated with cell 
death.  It is not possible from these results to determine whether doxorubicin induces 
ER stress without cell death in the HCMEC/D3, but if CRT exposure is due to ER 
stress then this would suggest that either the non-cancer cells are resistant to 
doxorubicin induced cell death or that ER stress is not linked to CRT surface 






4b.4.3 Treatment of both OVcar3 and SKov3 cells wit h thapsigargin and 
doxorubicin alone and in combination increases surf ace exposure of 
endogenous CRT. 
Since surface translocation of CRT in various cancer cells has been reported to occur 
following ER stress this was examined in ovarian cancer cells. Initial 
immunocytochemistry studies were carried out in SKov3 cells treated with the ER 
stressors doxorubicin and thapsigargin individually and in combination. It was evident 
that both thapsigargin and doxorubicin alone, and in combination, enhanced surface 
exposure of endogenous CRT compared with untreated cells (Figure 4b.5).  This was 
further examined in OVcar3 and SKov3 cells undergoing different stages of apoptosis 
or necrosis using flow cytometry. Representative data are shown in (Figure 4b.3) and 
combined data in (Figure 4b.4). Doxorubicin and thapsigargin significantly altered the 
MFI of fluorescently labelled, externalised, endogenous CRT in both cell types at all 
stages of cell death. For instance in SKov3 cells treated with 2.5 µM doxorubicin 0.5 











































 Figure 4b.2.  Doxorubicin dose-dependently induces apoptosis and necrosis in 
OVcar3 ovarian cancer cells, but not HCMEC/D3 human  endothelial cells.  
OVcar3 and HCMEC/D3 cells were treated with increasing concentrations (0, 0.125, 
0.25, 0.5, 1, 2.5 µM) of doxorubicin for 16 hours. Externalised CRT and apoptosis and 
necrosis were detected by flow cytometry. (a) and (b) the percentage of OVcar3 and 
HCMEC/D3 cells undergoing apoptosis and necrosis as determined by annexin V and  
PI staining. (c) and (d) MFI of CRT staining in OVcar3 and HCMEC/D3 cells at different 
stages of cell death (cells gated on PI and annexin V staining). Note different y axis 
scales in (c) and (d) Data show the mean + SD. Experiments were repeated three 













Table 4b.1.  Doxorubicin induces apoptosis and necrosis in OVcar 3 ovarian 
cancer cells, but not HCMEC/D3 human endothelial ce lls. OVcar3 and HCMEC/D3 
cells were treated with increasing concentrations of doxorubicin for 16 hours. 
Externalised CRT and apoptosis and necrosis were detected by flow cytometry. Upper 
panel = % of HCMEC/D3 cells undergoing apoptosis and necrosis; second from top 
panel = % of OVcar3 cell undergoing apoptosis and necrosis; third from top = MFI of 
CRT staining in HCMEC/D3 cells at different stages of cell death; bottom panel = MFI 
of CRT staining in OVcar3 cells at different stages of cell death. Data are mean + SD 



















Figure 4b.3.  The ER stressors doxorubicin and thapsigargin alone  and in 
combination induce CRT exposure in SKov3 and OVcar3  ovarian cancer cells.  
Cells were treated with doxorubicin (DX, 2.5 µM), ± thapsigargin (TG, 0.2, 0.5 µM) for 
16 h and their apoptosis/necrosis status was determined by flow cytometry using 
annexin v (annV) and PI staining before and after treatment. (a) Differences in cell 
surface CRT expression as monitored by changes in fluorescent intensity on pre-
apoptotic, apoptotic and necrotic OVcar3 cells. (b) and (c) Dot plot graphs show the 
changes in the percentage of viable cells (lower left quadrant), early apoptotic cells 
(lower right quadrant), late apoptotic cells (upper right quadrant) and necrotic cells 
(upper left quadrant) of (b) SKov3 and (c) OVcar3 cancer cells respectively. The 
bolded numbers represent the percentage of apoptosis and necrosis in the right, left 
lower or upper quadrant, respectively. Representative data from experiments 




















Figure 4b.4. Surface expression of endogenous CRT i s significantly increased 
in ovarian cancer cells in varying stages of apopto sis and necrosis in cells 
treated with doxorubicin and/or thapsigargin.  OVcar3 (a,c) and SKov3 cells (b,d) 
were treated ± doxorubicin (DX, 2.5 µM) and/or thapsigargin (TG, 0.2, 0.5 µM) for 16 
h. Extracellular CRT was assessed by flow cytometry after staining with specific 
antibodies.  Apoptosis and necrosis were assessed using annexin V and PI, with the 
fluorescent intensity of CRT stained cells on different cell populations gated on PI and 
annexin V.  (a), (b) the percentage of OVcar3 and SKov3 at different stages of cell 
death (c), (d) the MFI of externalised CRT in OVcar3 and SKov3 in the different stages 
of cell death. Data show the mean + SD of three separate experiments. *p<0.05 vs 















Figure 4b.5 . Surface exposure of CRT from cancer cells is induced by 
doxorubicin and thapsigargin individually and enhanced by treatment with both 
together. SKov3 cells were treated ± doxorubicin DX (2.5µM) ± thapsigargin TG (0.2, 
0.5µM) for 16 hours, fixed with 4% (w/v) paraformaldehyde and surface CRT was 
visualised by immunocytochemistry staining using rabbit anti-human-CRT Ab and goat 
anti-rabbit IgG-FITC antibodies respectively. Green labelling represents externalised 
endogenous CRT; blue labelling represents DAPI stain of cell nuclei. Images are 
representative from at least three experiments showing similar results and were taken 






in early apoptotic, late apoptotic and necrotic cells respectively (p=<0.05 for all, n=3) 
(Figure 4b.4 (d)).  In similarly treated OVcar3 cells the MFI was 6.0 ± 0.84, 484 ± 150, 
599.3 ± 317.9 and 804.1 ± 381.2 in living, early apoptotic, late apoptotic and necrotic 
cells respectively  (p=<0.05 for all, n=3) (Figure 4b.4(c)).  
 
4b.4.4 Inhibition of ER stress by TUDCA reduced ext ernalization of CRT from 
doxorubicin treated ovarian cancer cells.  
The previous data indicate that cell death induced by agents reported to induce ER 
stress is accompanied by externalisation of endogenous CRT. The role of ER stress 
in this CRT translocation was examined further using TUDCA. OVcar3 and SKov3 
cells were treated with TUDCA (200 or 400 µM) ± doxorubicin or thapsigargin and cell 
viability status and levels of externalised endogenous CRT binding were determined 
by flow-cytometry.  In OVcar3 cells treated with ER stressors both concentrations of 
TUDCA consistently partially reduced the MFI of detected externalised CRT at all 
stages of cell death (Figure 4b.6). This reduction only failed to reach significance in 
necrotic cells induced by doxorubicin treatment. For instance, in late apoptotic cells 
MFI was reduced from 231.6 ± 21.21µM in doxorubicin alone treated cells to 188.7 ± 
23.67µM in the presence of TUDCA (p=<0.05, n=6) (Figure 4b.6 (c, d)).  No dose 
dependent effect of TUDCA was observed.   
Similar results were obtained for SKov3 cells; TUDCA induced a significant decrease 
in externalised CRT at all stages of cell death induced by both doxorubicin and 
thapsigargin (Figure 4b.7) Interestingly, in these cells the higher concentration of 
TUDCA (400 µM) did appear to be more effective at reducing CRT translocation. The 
data indicate that again TUDCA was only partially effective.  This may reflect that either 
TUDCA is not fully effective at inhibiting ER stress induced by the two agents used 
here or that more than one pathway can induce CRT translocation. The former could 
be assessed by following expression of the ER stress proteins BiP/GRP78 e.g. using 
commercially available kits or by assessment of intracellular calcium using cell 
permeable calcium dyes which increase in fluorescence when bound to Ca2+. These 
results were confirmed in OVcar3 cells by immunocytochemistry staining and 
















































Figure 4b.6. TUDCA reduces cell death and externali sation of endogenous CRT 
in doxorubicin or thapsigargin treated OVcar3.   Cells were treated with TUDCA 
(200 µM) and/or either doxorubicin (DX, 2.5 µM) or thapsigargin (TG, 0.2µM) for 16hr.   
Extracellular CRT and apoptosis and necrosis were assessed by flow cytometry with 
fluorescent intensity of CRT stained cells gated on PI and annexin V. (a) and (b) Flow 
cytometry dot plots showing the protective effect of TUDCA on (a) doxorubicin and (b) 
thapsigargin induced OVcar3 cell death. (c) and (d) MFI of CRT staining at different 
stages of cell death. The results shown are representative of three independent 
experiments. * =0 µM vs. 2.5 µM DX, 200 µM TUDCA and 400 µM TUDCA) (c), * =0 
µM vs. 0.2 µM TG, 200 µM TUDCA and 400 µM TUDCA (d).  # 2.5 µM DX vs. 2.5 µM 
DX +200,400 µM TUDCA, # 0.2 µM TG vs. 0.2 µM TG +200,400 µM TUDCA (c,d 



















































Figure 4b.7. TUDCA reduces cell death and externali sation of endogenous CRT 
in doxorubicin or thapsigargin treated SKov3.   Cells were treated with TUDCA (200 
µM) and/or either doxorubicin (DX, 2.5 µM) or thapsigargin (TG, 0.2µM) for 16hr.   
Extracellular CRT and apoptosis and necrosis were assessed by flow cytometry with 
fluorescent intensity of CRT stained cells gated on PI and annexin V. (a) and (b) Flow 
cytometry dot plots showing the protective effect of TUDCA on (a) doxorubicin and (b) 
thapsigargin induced SKov3 cell death. (c) and (d) MFI of CRT staining at different 
stages of cell death. The results shown are representative of three independent 
experiments. * =0 µM vs. 2.5 µM DX, 200 µM TUDCA and 400 µM TUDCA) (c), * =0 
µM vs. 0.2 µM TG, 200 µM TUDCA and 400 µM TUDCA (d),  # 2.5 µM DX vs. 2.5 µM 
DX +200,400 µM TUDCA, # 0.2 µM TG vs. 0.2 µM TG +200,400 µM TUDCA (c,d 














Figure 4b.8. TUDCA reduced the amount of endogenous CRT externalised on 
the cell surface of OVcar3 ovarian cancer cells treated with the ER stressor 
thapsigargin.  OVcar3 cells were treated with control media, TUDCA (200, 400 µM) 
± thapsigargin (TG, 0.2, 0.5µM) or thapsigargin alone for 16 hours and fixed with 4% 
(w/v) paraformaldehyde.  Surface CRT was visualised by immunocytochemistry 
staining using rabbit anti-human-CRT Ab and goat anti-rabbit IgG-FITC antibodies 
respectively. Green labelling represents externalised CRT binding to cancer cells; blue 
labelling represents DAPI stain of cell nuclei. Images are representative from at least 












4b.4.5 Effect of ER-stressors and inhibitors on CRT  expression and release from 
OVcar3 cells . 
The previous data suggest that doxorubicin and thapsigargin stimulate CRT 
translocation to the cell surface at least partially via induction of ER stress. It is also 
possible that this translocation is associated secretion of CRT from the cells. Indeed, 
CRT has been considered a biomarker of elevated ER stress associated with various 
malignancies (Wiersma et al., 2015) including ovarian cancer (Galazis et al., 2012, 
Abbott et al., 2010, Bengtsson et al., 2007). Thus, CRT expression and secretion in 
ovarian cancer cells in response to ER stressors was examined in the cell culture 
system used here.  
OVcar3 cells were treated with doxorubicin (0.25, 2.5µM) or thapsigargin (0.2µM) ± 
TUDCA. Cell expression of CRT was examined by western blotting of cell lysates and 
lysates and secreted CRT in the culture medium was quantified by ELISA. Both 
doxorubicin and thapsigargin induced a significant increase in cellular CRT expression 
by at least 4 fold (Figure 4b.9 (c, d)). This was significantly decreased by pre-
incubation with TUDCA, although interestingly TUDCA alone did increase CRT 
expression.   Both doxorubicin and thapsigargin also significantly increased secretion 
of CRT which was again significantly decreased by pre-treatment with TUDCA (Figure 
4b.9 (a, b)). These data suggest that CRT expression is increased in ovarian cancer 
cells in response to ER stress and that following translocation of CRT to the cell 
surface some of the CRT remains associated with the external surface of the cell and 

























Figure 4b.9. Effect of doxorubicin and thapsigargin  on secretion and expression 
of CRT in OVcar3 cells.  Cells were treated with doxorubicin (DX, 0.25, 2.5µM), or 
thapsigargin (TG, 0.2µM) for 16 h ± TUDCA. (200µM).  The culture supernatant was 
collected for measurement of secreted CRT by ELISA and the cells were lysed and 
analysed by SDS-PAGE and western blotting to examine relative cellular expression 
of CRT. (a) and (b) ELISA of CRT release from OVcar3 cells - raw data showing mean 
optical density (OD) at 450nm from one experiment. (b) ELISA of CRT release from 
OVcar3 cells showing mean secreted concentrations calculated using a CRT standard 
curve - results from 6 independent experiments (c) Representative western blot of 
CRT expression in OVcar3 cells. (d) Densitometry plots of CRT protein expression 
relative to β-actin as the loading control. Data are mean ± SD of 10 independent 
experiments. *p = 0.05 vs. control,   #2.5 doxorubicin vs. 2.5 µM+200 µM TUDCA, 
##0.25 µM doxorubicin vs. 0.25 µM doxorubicin+200 µM TUDCA, ###0.2 µM 




4.1. Discussion  
Apoptosis or programmed cell death is generally considered to be immunogenically 
silent since the dying cell contents are confined within undisrupted cell membrane- 
bound compartments that are efficiently cleared by phagocytes without inducing an 
adaptive immune response.  However, it is now accepted that in certain circumstances 
cells dying by apoptosis can have immunogenic properties and thus trigger an 
adaptive immune response known as ICD.  In the case of tumour cells undergoing ICD 
immune responses against cancer cell specific antigens or altered self-antigens can 
occur (Galluzzi et al., 2017). A critical aspect of ICD is surface expression of DAMPs 
which are required for an efficient immune response. As described in the Introduction 
these molecules are exposed by dying or stressed cells and are recognised by pattern 
recognition receptors (PRRs) on innate immune cells such as monocytes, 
macrophages and DCs. This interaction stimulates the activation and maturation of 
these cells, engaging the adaptive immune system (Matzinger, 2002) and facilitating 
recognition and destruction of a large number of tumour cells with minimal toxicity 
towards non-tumour cells.  
Engagement of the adaptive immune system as cancer therapy raises the possibility 
that vaccine based anti-tumour therapies may be developed. This is particularly 
attractive for cancers that are difficult to treat such as ovarian cancer, which due to 
late diagnosis and a high rate of relapse, still has a 5 year survival of less than 50%.   
It is now widely accepted that extracellular, surface bound CRT acts as a DAMP and  
has a key role  in mediating ICD of tumour cells  (Chaput et al., 2007) (Giglio et al., 
2018). Thus, further understanding of the mechanisms involved in CRT exposure at 
the cell surface is required. A general consensus is that various chemical 
(anthracyclines, fatty acids) and physical (radiation) perturbations of tumour cells can 
lead to ER stress and redistribution of CRT from the ER to the cell surface (Molinari et 
al., 2011, Buoncervello et al., 2012). Doxorubicin can induce rapid translocation (within 
minutes) of CRT to the surface of pre-apoptotic cells (Obeid et al., 2007). It is proposed 
that this surface exposed CRT is subsequently recognised by DCs and induces 
immunogenic uptake of dying cancer cells by CD11c-positive DCs and ultimately 
tumour cell destruction by the host immune system (Son et al., 2017). Indeed 




These studies suggest that therapeutic strategies designed to increase tumour cell 
surface CRT may aid cell destruction. An increase in extracellular, cell surface CRT 
could be induced by translocation of intracellular CRT from the ER or by binding of 
exogenously added CRT. The studies described in this chapter investigated both 
strategies to enhance surface levels of CRT on ovarian cancer cells.  
The binding of exogenous CRT was studied using FITC-labelled protein and it could 
be seen that CRT bound to the surface of cancer cells even under resting cell culture 
conditions.  This binding was significantly increased in all three ovarian cancer cell 
types studied, OVcar3, SKov3 and A2780, as well as FaDu pharyngeal carcinoma 
cells, following treatment with the ER stressors doxorubicin and thapsigargin.  This 
suggests that the enhancement of CRT binding stimulated by these agents is a 
general response of cancer cells, although this could be tested further by examining 
other cell types. The results obtained agree with a recent report that both exogenous 
CRT and endogenous bind to ovarian cancer cells under stress conditions (Osman et 
al., 2017). The enhanced binding induced by doxorubicin and thapsigargin was 
associated with a decrease in cell viability and an increase in apoptotic and necrotic 
cells with increased mean FITC-CRT fluorescence observed on cells in all stages of 
cell death.  This suggests that cell surface changes associated with cell death induced 
by these agents increases the ability of the cell surface to bind exogenous CRT.     
One possible surface binding site for CRT is phosphatidylserine (PS), a membrane 
phospholipid that is transferred from its normal localisation, on the inner leaflet of the 
plasma membrane, to the outer leaflet during apoptosis. It has been reported that CRT 
binds PS with high affinity in a Ca2+-dependent manner (Wijeyesakere et al., 2016) 
(Tarr et al., 2010b) and, since, as previously mentioned, measurement of early and 
late apoptosis by annexin V takes advantage of this PS externalisation it can be 
deduced that PS is present on the surface of the cells studied (Martin et al., 1995).  
However, FITC-CRT also bound at high levels to necrotic cells and these do not 
express surface PS (as assessed by annexin V binding).  This suggests that on these 
cells there is an alternative CRT binding site.  Alternatively, it is possible that in necrotic 
cells the FITC-CRT can enter cells through the damaged membrane and bind to 
intracellular exposed PS; however this would seem unlikely due to the lack of annexin 




certain cancer cells treated with doxorubicin (e.g. mouse colon cancer cells) before 
PS is externally presented (Chaput et al., 2007) suggesting that PS may not be the 
CRT binding site on early apoptotic cells.  However, the assay used here depends on 
PS/annexin V binding to distinguish apoptotic cells and so it is not possible to deduce 
whether very early apoptotic cells bind FITC-CRT.  
Both thapsigargin and doxorubicin are known to induce ER stress, but by different 
modes of action. Thapsigargin inhibits calcium pumps leading to depletion of Ca2+ 
stores in the ER whereas doxorubicin induces ER stress  (Panaretakis et al., 2009) 
and apoptosis by intercalating into a number of key DNA and RNA polymerases and 
altering the Bcl-2/Bax central checkpoint apoptosis pathways which are prevalent in 
different  cancer cells (Reed, 2006). In order to examine whether the ER stress 
function of thapsigargin and doxorubicin was related to their ability to enhance 
exogenous CRT binding to ovarian cancer cells, TUDCA an effective ER stress-
relieving drug was used.  TUDCA partially protected ovarian cancer cells against both 
doxorubicin and thapsigargin induced cell toxicity and partially reduced FITC-CRT 
binding caused by these two agents. These data support the hypothesis that the 
degree of CRT binding is related to the cellular changes associated with apoptosis 
and necrosis in ovarian cancer cells.   
The second part of these studies investigated the effect of doxorubicin and 
thapsigargin on translocation and externalisation of endogenous CRT.  Again, both 
agents were significantly toxic and the increase in apoptotic and necrotic cells was 
accompanied by significantly increased cell surface exposure of CRT as assessed by 
the labelling of unpermeabilised cells with anti-CRT antibodies detected by 
fluorescence.  CRT was detected by both flow cytometry and immunocytochemistry 
with similar results. Interestingly, control experiments using doxorubicin showed that 
the drug was not cytotoxic against non-cancer cells i.e. normal human endothelial 
cells.  This lack of cell death was mirrored by a lack of enhanced surface CRT.  These 
results suggest that in the cancer cells the externalization of CRT is associated with 
cell death. However, it is possible that doxorubicin does induce cell death in the non-
tumour cells, but by an alternative mechanism that requires a greater time course for 
induction than the relatively short 16 hours studied here. For instance it has been 




by a different mechanism. Endothelial cells and cardiomyocytes treated with 0.5 µM 
doxorubicin for 72 hours showed increased apoptosis via a H2O2-mediated 
mechanism (Wang et al., 2004). 
The observation that ovarian cells treated with doxorubicin and the ER stressors 
thapsigargin externalise endogenous CRT agrees with the existing literature in other 
cancer cell types. For example, doxorubicin and thapsigargin treated murine colon 
cancer cells had enhanced surface CRT (Obeid et al., 2007). Interestingly, a similar 
effect was observed in Jurkat T-lymphocytes treated with 4 µg/ml doxorubicin for 4 
hours.   The doxorubicin enhanced surface translocation, but this was significantly 
inhibited in adherent cells engaged with integrin-mediated adhesion (Liu et al., 
2016a).The authors suggest that integrins are able to reduce CRT translocation to the 
cell, suppressing ICD and adding complexity to the cellular environment required for 
doxorubicin to induce ICD.  It has also been shown that other mediators can induce 
CRT translocation, for instance human ovarian cancer cell lines treated with nerve 
growth factor showed increased surface CRT (Vera et al., 2012) (Vera et al., 2017).  
Since the data clearly indicated surface externalisation of CRT it was possible that this 
was the result of enhanced CRT expression rather than just a relocation of existing 
cellular CRT. Examination of this by western blotting indicated that both doxorubicin 
and thapsigargin increased CRT expression.  This is in contrast to the results of (Liu 
et al., 2016a) who found that doxorubicin treatment of Jurkat T-lymphocytes resulted 
in a negligible change in total calreticulin. It is possible that the different cell types have 
differential responses to doxorubicin e.g. solid tumour vs suspension haematological 
cells.  
The secretion of CRT from ovarian cancer cells in response to doxorubicin and 
thapsigargin was also studied.  Both ER stressors induced significant levels of CRT 
release into the culture medium. This has been previously reported in A2780 ovarian 
cancer cells treated with 1 µM of thapsigargin for 4 h (Vera et al., 2017). This suggests 
that dying cells (early, late apoptosis & necrotic), may be a source of exogenous CRT.  
If this CRT is able to bind to local dying cells, as suggested here, marking them for DC 
recognition than then this may be an additional mechanism by which CRT can drive 
ICD. These findings highlight an important regulatory role of CRT that may be 




This is the first study that sought to determine whether TUDCA would inhibit cell death 
in tumour cells treated with doxorubicin and thapsigargin as pharmacological agents 
used to induce cell death. TUDCA alone was not cytotoxic, but TUDCA did partially, 
but significantly reduce cell death caused by both agents, suggesting that ER stress 
contributes to their induction of cell death in ovarian cancer cells.  However, this 
protective effect was not complete. It is possible that doxorubicin and thapsigargin 
promote cell death through more than one pathway and that this second pathway is 
ER stress independent. Interestingly, TUDCA has also been reported to reduce 
tunicamycin, UV-irradiation 4- phenylbutyric acid-induced cell death in HepG2 human 
liver carcinoma cells via ER stress dependent and independent pathways (Uppala et 
al., 2017). Specifically, the authors noted a role for TUDCA inhibition of PARP (poly 
ADP-ribose polymerase) cleavage in the observed reduction in cell death. Additionally, 
they also noted that TUDCA alone was not cytotoxic, confirming the data presented 
here. It is also possible that the treatment conditions for TUDCA were not optimal.  
Although, the time and dose of TUDCA used were informed by the existing literature, 
further optimisation studies for the cell culture system used here could be carried out.   
Importantly, the presented results also showed that the reduction in cell death induced 
by TUDCA was accompanied by a significant reduction in doxorubicin and 
thapsigargin induced exogenous CRT binding, CRT externalisation, total cellular CRT 
expression and CRT release in ovarian cancer cells. These data suggest that all of 
these functions are dependent on ER stress and/or cell death. Indeed, it has been 
reported that TUDCA impacts the PERK-eIF2α-ATF4-CHOP arm of the UPR  (Uppala 
et al., 2017) and that  a number of these pathway components (e.g. PERK and eIF2α) 
are associated with ER stress influenced CRT translocation induced by thapsigargin 
and doxorubicin treatment of cancer cells (Martins et al., 2010).  
These data demonstrate for the first time that doxorubicin and thapsigargin are able 
to induce secretion of CRT.  CRT secretion has also been reported to be induced by 
thapsigargin in mouse embryonic fibroblasts, although interestingly the secreted CRT 
(or other secreted ER chaperones) did not contribute to induction of the innate immune 
response as assessed by phagocytic uptake of these fibroblasts (Peters and 






It is thought that ICD of tumour cells is triggered when CRT is translocated to the cell 
surface of tumour cells where it acts as an ‘eat-me’ signal, enhancing phagocytic 
uptake of the cancer cells and consequently activation of the adaptive immune 
response (Gardai et al., 2005).  The studies presented in this chapter show that agents 
that induce ER stress i.e. the cytotoxic anthracycline doxorubicin and thapsigargin, 
promoted cell death in ovarian cancer cells with an increase in early and late apoptotic 
and necrotic cells. This was associated with enhanced binding of exogenous CRT and 
surface externalisation of endogenous CRT as well as increased expression and 
cellular release of the protein.  All of these cellular responses were significantly 
inhibited by TUDCA, an agent known to reduce ER stress by acting on components of 
the UPR pathway, suggesting that ER stress is at least partially responsible for the 
changes in CRT. 
From these data it is possible to hypothesise that cytotoxic agents such as doxorubicin 
may act in complementary ways to induce ICD.  Specifically, the CRT translocated to 
the cell surface may be supplemented with cell released CRT binding directly to the 
surface of both the immediate cell and its neighbours.  This may enhance uptake by, 
and activation of, phagocytic cells such as DCs and thus the engagement of adaptive 
immunity which can act to clear multiple tumour cells. The results also raise the 
possibility that therapeutic strategies designed to increase extracellular CRT, either by 
induction of tumour cell lysis or exogenous application may be effective. 
These findings highlight an important regulatory role of CRT that may be exploitable 
for cancer immunotherapy. The ability of tumour cells with enhanced surface CRT 
levels induced by endogenous translocation or exogenous application will be 










Chapter 5    Investigation into whether exogenous C RT or cancer cell expressing 
of surface CRT can induce maturation of DCs and sub sequent activation of T- 
cells. 
5.1. Introduction  
As previously described immunogenic elimination of cancer cells by the host requires 
the innate immune system to recognise tumour antigens as non-self. Specifically, the 
priming of adaptive immune cells e.g. T-cells is required, which then act against cells 
displaying the antigens.  A crucial step in this process is the presentation of the tumour 
antigens on the surface of APCs, with DCs being the most versatile and efficient of 
these. Dendritic cells are found in two main states, immature dendritic cells (imDCs)  
which are the normal steady state cells, and mature DCs (mDCs) which are 
phenotypically  and functionally different and are able to present  antigens to, and 
activate, T-lymphocytes (Dudek et al., 2013). Specifically imDCs recognise non-self-
cells and internalise their antigens which triggers the maturation process. During this 
these antigens are processed and presented at the cell surface in association with 
MHC class I and II molecules, the DCs migrate to the lymph nodes and prime naïve T 
cells for their cytotoxic response against these antigens.  
The major functional changes between imDCs and mDCs are expression of 
chemokine receptors that allow the DCs to become responsive to chemokines that 
facilitate their migration to the lymph tissue (Morelli et al., 2001). Additionally, the DCs 
start to secrete immunomodulatory cytokines such as IL17, IFNγ, IL4, IL5, IL10 and 
TNF alpha which allow them to activate the T-lymphocytes.  The T cells become 
cloned via mitosis, and differentiate to mature cells that help regulate and suppress 
the immune system (Morelli et al., 2001). DC phenotype changes include surface up-
regulation of CD80, CD83, CD86 and MHC II, and the secretion of the cytokines 
interleukin IL-2, IL-12 and granulocyte-macrophage-colony-stimulating factor (GM-
CSF) (Srivastava, 2002). Thus, imDCs and mDCs can be distinguished from each 
other based on their expression of these specific cell surface markers. In particular, 
CD80, CD83, CD86, CD11C and HLA-DR all have increased expression levels on 






Table 5.1. Major cell surface markers on mature DCs  
  
The activation of T- cells by mDCs is a critical step in cell mediated immunity (Figure 
5.1). T-lymphocyte production occurs in bone marrow and the cells migrate to the 
thymus to complete their maturation. The majority of T-cells are then found in the 
circulation and the lymph nodes  (Germain, 2002).  Most T cells are considered naïve 
(immature CD8+ cells) and have the potential to become cytotoxic T-cells. When 
activated, cells within the lymph nodes have the ability to recognise different 
pathogens via presentation of their antigens on the surface of migrated mDCs 
(Geginat et al., 2015). Once in the lymph node, the antigenic cargo of the DCs, 
presented via MHC molecules, is recognised by naïve T-cells which then undergo an 
activation period to become cytotoxic T cells.    This recognition occurs initially via the 
T-cell receptor (TCR) on the T-cell, which engages with the MHC complex on the mDC 
(Tseng et al., 2013). T cell expressed CD28 interaction with co-stimulatory molecules 
(CD80 and CD86) on DCs  leads to  synthesis of interleukins (e.g.IL2 and IL6) which  
drives proliferation and differentiation of the T-cells, ultimately leading to their clonal 
expansion (Pennock et al., 2013). CD8 is a surface glycoprotein which is primarily 
expressed on cytotoxic T cells and acts a co-receptor for the TCR. An individual T-cell 




which functionally is usually found as dimer, usually with one CD8- alpha (α) and one 
CD8 - beta (β) chain.   
 
 
Figure 5.1. Schematic representation of the major s ignals involved in activating 
T-cell responses (TCR = T- cell receptor). T-cell activation requires three signal 
inputs: stimulation of the T- cell receptor (TCR) by MHC/peptide complexes on antigen 
presenting cells (APCs) e.g. dendritic cells (signal 1); interactions between co-
stimulatory ligands on the APC and CD28 on the T cell which initiate T cell proliferation 
(signal 2); secretion of cytokines which contribute to regulation of the immune 
response (signal 3) (De Koker et al., 2011).  
 
The surface of imDCs has numerous cytoplasmic processes which increase surface 
area, enhancing contact with non-self-cells or pathogens which the DCs can then 
recognise through their expression of pattern recognition receptors (PRRs). These 
receptors recognise conserved molecular patterns on the non-self-cell or pathogen i.e.  
pathogen- or damage-associated molecular patterns (PAMPs and DAMPs) (Gold et 
al., 2015).  
As discussed in Chapter 1 (Introduction) cell surface exposed CRT acts a DAMP 
during ICD (Kumar et al., 2011).  It is translocated to the cell surface of apoptotic and 




oxaliplatin, and photodynamic therapy (Kepp et al., 2014) and can allow these cells to 
communicate with APCs (Feng et al., 2018). It has been reported that CRT on the 
surface of dying cells during irradiation and chemotherapy such as anthracyclines can 
induce DC uptake of tumour cells e.g. colon cancer cells (Obeid et al., 2007); inducing 
DC maturation and ultimately an ICD response. This interaction between CRT and 
imDCs enhances signalling events involved in the maturation of DCs (Kuppner et al., 
2001).  Thus, CRT has the ability to activate the adaptive immune system through 
DCs. It has also been reported that CRT additionally acts as an “eat-me” signal on 
apoptotic cells, lead to initiation of phagocytosis, which promotes secretion of 
inflammatory cytokines (e.g., IL-12) (Pandya et al., 2019). 
Previous studies have shown that it is possible to study in vitro maturation of imDCs 
into mDCs using the markers described above to distinguish between the two cell 
types (Han et al., 2009).   Two major sources of imDCs have been described in the 
literature to study  in vitro maturation  (a) imDCs derived from monocytes directly 
isolated from peripheral blood and (b)  imDCs derived from THP-1 cells, an 
immortalised cell line derived from the peripheral blood of a childhood case of acute 
monocytic leukaemia (Bosshart and Heinzelmann, 2016). Differences have been 
found in the responses of these two preparations, in particular it has been noted that 
responses in monocyte-derived DCs are more variable, presumably reflecting the 
heterogeneity in the donor population (Patente et al., 2018). 
Previous chapters of this thesis have shown that ovarian cancer cells treated with 
agents that induce ER stress express endogenous CRT on their cell surface and also 
that exogenously added CRT binds to the surface of ovarian cancer cells. This 
highlights two strategies by which CRT levels on the surface of ovarian cancer cells 
can be enhanced.  Since CRT has been shown to act as a DAMP, this raises the 
possibility that artificially raising CRT levels on the surface of ovarian cancer cells 
could activate DCs, inducing DC maturation and subsequent T-cell proliferation.  This 
could be a promising cancer therapy for ovarian cancers.  Indeed a similar strategy 
has been utilised using the cancer antigen New York esophageal squamous cell 
carcinoma 1 (NY-ESO-1) which has been shown to induce the immune system in 
many malignancies. NY-ESO-1 is expressed on various different kinds of cancers 




cancer, oesophageal cancer, hepatocellular cancer, head and neck cancer, non-small 
cell lung cancer, ovarian cancer, prostate cancer, and breast cancer (Jungbluth et al., 
2001, Sharma et al., 2003).  In  recent years, the first NY-ESO-1 cancer vaccine trials 
have been carried out and show its ability to activate T- cytotoxic cells (Thomas et al., 
2018). Thus, cancer immunotherapy can be summarised as the treatment of cancer 
by promoting and boosting the immune response (Mellman et al., 2011) and 
theoretically could be an important strategy in the  fight against cancer.  
 
5.2. Aims 
The overall objective of this chapter was to examine whether EOC cells expressing 
CRT could enhance DC maturation and subsequent T-cell proliferation in an in vitro 
experimental model. Ovarian cancer cells were treated with agents shown in Chapter 
4 to increase CRT surface exposure.  The ability of these treated cells to induce imDC 
cell maturation was then examined initially in imDCs derived from THP-1 cells to 
develop the protocol and then imDCs derived from freshly isolated peripheral blood 
monocytes. DC maturation was assessed by expression of key markers as described 
above. The ability of matured DCs to induce T-cell proliferation was then assessed in 
freshly isolated human T-cells from peripheral blood. 
Therefore the specific aims of this chapter were: 
• To establish a technique to isolate CD14+ monocytes from peripheral blood 
samples from healthy blood donors 
• To establish a technique to derive imDCs in vitro from THP-1 cells and isolated 
CD14+ monocytes.  
• To establish a technique to assess maturation of imDCs to mDCs in vitro  
• To establish a technique to isolate CD8+ T cells from peripheral blood samples 
from healthy blood donors 
• To investigate whether ovarian cancer cells pre-treated with doxorubicin (and  
expressing surface CRT) induce DC maturation  
• To examine whether exogenous CRT can induce DC cell maturation. 
• To study the potential of the DCs matured as above to induce T-cell proliferation 




5.3. Methods  
5.3.1. Cell culture 
THP-1 and OVcar3 ovarian cancer cells were cultured as described in Chapter 2 
section (2.3.1.) and (2.3.2.). Where indicated OVcar3 cells were treated with 0.5,1, 2.5 
µM doxorubicin for 16 h and harvested and co-incubated with imDCs. THP-1 cells 
were treated as indicated to induce differentiation to imDCs. 
 
5.3.2. Isolation of human blood mononuclear cells ( Protocol 1).        
A CD14+ monocyte magnetic bead separation technique was used to isolate 
monocytes from other leukocytes obtained from peripheral blood samples by depleting 
a mixed cell population of unwanted leukocyte populations i.e. negative selection.  
Briefly, 50 ml of blood was collected from heathy donors into EDTA vacutainer tubes 
after obtaining written informed consent (UEMS ethics approval number 
18102/152∆1). After centrifugation to collect the buffy coat the resulting leukocyte 
preparation was enriched for monocytes using a magnetic bead separation technique. 
1. 2 volumes of room temperature PBS (without Ca2+ and Mg2+, PBS-) was added to 
one volume of the blood. 15 ml Ficoll-Hypaque was added to new 50 ml centrifuge 
tubes and 30 ml of the diluted blood was carefully overlaid on the top. Tubes were 
centrifuged for 30 minutes at 900 x g at room temperature without the brake. Using 
a sterile transfer pipette all but 5 ml of the supernatant was removed, and kept in 
a separate 50 ml tube. The remaining 5 ml were vacuum aspirated, thus removing 
the upper layer containing most of the platelets. This was discarded. 
2. Using a sterile transfer pipette the cloudy interface (buffy coat) between the plasma 
and red blood cells was removed and placed in new 50 ml centrifuge tubes. Cells 
were washed by adding 3 volumes of PBS and centrifuging for 15 minutes at 500 
x g at room temperature. After removing the supernatant, a new wash was done 
with chilled PBS and centrifuging at 4ºC. (This discarded most of the platelets and 
remaining Ficoll). 
3.  5 ml of sterile NaCl (0.2% w/v) were added to lyse residual red blood cells.  After 
3 minutes, 20 ml of chilled PBS- with 2mM EDTA (PBS-E) were added and the 




100x dilution using trypan-blue, (10 µl of cell suspension mixed with 10 µl of trypan 
blue). 
4. After this the cells were enriched for monocytes using the Monocyte Isolation Kit II 
(Miltenyi Biotec). The cell suspension was initially filtered to remove cell 
aggregates before starting the magnetic-activated cell sorting (MACS) procedure. 
• Cells were resuspended in 40 µL MACS-Buffer (PBS [100 ml] with 0.5% (w/v) BSA) 
and 2mM EDTA) per 107 white cells. 
• 10 µL of FcR Blocking Reagent was added per 107 total cells. 
• 10 µL of Pan Monocyte Biotin-Antibody Cocktail, human was then added per 107 
total cells to label non-CD14+ monocytes. 
• Following complete mixing the cells were incubated for 5 minutes at 4oC. 
• 30 µL of MACS-Buffer was added per 107 total cells. 20 µL of Anti-Biotin Microbeads 
was added of per 107 total cells which were then mixed well and incubated for a 
further 10 minutes at 4oC. Cells were then washed by adding 2 ml of buffer per 107 
cells and centrifuging at 300xg for 10 minutes.  
• The supernatant was discarded completely and the cells re-suspended, up to 108 
cells, in 500 µL of Macs Buffer. A separation LS column was then placed in the 
magnetic field of a MAC  separator column (Molinari et al., 2011)  
• The column was prepared by rinsing with 3 ml of Macs Buffer to extract bubbles. 
The cell suspension was then applied onto the column and the unlabeled cells (i.e. 
those which the antibody coated magnetic beads (monocytes) did not attach to)  
passed through, were collected, and the column washed with 3 x 3 ml of Macs 
Buffer with every wash flow-through collected. This constituted the CD14+positive 
cells. 
• The column was removed from the separator and placed on a centrifuge tube. 
Buffer was pipetted onto the column and the magnetically labeled non-monocytes 
were flushed out by firmly pushing the plunger into the column.  
5. To confirm monocyte enrichment cells were stained with Diffquik as described 
in Chapter 4 and analysed by flow cytometry using antibodies against the 






5.3.3. Generation of mDCs from monocytes (Protocol 2) 
A- Generating imDCs from isolated peripheral monocytes . 
imDCS were generated from isolated monocytes by 7 day treatment with IL4 and GM-
CSF following the protocol of (Berges et al., 2005). 
1. Monocytes were seeded in 6 well plates at  0.3 - 0.5 x 106/ml in 2 mls  of cell culture 
medium supplemented with  500U/ml IL-4 + 800 U/ml GM-CSF to induce 
differentiation. 
2. Cells were incubated in a tissue culture incubator at 37°C with 5% CO2. 
3. 850 µl of medium from the culture was removed at day 3 and centrifuged at 300 x 
g for 5 minutes at 4°C. The  supernatant was aspirated and the pellet resuspended  
in 1 ml of cell culture medium containing 2x concentration of 500U/ml IL-4 + 800 
U/ml GM-CSF i.e. 1000U/ml IL-4 + 1600 U/ml GM-CSF. This suspension was 
added back to the culture, diluting the GM-CSF and IL-4 to the original 
concentration. 
4. Step 3 was repeated at day 6. 
5. At 7 days cells were stained for markers of immature dendritic cells (increased 
CD11c, HLA-DR and CD83 compared with monocytes (Johansson et al., 2008), 
using flow cytometry as in section (5.5) below. 
 
B. Generation of imDCs from THP-1 cells  
THP-1 cells were harvested by centrifugation, resuspended in culture medium 
supplemented with 10% (v/v) FCS at a concentration of 2 x 105 cells/ml, and 
transferred in a final volume of 14 ml into 75 cm2 tissue culture flasks. To induce 
differentiation into imDCs, IL-4 (500 IU/ml) and GM-CSF (800 IU/ml) were added as 
above. Cells were cultured for 7 days with change of media every 2 days by 







C.  Generation of mDCs from imDCs 
Lipopolysaccharide (LPS) is known to activate antigen-presenting cells. Thus, LPS 
was added at 1 µg /ml as a positive control to induce maturation of imDCs using the 
protocol of  (Sim et al., 2016). imDCs were cultured with LPS for a further 4 days (i.e. 
total of 11 from initiation of monocyte differentiation with GM-CSF and IL4).  mDCs 
were harvested by flushing the culture dish with PBS-E. Only non-adherent cells were 
harvested. Maturation of DCs was assessed by surface expression of markers of 
maturation i.e. CD14, CD83, CD11c, CD80, HLA-DR and CD86 by flow cytometry.   
 
5.3.4. Co-culture of imDCs with doxorubicin (DX) pr e-treated OVcar3 cells or 
purified CRT (see Figure 5.2). 
Additionally:  
1. The effect of exogenous CRT alone to induce imDC maturation was examined by 
culture of imDCs with 0.5 1, 2.5 µg/ml CRT for 4 days. As a positive control, 1µg/ml 
LPS was added as above.   
2. The effect of doxorubicin-treated OVcar3 cells on DC maturation was also 
examined.  OVcar3 cells were treated with varying concentrations of doxorubicin 
(0.25, 1, 2.5µM) for 16h (as determined in chapter 4) to ensure surface exposure 
of CRT and then washed three times with PBS to remove the doxorubicin.  OVcar3 
cells were then co-cultured with imDCs at a ratio of 1:1 in RPMI 1640 supplemented 
with GM-CSF, IL-4 (as above) and 10% (v/v) FBS for 4 days. As a control, imDCs 
were co-cultured with untreated OVcar3 cells. Maturation of DCs was assessed by 
surface expression of markers of maturation i.e. CD14, CD83, CD11c, CD80, HLA-
DR and CD86 by flow cytometry.  The OVcar3 cells were stained with an antibody 
against epithelial cell adhesion molecule (EpCAM) which is highly expressed on 
ovarian cancer cells (Nunna et al., 2014). i.e. anti-EpCAM CY-5 (1:50 dilution).  
This allowed these cells to be gated out of the analysis (see section 5.9.). For all 
antibodies cells were incubated for 30 min in the dark at room temperature, washed 
once with PBS and analysed by flow cytometry.  
3. Control experiments to confirm that OVCar3 cells did not express DC markers were 




CD14-FITC, anti-CD83-PE, PE anti-human CD11c, PE anti-human CD80, PE anti-
human CD83, anti-HLA-DR-PE and anti-CD86-PE. Cells were incubated for 30 min 
at room temperature and expression of EpCAM and DCs markers were analysed 
by flow cytometry (see section 5.9.). Similarly, DCs were stained with EpCAM to 
confirm that they did not express this marker which would result in them being 













Figure 5.2. Schematic diagram describing the experi mental design of treatments 
potentially inducing DC maturation. imDCs were generated from THP-1 cells or 
isolated monocytes by 7-day treatment with IL-4 and GM-CSF. At day 7, cells were 
stained for markers of immature dendritic cells CD11c, HLA-DR and CD83, CD80, 
CD86 (compared with monocytes). imDCs were then cultured for a further 4 days with 
LPS (positive control), 0.5 1, 2.5 µg/ml CRT or OVcar3 previously treated with varying 
concentrations of doxorubicin (DX, 0.25, 1, 2.5µM) for 16h to ensure surface exposure 
of CRT. Maturation of DCs was assessed by surface expression of markers of 
maturation i.e. CD14, CD83, CD11c, CD80, HLA-DR and CD86 by flow cytometry and 





5.3.5. ELISA protocol 
Cell culture supernatants were collected for the measurement of secreted IL-12, IL-23 
by ELISA since these cytokines have been reported to be secreted by DCs as they 
mature (Mayordomo et al., 2018).Supernatants were analysed for IL12/23 using a 
commercially available 12/23 (p40) ELISA MAX™ kit as described in Chapter 2. 
 
5.3.6. Isolation of human T lymphocytes 
Human T cells were isolated by negative selection from whole blood using a magnetic 
bead CD8+ T Cell Isolation Kit (Miltenyi Biotec).  
1. Human peripheral blood was obtained from healthy donors as described in section 
5.3.2. 
2. 3 ml of room temperature polymorph density gradient media was pipetted into an 
8 ml round-bottom polystyrene tube. Gently, 3 ml of whole blood was added on top 
of the polymorph media to avoid mixing.  
3.  The tubes were centrifuged at 500 x g for 45 minutes at room temperature. 
4. Following the centrifugation, the peripheral blood mononuclear cells (PBMC) 
separated from other blood components into the top cell layer appearing, from the 
top down, as the first cloudy band. 
5. Carefully, the plasma was removed from above the PBMC layer, and a P1000 
micropipette was used to transfer the PBMC layer to a fresh centrifuge tube. 
• The PBMCs were washed twice with PBS, centrifuging cells at 500g for 5 minutes 
each time, and then cells were counted. The cell pellet was then resuspended in 
40 µL of MACS- buffer per 10⁷ total cells. 
• 10 µL of Biotin-Antibody Cocktail was added of per 10⁷ total cells, mixed well and 
the cells incubated for 5 minutes at 4oC. 
• 30 µL MACS-buffer was added of per 10⁷ total cells. 
• 20 µL of CD8+ T Cell Microbeads Cocktail was added per 10⁷ total cells then mixed 
well and incubated for 10 minutes at 4oC. 




• The LS Column was placed in the magnetic field of a MACS separator. The 
columns were rinsed with 3 ml of MACS-buffer and the cell suspension was applied 
onto the column. Flow-through containing unlabelled cells was collected, 
representing the enriched CD8+T cells. 
• 3 ml of buffer was washed through the column and the flow through again collected 
and added to the flow-through previously collected.  
• Purity of the T cell population was assessed by flow cytometry using anti-CD8-
FITC and anti-CD3-APC 
 
5.3.7. Examination of T-cell activation by mDCs (se e Figure 5.3). 
 T cell activation under a range of experimental conditions was assessed by 
measurement of proliferation in which cells were fluorescently labelled and cell 
divisions were followed by assessing subsequent labelling of daughter cells using flow 
cytometry. T-cells were labelled with a Cell Trace carboxyfluorescein succinimidyl 
ester (CFSE) cell proliferation kit according to the manufacturer’s protocol (Invitrogen). 
Briefly, harvested T cells were stained with 2.5 µM CFSE in 0.1% w/v BSA/PBS for 10 
minutes at 37°C. Subsequently, T cells were incubated in fresh medium for 10 minutes 
on ice and excess dye was removed by 3 washes. DCs matured as indicated (or 
relevant controls) were harvested, washed once, resuspended at a density of 1 x 106 
cells/ml in RPMI 1640 with 10% (v/v) FCS,  500 U/ml GM-CSF and 500 U/ml IL-4, and 
plated at the indicated ratios in round-bottom 96-well plates in the presence of 1 x 105 
CFSE-labelled T-cells/well. DC-T cell co-cultures were incubated for 5 days at 37°C in 
a humidified 5% CO2 incubator. At day 5, cells were harvested and an additional 
staining were performed with anti-CD3-PerCP-Cyanine5.5 for 30 minutes at 4°C and 
the cells were analysed by flow cytometry to examine the CFSE-staining pattern. Cells 
were gated on CD3-positivity (to gate out the mDCs) since it is expressed almost 







5.3.8. Treatment of T cells with human T-activator CD3/CD28 Dynabeads.  
Since CD3 and CD28 are essential co-stimulatory signals for T cell expansion (Li and 
Kurlander, 2010) antiCD3/anti-CD28 coated magnetic beads were also incubated with 
freshly isolated T cells as a positive control for cell expansion (Figure 5.4). 
Dynabead preparation. 
Magnetic Dynabeads coated with anti-CD3/anti-CD28 (Invitrogen) were resuspended 
in the vial by thorough mixing and the desired volume of Dynabeads was transferred 
to a fresh tube and washed well with 1ml of MACS-buffer. The tube was then placed 
on a magnet for 1 minute and the supernatant discarded. The tube was removed from 
the magnet and the washed Dynabeads resuspended in the same volume of culture 



















Figure 5.3. Schematic diagram describing the experi mental design of T-cell 
isolation and activation/proliferation as assessed by CFSE staining. T-cells 
harvested from peripheral blood mononuclear cells (PBMCs) were stained with 
carboxyfluorescein succinimidyl ester (CFSE to allow subsequent assessment of cell 
proliferation. Subsequently, T-cells were incubated with mature dendritic cells (mDCs) 
derived from iDCs immature dendritic cells treated with either 0.5, 1, or 2.5µg/ml of 
CRT and 1µg/ml LPS; OVCar3 pre-treated with 2.5µg/ml doxorubicin (DX or OVcar3 
pre-treated with 2.5µg/ml CRT to induce maturation. mDC-T cell co-cultures were 
incubated for 5 days, cells harvested, and an additional staining performed with anti-
CD3-PerCP-Cy5.5 before flow cytometry analysis to examine the CFSE-staining 
pattern. Cells were gated on CD3-positivity (to gate out the mDCs) since it is 





5.3.9. Activation of human T cells with CD3/CD28 T- activator Dynabeads. 
1. 8 × 104 purified T cells in 100–200 µL medium were placed in a 96-well tissue 
culture plate. 
2. 2 µL of pre-washed and resuspended Dynabeads was added to obtain a bead-to-
cell ratio of 1:1 and cells incubated in a humidified CO2 incubator at 37°C, 
according to specific experimental requirements. 
3. The activated T cells were harvested and used directly for further analysis. 
4. For flow cytometry the beads were removed prior to staining by placing the tube 
on a magnet for 1–2 min to separate the beads from the solution. The supernatant 














Figure 5.4. Diagram indicating the mechanism by whi ch T cell expansion 
activated by anti-CD3/anti-CD28 coated Dynabeads (b eads) mimics T-cell 





5.3.10. Flow cytometry 
All flow cytometry was carried out using a Guava flow cytometer instrument (Millipore, 
Hertfordshire, UK) as described in Chapter 2 (Materials and Methods) 
Characterisation of isolated monocytes 
Isolated monocytes were fluorescently stained with Alexa Fluor® 488 anti-human 
CD14 antibody, PE anti-human CD16 antibody. The live cell population was gated on 
an FSC-A vs SSC-A plot, based on size and granularity (complexity).  
 
Cell surface marker characterization of imDCs and m DCs 
1. DCs were detached from the culture dish by pipetting, washed once with 
PBS/EDTA and resuspended at a concentration of 1 x 106 cells per 100 µl of 
staining buffer in 1.5 ml micro centrifuge tubes. 
2. For flow cytometric analysis, 5µl of fluorescently-labelled monoclonal antibodies 
against cell surface markers were added to separate cell aliquots i.e.  PE-anti-
human CD11c, PE-anti-human CD80, PE- anti-human CD83, PE anti-human 
CD86, PE anti-human HLA-DR, Alexa Fluor 488-anti CD14. 
3. Cells were incubated in the dark for 30 minutes at 4°C. Isotype-matched Alexa 
Fluor® 488 Mouse IgG1, κ Isotype Ctrl (FC), PE Mouse IgG1, κ Isotype Ctrl (FC), 
PE Mouse IgG2b, κ Isotype Ctrl antibodies were used as isotype controls (Table 
5.2). Unstained cells were also analysed as a negative control. 
4. Levels of surface marker expression were analysed using flow cytometry. 
 
Analysis of maturation of DCs incubated with doxoru bicin treated ovarian 
cancer cells. 
The experiments examining the effect of doxorubicin treated OVCar3 cells on DC 
maturation involved a two cell type culture model i.e. DCs and OVCar3 and thus the 
OVcar3 cells were stained with anti-EpCAM CY-5 to detect EpCAM which is highly 
expressed on ovarian cancer cells, allowing these cells to be gated out of the analysis.  




These were (1) confirmation that OVcar3 cells did not express DC surface markers 
confirmation (2) confirmation that DCs did not express EpCAM. 
 
 
Table 5.2. Details of the antibodies and the isotyp e controls used for 
characterisation of imDCs & mDCs. 
 
5.3.11. Statistical analysis 
Statistical analyses were carried out using GraphPad PRISM software 7 and Microsoft 
Office Excel. The Mann Whitney U test was used to test the significance of variables 
between the two groups. P<0.05 was considered statistically significant. The graphical 
representation of the data is mean ± standard deviation (SD).  
 
5.4.   Results  
5.4.1. Generation of imDCs from the human monocytic  THP-1 cell line. 
Human monocytic THP-1 cells (Figure 5.5) were differentiated to imDCs by incubation 
with GM-CSF and IL-4 for 7 days and levels of surface markers of differentiation were 
assessed by flow cytometry. It has been reported that imDC have relatively high 
surface expression of CD11c, HLA-DR and CD83 compared with monocytes 




Figure 5.6 demonstrates that at  day 7, THP-1 cells showed increased expression of 
all surface markers studied with this reaching significance for CD11c, CD86 and HLA-
DR markers (59.4 ± 7.592 vs 17.94 ±14.27; 65.03 ± 18.49 vs 31.07 ± 15.23  and 65.03 
± 18.49 vs) respectively (figure 5.6 c). These data indicate that THP-1 monocytes can 











Figure 5.5.  Morphology of THP-1 cells at 0 day . (a)  The THP-1 cell line observed 
under bright field microscopy, (b) THP-1 cells observed under light microscope 






























Figure 5.6.  THP-1 cells  can be induced to express markers of imDCs.   THP-1 cells 
were treated with GM-CSF and IL-4 for 7 days and surface expression of  CD11c, 
HLA-DR, CD80, CD 83 and CD 86 were assessed by flow cytometry before (0 days) 
and after (7 days) treatment. Isotype controls and unstained cells were included in all 
analyses. (a) Flow cytometry histograms of stained THP-1 cells at day 0 (b) flow 
cytometry histograms of THP-1-derived immature dendritic cells at 7 day; (c & d) table 
and graph showing the % of cells in each population expressing the markers 
assessed. Results are mean ± SD,   ##p< 0.01 vs unstimulated cells at 0 day, n=5. 
n.s. denotes not significant. (a) and (b) are representative results from one of 5 





5.4.2. Phenotypic maturation of imDCs derived from THP-1 monocytes to mDCs 
by LPS. 
The imDCs (from THP-1 cells) described above were treated with 1µg/ml LPS for a 
further 4 days and then assessed for surface markers of mDCs. Figure 5.7 
demonstrates that the derived cells showed characteristics of mDCs including a 
significant 1.6-fold increase in expression of CD11c from 59.4 ± 7.592 to 79.6 ± 6.96. 
A similar response was observed when cells were stained for HLA-DR with a 
significant 1.8- fold increase from 58.73 ±10.17 to 85.67 ± 6.537. Significant 
upregulation of surface expression of CD80 from 40.68 ± 22.58 to 81.14 ± 7.202, CD86 
65.03 ± 18.49 to 84.12 ± 4.58 and CD83 51.02 ± 21.49 to 75.2 ± 8.64 were also 
observed. There was also a significant decrease in CD14 expression from 69.72 ± 
15.08 to 23.32 ± 19.02 (Figure 5.7 b). These data suggest that imDCs derived from 
THP-1 cells can be matured to cells expressing markers of mDCs by LPS. 
 
5.4.3. The effect of  CRT on maturation of THP-1 derived imDCs . 
The experiments above establish a methodology to examine DC maturation in vitro. 
Since ICD requires DC maturation, and cancer cells undergoing ICD expose CRT on 
their cell surface, experiments were carried out to examine whether CRT alone can 
induce DC maturation. Immature DCs were incubated with increasing concentrations 
of CRT and maturation was assessed by surface marker staining.  The data presented 
in Figures 5.8 and 5.9 demonstrate that exogenous CRT can induce maturation of 
THP-1 derived imDCs.  This effect appears to be dose dependent with  0.5 µg/ml CRT 
only inducing a significance increase in the expression level of HLA-DR, although it 
did induce a significant reduction in the expression level of CD14 from 69.72 ± 15.08 
to 6.5 ± 2.302 (Figure 5.9 a).  In contrast both 1 and 2.5 µg/ml CRT (Figure 5.9 b, c) 
induced significant changes in the maturation surface markers CD14, CD11c, CD80, 
CD83, and HLA-DR.  For instance HLA-DR levels were increased from 58.73 ± 10.17 
to 80.47 ± 3.82 at 1 µg/ml CRT and 77.92 ± 4.46 at 2.5 µg/ml CRT. However, although 
CD86 levels were increased by both 1 and 2.5 µg/ml CRT these increases did not 




at1 µg/ml CRT ,and 5.8 ± 2.775 at 2.5 µg/ml CRT respectively vs imDCs (69.72±15.08) 


















Figure 5.7 . DC maturation status examined using flow cytometry analysis of 
surface markers . imDCs derived from THP-1 cells were matured by incubation with 
LPS for 4 days and the change in surface levels of CD11c, CD80, CD83, CD86 and 
HLA-DR and CD14 were measured by flow cytometry. (a)  and (b) show % of cells 






















Figure 5.8. CRT induced maturation of THP-1 derived  imDCs to mDCs. THP-1 
derived imDC were stimulated with LPS (1 µg/ml, a positive control) and increasing 
concentrations of CRT for 4 days.  DC maturation was assessed by flow cytometric 
analysis of mDC surface markers.  Cells were treated with (a) 1µg/ml LPS (b) 0.5µg/ml 
CRT (c) 1µg/ml CRT (d) 2.5µg/ml CRT. % indicated in each panel shows percentage 
of cell population expressing  the marker measured  Representative histograms from 




































Figure 5.9. CRT induced expression of mDC markers i n THP-1 derived imDCs. 
THP-1 derived imDCs were stimulated with different concentrations of CRT for 4 days.  
DC maturation was assessed by flow cytometric analysis of mDC surface markers.   
Cells were treated with (a) 0.5µg/ml CRT, (b) 1µg/ml CRT (c) 2.5µg/ml CRT. (d) 
Combined data for comparison.  Data are shown as mean ± SD.  ##p< 0.01, #p<0.05 





The data presented in Figures 5.5 - 5.9 examine the responses of DCs derived from 
the THP-1 monocytic cell line. These experiments were performed in order to establish 
these techniques in the laboratory. However, it has been reported that differential 
responses have been observed between blood and THP-1 derived DCs (Daigneault 
et al., 2010) and therefore further experiments were carried out to establish a protocol 
to derive DCs from human peripheral blood monocytes. 
5.4.4. Monocyte isolation  
Monocytes were isolated from peripheral blood of healthy donors using protocol 1 (10 
isolations in total). Enrichment of monocytes was achieved by magnetic separation by 
MACS® Technology (Miltenyi Biotec). Purification required several procedures 
including isolating PBMC by density centrifugation of blood into plasma, buffy coat and 
erythrocytes (Figure 5.10 a). The morphology of monocyte cells was initially observed 
using a light microscope after separation from PBMCs. Monocytes have unilobed 
nuclei with an amoeboid shape after staining by Diff-Quick stain (Figure 5.10 b).   
Isolated cells were also characterized by flow cytometry using antibodies against 
monocyte specific antigens i.e. anti-CD14 –FITC   and anti-CD16 –PE (Figure 5.11). 
It can be seen that in a typical isolation approximately 85% of the isolated monocytic 
cells express CD14 which is considered to be the major marker of monocytes (Menck 
et al., 2014).  CD16 allows further differentiation into monocyte subpopulations (Mandl 
et al., 2014).  Over 50% of the monocytes isolated were CD14++ CD16− monocytes 
i.e. classical monocytes. These data indicate an enriched monocyte preparation. 
 
5.4.5. Generation of imDCs from isolated peripheral  monocytes.  
Isolated monocytes were differentiated to imDCs as described for THP-1 cells and 
then stained for DC surface markers (CD80, CD83, CD86 and HLA-DR) using flow 
cytometry. As shown in (Figure 5.12 a, b) freshly isolated peripheral monocytes 
expressed low levels of all markers at day 0 (Figure 5.12 a). However, following 7 days 
treatment with the differentiating factors GM-CSF and IL4 the cell population showed 
a significantly increased expression of: CD11c (from 14.89  ± 1.17 to 64.86 ± 7.547%), 
HLA-DR (from 23.83 ± 1.28 to 68.67 ± 7.742%),  CD80 (from 11.5 ± 0.89 to 64.13 ± 
9.71%);  CD83 (from 16.44 ± 3.25 to 60.7 ± 12.43%) and CD86 (from 18.88 ± 7.153%  














Figure 5.10.  Isolation procedure for purification of monocytes f rom peripheral 
human blood.  (a) Leukocyte buffy coat layer after separation of blood on a Ficoll 
gradient and (b) monocytes under light microscopy, stained by Diff-Quick stain, 









Figure 5.11. Characterisation of enriched monocyte population. Isolated 
monocytes were stained with fluorescent anti-CD16 PE and anti- CD14 FITC 

























Figure 5.12 .  Peripheral monocytes can be differentiated into imD Cs.  Monocytes 
isolated from peripheral blood were incubated for 7 days in the presence of GM-CSF 
(800U/ml) and IL-4 (500U/ml).  Cells at day 0 and 7 were analysed by flow cytometry 
for a panel of markers expressed on DCs. Unstained cells and isotype controls were 
included for all markers (a)   flow cytometry histograms of monocytes analysed at day 
0 day (b) flow cytometry histograms of monocyte derived imDCs at 7 day (c) and (d) 
expression of DC markers at day 0 and after 7 days of differentiation. Results are 
mean ± SD. ##p< 0.01 vs unstimulated cells at 0 day, n=5. (a) and (b) are 
representative data from one experiment repeated 5 times with similar results. The 






5.4.6. Generation of mDCs from imDCs derived from p eripheral blood 
monocytes.  
imDCs derived from peripheral monocytes were stimulated with 1µg /ml LPS to induce 
differentiation into mDCs. Cell surface expression of the mDC markers CD11c, CD80, 
CD83, CD86 and HLA-DR all significantly increased after 4 days treatment compared 
with the unstimulated cells. CD11c increased from 64.86 ± 7.55 to 78.22 ± 4.58%; HLA-
DR from 68.67 ± 7.74 to 80.37 ± 7.79%; CD80 from 64.13 ± 9.71 to 79.41 ± 3.85%; 
CD83 from 56.63 ± 6.14 to 73.6 ± 4.16% and CD86 from 67.29 ± 10.95 to 78.6 ± 7.3%. 
CD14 showed an approximately 6 -fold reduction in expression in mDCs (7.63 ± 
6.54%) compared with imDCs (65.48 ± 14.82%). These data confirmed that monocyte 
derived imDCs could be matured in vitro to mDCs by LPS (Figure 5.13).  
 
5.4.7. CRT promotes monocyte derived imDC maturatio n. 
CRT was able to induce expression of DC maturation markers in THP-1 derived 
imDCs and so this was also tested in monocyte derived imDCs. imDCs treated with 
CRT at all concentrations tested (0.5, 1, 2.5 µg/ml) showed increased expression of 
CD11c, CD80, CD83, CD86 and HLA-DR compared with untreated monocyte derived 
imDCs (Figures 5.14 (a, b, c, d)). This increase was significant for HLA-DR and CD83 
for cells treated with 0.5 µg/ml CRT and significant for all markers at the two higher 
CRT concentrations. For instance, 2.5 µg/ml CRT increased CD11c levels from 64.86 
± 7.55 to 78 ± 2. 74%, HLA-DR from 68.67 ± 7.74 to 83.2 ± 2.95%, CD80 from 64.13 
± 9.71 to 83.2 ± 7.16%, CD83 from 56.63 ± 6.14 to 79.6 ± 2.6% and CD 86 from 67.29 
± 10.95 to 83.54 ± 2.82% (p< 0.05, n=5  for all)  (Figures 5.15 (a, b, c, d)). CD14 
expression was significantly reduced by treatment with all CRT concentrations studied. 
Hence, it appears from this experiment that CRT can induce maturation of imDCs 

























Figure 5.13. imDCs derived from peripheral blood mo nocytes can be 
differentiated into mDC by LPS.   Monocyte-derived imDCs (cells at day 7 after 
isolation) were treated with 1µg/ml LPS for 4 days (cells at day 11 after isolation) and 
then assessed by flow cytometry for markers of DC maturation. (a) Table of average 
data from 5 separate isolations displayed as mean ± S.D, n=5. (b) Data presented 
























Figure 5.14. Exogenous CRT can induce maturation of  imDCs derived from 
peripheral monocytes. Monocyte derived imDCs were treated for 4 days with (a) LPS 
(positive  control), (b) 0.5,  (c) 1,  (d) 2.5 µg/ml CRT and then analysed by flow 
cytometry for cell surface markers of DC maturation as indicated. Unstained cells and 
isotype controls were included as controls. Representative histograms from one 
experiment are shown. The experiment was repeated three times with similar results. 
Percentages shown in each panel indicate the percentage of the cell population 



















































Figure 5.15. CRT induced expression of mDC markers in peripheral blood 
monocyte derived imDCs. Peripheral blood monocyte derived imDCs (cells at 7 days 
after isolation) were stimulated with different concentrations of CRT for 4 days (cells 
at 11 days after isolation).  DC maturation was assessed by flow cytometric analysis 
of mDC surface markers.   Cells were treated with (a) 0.5µg/ml CRT, (b) 1µg/ml CRT 
(c) 2.5µg/ml CRT (d) combined data for comparison.  Data are shown as mean ± SD 






5.4.8. DCs derived from peripheral blood monocytes exhibit a dendritic 
morphology. 
Morphological examination of the isolated monocytes before and after differentiation 
to imDCs and subsequent maturation to mDCs supported the phenotypic changes 
suggested by changes in expression of surface markers (Figures 5.15). Initially, 
isolated monocytes had a rounded shape and adhered to the plastic surface of the 
flask. During treatment with GM-CSF/IL-4 to induce differentiation into imDCs the cells 
appeared to increase in size and the cell clusters began to become larger and non-
adherent to the flask, but the numbers of cells did not expand. imDCs treated with 1 
µg/ml LPS or CRT (0.5, 1, 2.5 µg/ml) to induce maturation transformed into cells with 
stellate processes/cytoplasmic projections and an irregular shape. mDCs showed 
processes that extended in different directions with numerous granules and irregular 
nuclei (Hart, 1997) (Figure 5.16).  
 
5.4.9. Activation of DC maturation by ovarian cance r cells (OVcar3) treated 
with doxorubicin to induce surface expression of CR T. 
The data above indicate that exogenous CRT induces maturation of imDCs.  To 
examine this further, a series of experiments were carried out to investigate whether 
cancer cells treated with doxorubicin to induce surface expression of endogenous CRT 
could also stimulate DC maturation. OVcar3 cells previously treated with increasing 
concentrations of doxorubicin (0.25, 1, 2.5 µM for 16 hr), to induce cell surface CRT 
exposure, were co-cultured with imDCs derived from peripheral blood monocytes.  
Markers of DC maturation were then examined by flow cytometry with the OVCcar3 
cells gated out by staining with EpCAM. Since this co-incubation resulted in a mixed 
cell population initial studies examined possible cross staining of each cell type with 
markers of the other. 
Figure 5.17 indicates that over 90% of OVcar3 cells expressed EpCAM and that the 
cells only expressed low levels of the DC markers. Mann Whitney test results 
confirmed significant differences between all DC markers when compared with 






















Figure 5.16. The morphology of isolated peripheral blood monocytes 
changes during differentiation to imDCs and maturat ion to mDCs. Isolated 
monocytes were treated initially with GM-CSF and IL4 to induce differentiation to 
imDCs and then with LPS or increasing concentrations of CRT to induce 
maturation to mDCs. Changes in cell morphology were observed under bright field 
microscopy during cell culture (40× magnification). (a) Isolated monocytes at day 
0, 3 and 7 of GM-CSF and IL4 treatment, (b) imDCs observed at day 2 of treatment 
(i.e. day 9 after isolation) with either LPS or different concentrations CRT, (c) 
imDCs observed at day 4 of treatment (i.e. day 11 after isolation) with either LPS 





EpCAM was a suitable marker for the detection of OVCar3 cells in a mixed 
population with DCs. 
Experiments were then performed to confirm that DC did not express EpCAM. 
Figure 5.19 indicates that no EpCAM fluorescence was detected on the surface of 
mDCs and that the presence of anti-EpCAM antibodies did not interfere with 
staining by DC markers.  
 
5.4.10. Doxorubicin-treated ovarian cancer cells (OVcar3) i nduce DC 
maturation  
Doxorubicin treated OVcar3-induced DC maturation was assessed by cell surface 
markers (Figures 5.20 and 5.21). This effect appeared to be dependent on the 
original concentration of doxorubicin used to treat the OVcar3 cells. Although 
OVcar3 treated with all doxorubicin concentrations i.e. 0.25, 1, 2.5 µM induced a 
significant reduction in expression of CD14, only OVcar3 treated with higher 
concentrations significantly induced increased expression of the majority of the 
other markers studied. OVcar3 treated with both 1 and 2.5 µM induced increased 
expression of CD11c, CD80, CD83, CD86 and HLA-DR compared with untreated 
imDCs, although this did not always reach significance (Figure 5.21). For instance 
in DCs co-incubated with OVcar3 treated with 2.5 µM doxorubicin there was an 
increase in expression of: CD11c from 64.86 ± 7.55 to 80.8 ± 8.7%; CD83 from 
56.63 ± 6.14 to 69.2 ± 1.92%: CD86 from 67.29 ± 10.9 to 79 ± 3.67% and HLA-DR 
from 68.67 ± 7.74 to 78.2 ± 2.16%.   
The above experiments were also carried out using imDCs derived from THP-1 
cells to allow comparison of the functional responses of the imDCs derived from 
the two different sources.  It can be seen from figures 5.22 and figure 5.23 that 
OVcar3 treated with all three concentrations of doxorubicin tested (0.25, 1, 2.5 µM) 
and then co-incubated with THP-1 derived imDCs induced a significant reduction 
in CD14 expression on the DCs.  Co-incubation of imDCs with OVcar3 previously 
treated with 1 and 2.5 µM doxorubicin resulted in increased expression of all other 
markers of DC maturation, although again this did not always reach significance 




















Figure 5.17.  EpCAM is expressed on ovarian cancer cells, but DC markers 
are not.  OVcar3 ovarian cancer cells were stained for EpCAM (anti-EpCAM-Cy5) 
and DC markers (PE conjugated CD11c, HLA-DR, CD80, CD83 and CD86 and 
CD14-FITC) for 30 minutes and surface expression of the markers was assessed 
by flow cytometry.  Unstained cells and isotype controls were included as controls 
and for initial gating. (a) Gated OVcar3 cell population was over 90% positive for 
EpCAM expression (b), (c) EpCAM positive OVcar3 cells expressed very low levels 
of DC markers i.e. staining with fluorescently labelled specific antibodies is almost 
identical to isotype controls. Representative plots are shown from a typical 
















Figure 5.18. Ovcar3 cells express high surface leve ls of EpCAM and low 
levels of DC markers.  OVcar3 cells were stained with fluorescent antibodies 
against EpCAM and markers of DC maturation (PE conjugated CD11c, HLA-DR, 
CD80, CD83 and CD86 and CD14-FITC) and expression of each marker was 
assessed by flow cytometry. Data show the mean ± SD of three separate 
experiments. *unstained OVcar3 cells vs. anti-EpCAM, # anti-EpCAM vs. DC 


























Figure 5.19 mDCs do not express EpCAM.  mDC were stained with anti- EpCAM 
and DCs markers (CD14, CD11c, CD80, CD83, CD86 and HLA-DR), incubated for 30 
minutes at the room temperature, then analysed by flow cytometry. (a) Dot plot 
showing fluorescence intensity of staining with EpCAM vs DC markers indicating that 
no EpCAM fluorescence was observed (b) Percentage flow cytometry histograms 
confirming that DCs markers were highly expressed on DC cells in the presence of 
anti-EpCAM. Representative plots are shown from a typical experiment carried out on 
three occasions. Percentages shown in each panel indicate the percentage of the cell 























Figure 5.20.  Co-incubation of doxorubicin treated OVcar3 cells w ith peripheral 
blood derived imDCs induced DC maturation.   OVcar3 cells were treated with 
increasing concentrations of doxorubicin (a) 0.25 µM, (b) 1 µM, (c) 2.5 µM, for 16 
hours.  The doxorubicin was washed off and the OVcar3 cells were co-incubated with 
imDCs for 4 days and markers of DC maturation (CD14, CD11c, CD80, CD83, CD86 
and HLA-DR) were assessed by flow cytometry.  OVcar3 cells were stained with anti-
EpCAM to allow these cells to be gated out of the analysis. Representative histograms 
are shown from 5 independent experiments. Percentages shown in each panel 






Figure 5.21. Co-incubation of doxorubicin treated O Vcar3 cells with peripheral 
monocyte derived imDCs induced DC maturation.   OVcar3 cells were treated with 
increasing concentrations of doxorubicin (a) 0.25 µM, (b) 1 µM, (c) 2.5 µM, for 16 hours 
and then co-incubated with peripheral monocyte derived imDCs for 4 days. The DCs 
were then assessed for markers of maturation (CD11c, CD80, CD83, CD86 and HLA-
DR) by flow cytometry.  OVcar3 cells were stained with anti-EpCAM to allow these 
cells to be gated out of the analysis. Results are mean ± SD, *p<0.05, **p<0.01 vs 




















Figure 5.22 . Co-incubation of doxorubicin treated OVcar3 cells w ith THP-1 
derived imDCs induced DC maturation.   OVcar3 cells were treated with increasing 
concentrations of doxorubicin (a) 0.25 µM, (b) 1 µM, (c) 2.5 µM, for 16 hours.  The 
doxorubicin was then washed off and the treated cells were co-incubated with THP-1 
derived imDCs for 4 days, after which markers of DC maturation (CD14, CD11c, 
CD80, CD83, CD86 and HLA-DR) were assessed by flow cytometry.  OVcar3 cells 
were stained with anti-EpCAM to allow these cells to be gated out of the analysis. 
Representative histograms are shown from one of 5 independent experiments. 
Percentages shown in each panel indicate the percentage of the cell population 






















Figure 5.23 .   Co-incubation of doxorubicin treated OVcar3 cells w ith THP-1 
derived imDCs induced DC maturation.   OVcar3 cells were treated with increasing 
concentrations of doxorubicin (a) 0.25 µM, (b) 1 µM, (c) 2.5 µM, for 16 hours and then 
co-incubated with THP-1 derived imDCs for 4 days. The DCs were then assessed for 
markers of maturation (CD11c, CD80, CD83, CD86 and HLA-DR) by flow cytometry.  
OVcar3 cells were stained with anti-EpCAM to allow these cells to be gated out of the 





5.4.11. Maturation of dendritic cells derived from peripheral monocytes is 
associated with increased secretion of IL12/IL23  
As previously mentioned it has been reported that maturation of DCs is not only 
characterised by changes in surface expression of maturation markers, but also by 
increased secretion of cytokines including IL12 and IL23 (Mayordomo et al., 2018) 
.Therefore, as an additional of marker of DC maturation in the in vitro system used 
here, levels of secreted IL12 and 23 were measured in DC culture media following 
cell treatments. It can be seen from (Figure 5.24 a) that IL12/23 secretion was 
significantly increased in the media of peripheral blood monocytes stimulated to 
undergo differentiation to imDCs by GM-CSF and IL4. Secreted levels increased 
with time over the 7 days of differentiation treatment i.e. from 402.0 ± 16.17 in 
freshly isolated monocytes to 631.1± 67.07 pg/ml after 3 days and 750.4 ± 143.9 
pg/ml after 7 days.  
Secreted levels of these cytokines were also examined in the culture media of 
imDCs induced to mature to mDCs.  Since the marker expression data suggested 
that exogenous CRT could induce DC maturation (Figure 5.24 b), cytokine 
secretion stimulated by CRT was also examined.  Although LPS, the classic 
stimulator of imDC maturation, did induce an increase in secreted IL12/23 levels 
this did not reach significance. However, CRT at all concentrations tested did 
significantly increase IL12/23 secretion.  DCs treated with 0.5 ,1, 2.5 µg/ml 
secreted 1081 ± 202.4 pg/ml, 1255 ± 238% pg/ml and 1227± 217.1 pg/ml 
respectively in comparison to the untreated imDCs (750.4 ±143.9pg/ml) (n=<0.05, 
n=3  for all (Figure 5.24 b).  These data confirm the marker expression results and 
suggest that exogenous CRT is a potent stimulator of DC maturation.  
Maturation of imDCs (from peripheral blood monocytes) by OVcar3 ovarian cancer 
cells pre-treated with doxorubicin was also accompanied by increased secretion of 
IL12/23 (Figure 5.25).  OVcar3 cells treated with 0.5, 1 or 2.5 µM doxorubicin 
induced secretion of  1221 ± 170.7 pg/ml, 1219 ± 188 pg/ml and 1506 ± 60.14pg/ml 
of IL12/23 from maturing imDCs respectively, compared with 750.4 ± 143.9 pg/ml 






















Figure 5.24.  Peripheral blood monocyte derived DC maturation by CRT is 
associated with secretion of the cytokines IL12 and  IL23. Peripheral blood derived 
monocytes were treated with (a) GM-CSF and IL4 to induce differentiation of imDCs 
or (b) LPS or CRT (0.5, 1, 2.5 µg/ml) to induce maturation to mDCs. Cell culture 
supernatants were collected and assessed for the content of IL-12/IL-23 (p40) using 
a commercially available ELISA kit. Data are mean ± SD, from three individual 
experiments with each determination performed in triplicate. *p<0.05 basal media vs. 
untreated cells at day 0.  #<0.05 treatments vs untreated cells at day 0 (PBMC 


















Figure 5.25.  Co-incubation of doxorubicin treated OVcar3 cells and peripheral 
monocyte-derived imDCs induces secretion of IL12/IL 23. imDCs derived from 
peripheral blood derived monocytes were co-incubated with OVcar3 ovarian cancer 
cells pre-treated with increasing concentrations of doxorubicin (0.25,1, 2.5 µM)  to 
induce DC maturation. After 4 days cell culture supernatants were collected and 
assessed for the content of IL-12/IL-23 (p40) using a commercially available ELISA 
kit. Data are mean ± SD, from three individual experiments with each determination 
performed in triplicate. *p<0.05 basal media vs. untreated cells at day 0.  #<0.05 





5.4.12. Maturation of dendritic cells derived from THP-1 ce lls is also 
associated with increased secretion of IL12/IL23 . 
The levels of secreted IL-12/IL-23 were also examined in DCs derived from THP-
1 cells to allow further comparison of the functional responses of the DCs derived 
from the two different sources. Differentiation of THP-1 cells to imDCs was 
accompanied by a significant secretion of IL12/IL23 (Figure 5.26).  At days 3 and 
7 of maturation by GM-CSF & IL4 secreted levels were 661± 301.5 pg/ml and 635.9 
± 190.1 pg/ml compared with levels at day 0 (359.5 ± 149.9 pg/ml). These 
responses were similar to those seen in peripheral monocytes (Figure 5.26 a). 
However, in contrast to the monocyte derived DCs only maturation induced by 
1µg/ml exogenous CRT was associated with a significant increase in IL12/23 
secretion (from 635.9 ± 190.1 pg/ml in control cells to 1255 ± 238 pg/ml, (Figure 
5.26 b, p<0.05, n=3).  THP-1 derived DCs treated with LPS as a positive control 
and 0.5 µg/ml CRT secreted increased levels of IL12/IL23, but these were not 
significant. Interestingly, 2.5 µg/ml CRT did not induce any increase in cytokine 
secretion which was in contrast to the results from peripheral monocyte derived 
DCs.  
Cytokine secretion from THP-1 derived imDCs that were stimulated to mature by 
co-incubation with doxorubicin-treated OVcar3 cells was also different to the 
results observed in DCs from peripheral monocytes.  Only OVcar3 treated with the 
highest concentration of doxorubicin (2.5 µM) induced significant cytokine 
secretion (from 750.4 ± 143.9 pg/ml to 1227± 217.1pg/ml, p<0.05, n=3) (Figure 
5.27). Although OVcar3 cells treated with 1 µM doxorubicin did induce increased 
cytokine secretion this was not significant. OVcar3 pre-treated with 0.5 µM 
doxorubicin had no effect on DC secretion of IL12/23 (Figure 5.27). These data 


























Figure 5.26.  THP-1 derived DC maturation is only a ssociated with secretion of 
the cytokines IL12 and IL23 when induced by high co ncentrations of CRT.  THP-
1 cells were treated with (a) GM-CSF and IL4 to induce differentiation imDCs or (b) 
either LPS or CRT (0.5, 1, 2.5 µg/ml) to induce maturation to mDCs.  Cell culture 
supernatants were collected and assessed for the content of IL-12/IL-23 using a 
commercially available ELISA kit. (b) Data are mean ± SD, from three individual 
experiments with each determination performed in triplicate. *p<0.05 basal media vs. 































Figure 5.27.  OVcar3 cells pre-treated with high co ncentrations of doxorubicin 
induce secretion of IL12/IL23 from THP-1 derived DC s during DC maturation. 
imDCs derived from THP-1 cells were co-incubated with OVcar3 ovarian cancer cells 
pre-treated with increasing concentrations of doxorubicin (0.25,1, 2.5 µM)  to induce 
DC maturation. After 4 days cell culture supernatants were collected and assessed for 
the content of IL-12/IL-23 using a commercially available ELISA kit. Data are mean ± 
SD, from three individual experiments with each determination performed in triplicate. 
*p<0.05 basal media vs. untreated cells at day 0.  #<0.05 treatments vs untreated cells 







5.4.13. The effect of mDCs on T-cell proliferation 
The results presented so far in this chapter indicate that imDCs can be derived in 
vitro and that these cells can then be induced to undergo maturation to mDCs as 
assessed by cell surface markers and secretion of co-stimulatory cytokines IL12 
and IL23.  As described in the introduction to this chapter mDCs are the interface 
between foreign and tissue-specific antigens and T lymphocytes. In vivo maturation 
of DCs, presentation of antigens and secretion of IL12 is associated with activation 
and thus proliferation of naïve T lymphocytes, ultimately leading to ICD. Since both 
exogenous and endogenous CRT were able to induce DC maturation the next set 
of experiments were carried out to examine whether CRT alone or these mature 
DCs could activate T cells.      
T lymphocytes were isolated from peripheral blood mononuclear cells from healthy 
donors by MACS® Technology using a CD8+ T Cell Isolation Kit (Miltenyi Biotec).  
Successful enrichment of the isolated cells with T- cells was determined by flow 
cytometry after dual labelling with fluorescently antibodies against T cell markers 
i.e. CD3-APC and CD8-FITC (Figure 5.28).  These data indicate a cell population 
highly enriched for naïve T cells. 
Isolated T lymphocytes were stained with CSFE and then incubated with mediators 
to induce activation/proliferation for 5 days.  Flow cytometry was then carried out 
(gating for CD-3 expressing cells i.e. mature T cells) to examine CSFE 
fluorescence in the proliferated cells. CFSE covalently labels intracellular 
molecules and thus when a CFSE-labelled cell divides the daughter cells each take 
half the CSFE.  This allows each cell division to be assessed by measuring the 
corresponding decrease in CSFE fluorescence (Quah, 2010) i.e. each peak of 






















Figure 5.28.  Flow cytometry analysis of a typical CD8 T-cell purification using 
negative selection magnetic bead technology.  Isolated lymphocytes were 
fluorescently stained with anti –human CD8-FITC antibody and anti –human CD3-APC 
antibody. The live cell population was gated on an FSC-A vs SSC-A plot and cell debris 
excluded from the analysis. Fluorescently stained cells were identified by gating out 





5.4.14. Activation of human T cells by Human T-Acti vator CD3/CD28 
Dynabeads®. 
Initial experiments were carried out using a positive control i.e. isolated T cells were 
incubated with magnetic beads bound to antibodies to the T-cell co-stimulatory 
molecules CD3/CD28 in the presence of the additional stimulator IL2. It can be 
seen from Figure 5.29 that the combination of the anti-CD3/CD28 Dynabeads and 
IL2 induced T-cell proliferation and that proliferation over 5 days could be 
effectively measured by CSFE staining and flow cytometry. The number of stained 
daughter cells increased at each cell division until day 5 (Figure 5.29 c). As 
expected fluorescent intensity steadily decreased in the cell populations as each 
daughter cell only took half of the fluorescence in the parent cell (Figure 5.29 a). 
Unstimulated cells did not divide. These results indicate that CSFE labelling and 
flow cytometry is an effective method of examining T-cell proliferation in vitro. 
5.4.15. Activation of human T cells by mDCs induced  to mature by various 
treatments (see Figure 5.30) 
Experiments were then carried out to examine whether mDCs induced to mature 
by (i) LPS (positive control), (Nagata et al., 2016) exogenous CRT or (iii) OVCar3 
cells pre-treated with doxorubicin to expose endogenous CRT, could subsequently 
stimulate naïve T-cell activation and proliferation.  After maturation by these 
methods DCs were incubated with T-cells stained with CSFE staining and after 5 
days T-cell proliferation was analysed by flow cytometry.      
The results are summarised in Figure 5.31.  It can be seen that DCs matured by 
all treatments induced T-cell proliferation.  For example T-cells incubated with DCs 
matured by 0.5 µg/ml CRT increased in number by approximately 1-fold at division 
1, 1.2 fold at division 2, 1.7 fold at division 3 and 2.2 fold at division 4 (Figure 
5.31.,b,c). DCs matured by 1 and 2.5 µg/ml also induced T-cell proliferation, with 
an apparent dose response i.e. the ability of DCs to induce T-cell proliferation 
appeared to be dependent on the concentration of CRT that the DCs were 
previously exposed to. For instance after 4 days numbers of T-cells were 395.6 ± 
5, 632.3 ± 57 and 702.8 ± 6 after co-culture of T-cells with DCs matured with 0.5, 





















Figure 5.29. T lymphocyte proliferation induced by human T-activator anti-
CD3/CD28 Dynabeads™ and assessed by CSFE fluorescen ce (a) Human T 
lymphocytes were stained with the CellTrace™ CFSE cell proliferation kit and cultured 
for 5 days with CD3/CD28 Dynabeads and IL-2. Cells were then analysed using flow 
cytometry with 488 nm excitation and a 530/30 nm emission filter. Successive 
generations of live cells are represented by the discrete green peaks. The blue colour 
indicates the unstimulated parent generation. (b) Microscopic image of T lymphocytes 
bound to anti CD3/CD28 microbeads at (day 0). (c) Graph showing numbers of 
























Figure 5.30. Schematic diagram showing the experime ntal plan of studies 
carried out to examine whether DCs induced to matur e by various treatments 
could subsequently stimulate T-cell proliferation. Immature DCs (imDCs were 
incubated with 0.5, 1, or 2.5µg/ml of CRT; 1µg/ml LPS ± 2.5µg/ml of CRT; OVCar3 
pre-treated with 2.5µg/ml doxorubicin (DX) or OVcar3 pre-treated with 2.5µg/ml CRT 
to induce maturation.  The mDCs were then co-cultured with carboxyfluorescein 
succinimidyl ester (CSFE)-labelled T-cells and T-cell proliferation was assessed after 

























































Figure 5.31. DCs induced to mature by either exogen ous or cancer cell surface 
bound CRT subsequently induce T-cell activation as assessed by proliferation. 
imDCs were incubated with 0.5, 1, or 2.5µg/ml of CRT; 1µg/ml LPS; OVCar3 pre-
treated with 2.5µg/ml doxorubicin; pre-treated OVcar3 + 2.5µg/ml CRT, to induce 
maturation.  The mDCs (1 × 106), were then co-cultured with CSFE-labelled T cells (1 
× 105) in 24-well plates in the presence of IL-2 (30µg/ml) and proliferation was 
assessed after 5 days by flow cytometry (a) Flow cytometry histograms showing 
proliferation of CSFE labelled T-cells (b) Mean number of cells at each division with 
the different treatments, (c) Table displaying results presented in (b), *p=0.05 day 5 vs 
day 0. (d) Comparison of T-cell numbers at the 3rd generation with the different mDC 




were more effective at inducing T-cell proliferation than the positive control, LPS 
(351 ± 10.52 T-cells after 3 days). 
Importantly, it was found that T- cells co-cultured with DCs that had been matured by 
co-incubation with 2.5µg/ml doxorubicin-treated OVcar3 showed the greatest levels of 
proliferation.  After 4 days T-cell numbers were 1005 ± 10 compared with the LPS 
(682.5 ± 9 T-cells after 4 days) i.e. OVcar3 with exposed CRT were approximately 
30% more effective at inducing T-cell proliferation than LPS. Interestingly, T-cell 
proliferation induced by DCs matured in the presence of both doxorubicin-treated 
OVcar3 and CRT did not show enhanced proliferation over maturation induced by 
OVcar3 alone 827.8±19 vs 1005 ± 10, perhaps suggesting that DCs matured by 
surface expressed endogenous CRT are most efficient at inducing T-cell proliferation. 
Surprisingly, DCs matured by both LPS and exogenous CRT (2.5µg/ml) were the least 
effective at stimulating T-cell proliferation. 
 
5.5. Discussion  
Options for effective ovarian cancer chemotherapy remain limited and therefore 
interest in alternative therapeutics such as immunotherapy and induction of ICD and 
immune-mediated eradication has increased (Drakes and Stiff, 2016, Mantia-
Smaldone et al., 2012). However, this remains a challenge due to the poor 
immunogenicity of cancer cells (Kandalaft et al., 2011). ICD requires recognition and 
uptake of cancer cells by professional phagocytes and APCs such as DCs and then 
activation of a T-cell mediated response to generate T cells that can recognise and 
destroy the cancer cells. Indeed, enhanced DC activation is linked to increased 
survival in a number of cancers  (Fu and Jiang, 2018). Recently, it has been reported 
that CRT at the cell surface enhances DC maturation and MHC-I based antigen 
presentation to promote activation of T- cytotoxic responses in non-small-cell lung 
cancer (Vansteenkiste et al., 2013). The work in this chapter aimed to examine 
whether similar responses could be observed in EOC. Since levels of surface bound 
CRT could be increased either by addition of exogenous CRT or by induction of the 
translocation of endogenous CRT to the cell surface, both approaches were 




Thus, the overall aim of this chapter was to investigate whether exogenous CRT or 
translocated (and cell bound) endogenous CRT could promote maturation of imDCs 
and T cell activation responses i.e. T-cell proliferation. imDCs were derived from both 
the THP-1 cell line and peripheral blood monocytes and both the differentiation of 
imDCs from monocytes and the maturation of DCs were fully characterised.   
The main findings of this chapter were: 
1. imDCs derived from both THP-1 and peripheral blood monocytes could be matured 
to cells displaying the phenotypic and secretory characteristics of mDCs by both 
exogenously added CRT and cancer cells with cell surface bound CRT. 
2. The mDCs induced by these treatments and exogenous CRT alone were able to 
stimulate T-cell activation as assessed by T-cell proliferation. 
 
Effect of exogenous CRT on maturation of imDCs .  
Previously published data reported that the THP-1 cell line can be differentiated into 
highly pure monotypic DCs presenting with the morphologic and functional properties 
of imDCs, including co-stimulatory (maturation marker) molecule expression on the 
cell surface (Berges et al., 2005).  
In this study imDCs were generated from the THP-1 cell line by incubation for 7 days 
with GM-CSF and IL-4 and a significant increase was observed in levels of the DC 
surface markers CD11c, CD86 and HLA-DR, although the increase in levels of CD80 
and CD83 did not reach significance. These data agree with similar reports in the 
literature. For instance, it has been reported that THP-1 cells and the CD34+ (KG-1) 
leukaemia cell line incubated with varying concentrations of rhGM-CSF and rhIL-4 for 
5 days showed upregulated levels of CD11c, CD80 and CD86 and of the cell-surface 
receptors CD40, CD209 (DC-SIGN) but failed to express  CD83 (Monti et al., 2003). 
THP-1 imDCs stimulated with the positive control, LPS, for 4 days to generate mDCs 
showed upregulation of CD11c, CD80, CD83, HLA-DR and CD86 but lower 
expression of CD14.  All of these changes in marker expression have been observed 
on the cell surface of mature dendritic cells (Tokunaga et al., 2005, Halin et al., 2005) 





















Figure 5.32. Schematic representation of the experi mental procedures used in 
this chapter. The human monocytic cell line THP-1 or CD14+ monocytes collected 
from peripheral blood (a) were differentiated to immature dendritic cells (imDCs) (b). 
These imDCs were exposed to 1µg/ml LPS as a positive control, CRT (0.5, 1, 2.5 
µg/ml) (c) or OVcar3 ovarian cancer cells pre-treated with doxorubicin (DX to induce 
surface CRT expression (d). DC maturation was assessed by expression of surface 
markers and cytokine secretion (e). The ability of these mature DCs or CRT to 





Exogenous CRT triggered a response to enhance maturation of THP-1 imDCs. 
Interestingly 0.5 µg/ml CRT was not sufficient to enhance expression of all maturation 
markers whereas expression of CD11C, HLA-DR, CD80 and CD83 were all increased 
by treatment with 1 and 2.5 µg/ml CRT for 4 days. This observation was supported by 
the ELISA for IL-12 /IL-23 which only showed increased secretion at 1 µg/ml in the 
THP-1 cell line.  
These results were supported by ELISA measurement of IL12/IL23 secretion 
(Reinhardt et al., 2006). Upregulated secretion of these cytokines has been reported 
in mDCs and this was also observed here. Maturation of THP-1 derived imDCs 
induced by exogenous CRT at increasing concentrations was accompanied by 
increased secretion of IL12/IL23 cytokines. These results demonstrate for the first time 
that CRT is able to induce maturation of human THP-1 derived DCs as assessed by 
increased secretion of cytokines IL12/IL23. These data are supported by studies on 
animal cells.  For instance, maturation of imDCs derived from BALB/c mouse bone 
marrow cells by rCRT/39-272 (30 µg/ml) purified from Escherichia coli, was 
accompanied by increased expression of IL-12/IL-23 (p40) and IL-1β (Li et al., 2015). 
 
The DC responses studied in THP-1 cells were also examined in DCs derived from 
freshly isolated CD14+ monocytes collected from a healthy donors and enriched using 
a magnetic separation method similar to that previously described (Neu et al., 2013). 
Similar to THP-1 cells, the stimulating factors GM-CSF and IL-4 efficiently 
differentiated imDCs from the isolated monocytes, inducing cells with high expression 
of HLA-DR, CD80, CD83, and CD86.  These data are similar to reports in the literature, 
for instance Thurner et al. (Thurner et al., 1999) showed significant upregulation of 
CD14, CD86 and CD83 in monocyte derived DCs induced by treatment with 500 U/ml 
IL-4 and 800 U/ml GM-CSF for 5 days.  
DC maturation was also studied in monocyte-derived imDCs by changes in surface 
expression of key maturation markers. 0.5 µg/ml CRT significantly increased 
expression of CD83 and HLA-DR only, but similarly to the THP-1 cells higher CRT 
concentrations (1, 2.5 µg/ml) were more efficient at inducing maturation of DCs. 
Treatment of imDCs with 2.5 µg/ml CRT led to significant changes in surface 




CD14) and secretion of the pro-inflammatory cytokines IL12/IL23.  This confirms that 
CRT is a potent stimulator of DC maturation. This has also been observed in other 
recent studies. For example Bajor et al. (Bajor et al., 2011) reported that imDCs 
derived from peripheral blood monocytes and stimulated by 10 µg/ml CRT showed 
increased expression of CD80 and CD86 on the surface of mDCs, and decreased 
expression of CD14.    
The observation that in both THP-1 and monocyte derived DCs expression of 
maturation markers was greater following exposure to higher concentrations of CRT 
suggests that there is a threshold level of CRT required to induce efficient maturation.  
Additionally, the highest concentration used i.e. 2.5. µg/ml was as effective as inducing 
DC maturation as the positive control, LPS, suggesting that the levels used in previous 
studies were unnecessarily high e.g. 10 µg/ml. (Bajor et al., 2011). 
 
In classical immune responses damaged or stressed cells display pathogen-
associated molecular pattern molecules (PAMPs), derived from microorganisms 
and/or damage-associated molecular pattern molecules (DAMPs) which are cell 
derived and can initiate immune responses to trauma in the absence of infection.  Both 
can be recognised by corresponding pattern recognition receptors (PPRs) on the 
surface of imDCs, triggering phagocytosis. The DCs engulf these signposted target 
cells and then enter a maturation process during which the phagocytosed cellular 
antigens are presented on the cell surface in association with MHC class I and II 
complexes.  These antigen complexes are then recognised by T cell receptors on 
both CD4+ and CD8+ T cells which triggers initial activation of naïve CD8+ T cells into 
activated cytotoxic CD8+ T cells. The process of DC maturation is accompanied by 
expression of surface molecules and secretion of cytokines which act as co-
stimulatory molecules for the T cell activation.    
 
Cell surface CRT is a recognised DAMP translocated to the cell surface in response 
to ER stress and has been reported to contribute to uptake by dendritic cells (Gold et 
al., 2015, Obeid et al., 2007, Bajor et al., 2011). Importantly CRT has been shown to 
be a C1q receptor on the cell surface of early apoptotic cells and the two proteins 
associate  to form an “eat me”  that interacts with  the globular region of CD91 on 




changes on the surface of dying cells signal to DCs. However, intriguingly in the data 
presented here CRT alone added exogenously very efficiently induced DC maturation 
in the absence of antigen processing or other dying cell surface molecules, suggesting 
that CRT is able to induce DC maturation in the absence of any other associated cell 
surface molecules or antigens.  
 
It is not fully understood how CRT induces maturation of DCs. However, recently, it 
has been shown that CRT has a very strong attraction for LPS which is a potent PAMP 
and that all preparations of recombinant CRT and CRT isolated from human tissue 
contain bound LPS, including the Pichia pastoris rCRT used here (Pandya et al., 
2019).  
This suggests that this is a physiologically relevant finding and that CRT-LPS act in 
concert to enhance immune responses, raising the possibility that the direct effects of 
CRT observed here are due to the combination of the two immune activators acting 
together to induce DC maturation, by an as yet unknown mechanism.   
 
 
The effect of surface exposed endogenous CRT on DC maturation. 
Translocation of intracellular CRT in cancer cells has been observed in response to 
chemotherapeutic agents such as the anthracycline, doxorubicin (Zitvogel et al., 2010) 
and as discussed in Chapter 1 (Introduction) CRT has been reported to activate APCs 
and regulate innate and adaptive immune responses. The results presented in 
Chapter 4b indicate that doxorubicin induced CRT exposure and secretion in various 
cancer cell lines. Therefore, since exogenous CRT very effectively induced DC 
maturation in both types of imDCs studied, experiments were carried out to examine 
whether surface exposed endogenous CRT could have the same effect. 
One of the key findings of this study was that OVcar3 ovarian cancer cells pre-treated 
with doxorubicin (to induce CRT translocation to the cell surface) did induce iDC 
maturation in both DC models studied.  This effect appeared to be dependent on the 
original concentration of doxorubicin used to treat the OVcar3 cells.  OVcar3 treated 
with both 1 and 2.5 µM induced increased expression of CD11c, CD80, CD83, CD86 




monocytes, although this did not reach significance for CD80.  OVcar3 treated with all 
concentrations of doxorubicin significantly reduced CD14 expression on both types of 
DCs. It is possible that these differences could be attributed to increased levels of 
translocated CRT on the surface of the dying cancer cells in response to the greater 
doses of doxorubicin (Michaud et al., 2011). These results indicate that cancer cells 
treated with a chemotherapy primarily used as a toxic agent may also play an 
important role in activating DCs and thus the adaptive immune system in EOC. 
Chapter 4 indicated that doxorubicin also induced secretion of CRT and it is possible 
that the secreted CRT induced DC maturation, since exogenous CRT was a very 
effective activator. However, the doxorubicin treated cancer cells used here were 
treated and then washed, to remove the doxorubicin, before co-incubation with the 
iDCs.  This suggests that it is more likely that CRT already translocated to the surface 
was activating the DCs, but does not fully rule out a role for secreted CRT.  
Additionally, in vivo, increased expression of CRT on tumour cells induced by 
photodynamic therapy in a mouse model correlated with increased maturation of 
dendritic cells, with enhanced expression of markers such as CD80 and CD86 (Wang 
et al., 2015). 
OVcar3 treated with 2.5 µM doxorubicin also induced significant secretion of the 
cytokines IL12/23 from maturing DCs, which play a critical role in T cell proliferation. 
Previously, reports indicated that treatment of tumour cells (MCF-7 breast cancer and 
A2780 ovarian cancer cells) with doxorubicin or 72 hours at different concentrations 
was sufficient to stimulate the activation of cell-mediated immunity by release of 
cytokines TNF-α, CXCL8, and CXCL1 (Edwardson et al., 2017). This supports the 
possibility that doxorubicin-treated tumour cells could enhance cell-mediated 
immunity.  
DC maturation by CRT has been reported in other systems. Treatment with a 
recombinant calreticulin fragment, rCRT/39-27 treatment induced phenotypic 







Effects of exogenous and surface exposed endogenous  CRT on T- cell 
proliferation 
It is now widely accepted that CD8+ T cell proliferation can be studied in vitro e.g. an 
early study by (Hodge et al., 2000) measured relative T-cell proliferation (cell number) 
of murine tumour cells after exposure to either rF- or rV-TRICOM vectors to enhance 
proliferation.  Since exogenous and endogenous surface-exposed CRT induced DC 
maturation, the next step was to examine whether the mDCs produced could activate 
the T cell responses normally observed in the development of an adaptive immune 
response i.e. clonal expansion or proliferation. Thus, pre-treated matured DCs were 
co-incubated with freshly isolated T-cells labelled with CSFE which allowed 
proliferative cycles to be followed (BJ, 2010).It has been reported that T-cells collected 
from human peripheral blood and incubated with antiCD3/CD28 showed increased 
proliferation at day 3 of treatment which then gradually declined to baseline levels after 
~10 days (Quah et al., 2007).Therefore, initial studies using magnetic beads coated 
with anti-CD3/CD28 were carried out to validate the technique. The results showed a 
robust stimulation of T cell proliferation with anti-CD3/CD28 coated beads which could 
be followed by flow cytometry to detect the CSFE labelled daughter cell populations. 
 
DCs matured by exogenous CRT alone, at all concentrations tested, induced T-cell 
proliferation.  However, as for the other immune responses studied, this was dose 
dependent, with cells matured by 2.5µg/ml CRT inducing the greatest proliferative 
effect.  It is not known whether this maturation was induced by the levels of LPS in the 
CRT preparation.  However, the reported LPS levels in Pichia pastoris CRT are very 
low (Pandya et al., 2019), so again it is possible that the effects seen are a response 
to the combination of the two activating agents. This is supported by the observation 
that the highest level of CRT used (2.5µg/ml) was considerably more effective at 
inducing T cell proliferation that the LPS alone used as the positive control. In contrast 
to these findings a conjugate of CRT and ovalbumin-derived peptide did not show 
enhanced T cell activation in vitro or in a mouse model (Del Cid et al., 2012).  
Importantly, the results showed, for the first time, that DCs matured by pre-incubation 
with OVcar3 cancer cells (with exposed surface CRT) also induced robust proliferation 
of T-cells and this response was greater than that observed with DCs matured with 




surface CRT acts in concert with other cell surface changes on treated cancer cells to 
induce an integrated response in DCs as they mature, resulting in DCs presenting 
enhanced co-stimulatory molecules to T cells compared with CRT or LPS alone. 
Previously published data also reported that an increase in DC CRT (induced by 
infection with recombinant Ad-CALR) enhanced the maturation of DCs which 
subsequently induced T cell proliferation.  Specifically the authors reported that the 
mDCs induced MAGE-A3-specific CD8+ cytotoxic T lymphocyte responses to non-




In summary, this chapter has established that exogenous and endogenous CRT are 
potent stimulators of DC maturation and that DCs matured by exposure to both 
exogenous CRT and ovarian cancer  cells previously treated with doxorubicin were 
subsequently able to induce DC8+ T cell activation and expansion. These data confirm 
that CRT is a key molecule in the development of ICD of tumour cells, and 
understanding the specific mechanisms that drive CRT to activate immune responses 
could highlight exciting new therapies for the treatment of ovarian cancer.  Clearly, 
strategies that enhance CRT on the surface of targeted tumour cells or increase levels 
of exogenous CRT could theoretically be exploited as treatments. However, although 
these findings highlight an important regulatory role of CRT that may be exploitable 
for cancer immunotherapy, the precise mechanisms by which CRT evokes such anti-













Chapter6 : Final discussion  
CRT is a Ca2+ binding protein chaperone primarily located in the ER of all eukaryotic 
nucleated cells. In recent years, knowledge of the functional complexity of CRT both 
within and outside the ER has expanded exponentially.  As a result CRT has been 
implicated in almost every aspect of normal physiological and pathological cell 
function, including important roles in health, disease, and the regulation of ICD i.e. 
immunogenically active apoptosis induced by some cancer therapies such as 
doxorubicin and types of radiotherapy (Eggleton and Michalak, 2013). In particular 
translocation of CRT from the ER to the cell surface is thought to mediate cancer cell 
engulfment by phagocytes and DC maturation and the subsequent activation of 
adaptive immune responses which can lead to cancer cell killing i.e. T cell expansion. 
Activation of ICD is now recognised as a potential therapeutic tool for the elimination 
of cancer cells and EOC is becoming a focus for this therapy. EOC is the most lethal 
of all gynaecological cancers due to non-specific initial symptoms and the advanced 
stage of the disease at diagnosis in around 75% of patients. Together with the low 5 
year survival rate of ovarian cancer patients in the UK (<50%) and only modestly 
improved treatment over the last decades, it is clear that research into strategies to 
induce ICD in ovarian cancer  could be of great benefit, contributing to development 
of new and more efficient treatments and diagnosis. 
The mechanism(s) by which CRT may be involved in ICD responses against ovarian 
cancer have been examined in this thesis using in vitro methodologies. This chapter 
will summarise the findings presented in this thesis, it will outline the gaps in the field 
which have been explored and those that require further work to develop a novel 
therapeutic strategy that exploits the immunogenic activity of CRT to selectively 
activate innate and adaptive immune responses to ovarian cancer cells. 
The first step of this research (Chapter 3) was to establish a purification step for 
recombinant human CRT expressed in E. coli and Pichia pastoris. Briefly, expressed 
CRT was purified by FPLC affinity and size exclusion chromatography and 
characterised for future use. This provided monomeric CRT that was used in further 
experiments as an in vitro model for investigating the immune roles of extracellular 




that physiologically CRT appears to be bound to LPS and that the two proteins may 
induce integrated cellular responses (Pandya et al., 2019). The Pichia pastoris CRT 
used here did contain low levels of CRT (Pandya et al., 2019) raising the possibility 
that some of the cellular responses seen may result from the effects of the two agents 
combined.        
In the second step (Chapter 4) strategies to enhance cell surface levels of EOC CRT 
were investigated since this is thought to be a critical requirement for ICD of cancer 
cells.  EOC binding of endogenous and exogenous CRT under ER stress and non-
stress conditions were investigated in a panel of ovarian cancer cell lines (SKov3, 
OVcar3, and A2780). Initially, exogenous CRT was labelled with FITC to allow direct 
analysis of bound CRT by microscopy and flow cytometry. Ovarian cancer cells bound 
exogenous CRT under resting conditions and this binding increased dramatically in 
cells under stress conditions e.g. doxorubicin or the ER stressor thapsigargin. This 
increased binding was accompanied by apoptotic cell death and bound CRT levels 
were significantly greater on dying cells compared with living cells. Pre-treatment of 
cells with TUDCA, which has been reported to relieve ER stress, partially but 
significantly, protected cells against doxorubicin and thapsigargin induced cell death 
and simultaneously had similar effects on CRT binding.   
The externalisation of endogenous CRT was also studied in cells treated with 
doxorubicin or thapsigargin. The resulting cell death was accompanied by an increase 
in surface exposure of CRT which again was greater in cells undergoing apoptosis 
and necrosis. This enhanced externalisation was accompanied by increased 
expression and secretion of CRT.  Pre-treatment of cells with TUDCA again, partially 
but significantly, reduced doxorubicin and thapsigargin induced cell death and also 
reduced CRT expression, externalisation, and secretion.    
It has been previously shown that CRT binds directly to PS (Tarr et al., 2010b) and 
since both early and late apoptotic cells have increased external membrane exposed 
PS as assessed by annexin V binding, it is assumed that surface bound CRT from 
both exogenous and endogenous sources bound  to the cell surface via interaction 
with PS.  These data suggest that in ovarian cancer cells agents such as doxorubicin 
induce apoptotic cell death by an ER stress mediated mechanism.  This cell death is 




some of which remains associated with the cell surface and some of which is secreted 
and may subsequently also bind to the cell surface, increasing total levels. This CRT 
may act as an ‘eat-me’ signal that promotes the uptake of CRT-coated tumour cells, 
presentation of the resulting antigens by dendritic cells and T cell activation (Obeid et 
al., 2007, Chaput et al., 2007) 
To investigate this possibility further the last stage of the study (Chapter 5), involved 
an in vitro investigation of the ability of exogenous and externalised cell surface CRT 
to enhance maturation of DCs and subsequent activation of a T cell response.  
Methodologies were established to: isolate peripheral blood monocytes and T cells; 
generate imDCs from both THP-1 cells and peripheral blood monocytes; characterise 
imDCs and mDCs and assess T cell proliferation. Flow cytometric analysis of surface 
markers of maturation indicated that both exogenous CRT and EOC previously treated 
with doxorubicin (to induce enhanced surface CRT levels) were able to stimulate 
maturation of DCs.  Further studies indicated that DCs matured with both sources of 
CRF were able to activate T- expansion.  Importantly the DCs matured by exposure 
to doxorubicin were most effective in inducing T cell activation. 
 
These results suggest that CRT, either cell bound or in solution, can initiate DC 
maturation.  CRT acts as a DAMP and, when cell associated, allows for the uptake of 
tumour cells by DCs, ultimately resulting in a T-cell mediated tumouricidal response 
(Hanke et al., 2013). Importantly, the results presented here suggest that this 
mechanism could be harnessed as a therapeutic strategy for ovarian cancer since 
EOC cells treated with doxorubicin initiated maturation of DCs and these mDCs were 
then able to activate robust T cell responses. Intriguingly, CRT alone i.e. not cell 
bound, induced DC maturation and these mDCs were also able to induce T cell 
expansion in the absence of presentation of tumour cell antigens.  It is not possible to 
deduce a mechanism for these responses from the data presented. However, a recent 
study showed that the release of CRT from dying cells, prior to PS cell surface 
appearance, binds to macrophages thereby inducing numerous immune activities 
including pro-inflammatory cytokines, cell polarization and migration (Osman et al., 
2017).  It is possible that the exogenous CRT may as a ‘sponge’ for even trace levels 
of LPS found in the solutions or media used e.g. trace levels of LPS have been found 




concert to enhance DC maturation. Indeed, it has been demonstrated that CRT and 
other chaperones elicited immune functions against tumours in vivo possibly due to 
LPS binding and that following removal of associated LPS, numerous immune 
responses were lost except ERK phosphorylation (Reed et al., 2003). The study in this 
thesis is the first to demonstrate a role for ovarian cancer cell associated CRT and 
exogenous CRT in maturation of DCs and that the DCs matured by both of these 
routes induce proliferation of T-cells. These data confirm that exogenous CRT is a 
powerful activator of immune responses and could potentially have therapeutic 
potential for ovarian cancer cells therapies. Figure 6.1 summarises the key findings 


















Figure 6.1. Flowchart representing the key finding of this study. Specifically, 
surface levels of CRT on EOC cells can be enhanced by treating cells with ER 
stressors such as doxorubicin and thapsigargin to externalise endogenous CRT or by 
adding exogenous CRT.  EOC cells displaying surface CRT and exogenous CRT can 







There are some limitations to this work that could be be improved in future studies.  
For instance it was noted that the TUDCA was not 100% effective at reducing CRT 
translocation or cell death.  This may have occurred because the TUDCA treament 
conditons needed optimisation and this could be addressed by preliminary opimisation 
studies.  Additionally, an alternative agent known to reduce ER stress could be used, 
for instance N-acetylcysteine (NAC). NAC reduces oxidative stress and, by inhibiting  
ROS-mediated ER stress, has been reported to prevent the ER-stress-related 
apoptosis pathway (Aggarwal et al., 2010). For instance, NAC exerts protective effects 
against iopromide-induced epithelial cell apoptosis by suppressing ROS 
overproduction and subsequent ER stress (Yang et al., 2014). 
 
Secondly, in vivo, CD4+ T lymphocytes or T-helper cells play a major role in the 
development of immune responses by interacting with other cells including CD8+ killer 
cells and are essential in the formation of protective memory CD8+ T cells.  Time did 
not allow an in depth investigation on the effects of CRT on CD4+ lymphocytes, but 
further studies in this area could have enhanced the data obtained. 
 
 
Further work and potential projects 
 
Manipulating CD 47 and CRT interactions.  A potential study that could be carried 
would be to manipulate surface levels of CD47 and CRT to determine the optimum 
ratio between “eat me” and “don’t eat me” signals that control the phagocytic fate of 
EOC cells. CD47 is a ubiquitously expressed surface glycoprotein that plays a critical 
role in immune self-recognition i.e. acts as a ('don't-eat-me' signal) mediating immune 
evasion of self-cells.  To achieve this it is recognised by signal regulatory protein-alpha 
expressed on macrophages, neurons, dendritic cells and neutrophils. Some cancers 
take advantage of this mechanism and express CD47 to avoid cell death. Blockade of 
CD47 e.g. with antibodies that prevent CD47-SIRPα interaction ultimately inhibits the 
"don't eat me" signal (Jiang et al., 1999). Since CRT is known to act as an “eat me” 
signal (de Bruyn et al., 2015) (Wiersma et al., 2015) then an examination of optimum 
blockade of CD47 and the mechanism of achieving optimum CRT levels to achieve 




Expression and evaluation of a bi-specific antibody  to bind to ovarian cancer 
cells. The results found here clearly demonstrate that EOC with enhanced levels of 
cell surface CRT could induce DC maturation and subsequent T cell expansion. Thus, 
one novel therapeutic strategy could be to exploit this pro-immunogenic activity of CRT 
to ovarian cancer cells by developing a bi-specific human antibody which carries CRT 
and recognises EpCAM on the surface of the EOC cells.  Administration of such an 
antibody therapeutically could potentially enhance CRT associated with the cell 
surface of the ovarian cancer cells, triggering an adaptive immune response and 
leading to cancer cell death. If used in combination with conventional chemotherapy 
such a strategy could reduce dosages and thus alleviate toxic side effects. The 
technology to produce a CRT/EpCAM antibody is being developed by one of the co-
supervisors on this project and initial experiments could evaluate the specific binding 
of this antibody to EpCAM expressing and non-expressing cells using an anti-CRT 













Figure 6.2. Possible use of EpCAM / CRT bi–specific  antibody fragments that 
directly target CRT to tumour cells.  Preliminary work has developed a bi-specific 
antibody fragment that carries CRT and recognises EpCAM (epithelial cell adhesion 
molecule). Since EpCAM is overexpressed on carcinoma cells, including ovarian 
cancer cells, administration of this antibody would facilitate enhanced surface levels 
of CRT on these cells. This could encourage both innate and adaptive immune 




Animal models.   Future work could also involve the use of animal models using 
similar approaches to those descibed in vitro. For instance administering rCRT,  an 
expression plasmid encoding CRT or CRT bound to the bi-specific antibody 
described above to improve the effective role of CRT to reduce tumour growth 



















Figure 6.3. Possible future in vivo strategies to test whether enhancing surface 
levels of CRT could be an anti-cancer therapeutic s tategy. In vitro studies have 
indicated that extracellular cell surface associated CRT promotes the immunogenicity 
of early apoptotic cancer cells, leading to their immunogenic cell death. Thus, 
strategies to enhance tumour associated extracellular CRT could have therapeutic 
potenial CRT e.g. innoculation of exogenous CRT or plasmids encoding CRT alone or 







Chapter 7.  Critique of the experimental approaches  used in this thesis.  
 
 
A number of additional experimental controls and experimental approaches could 
have been included in the data and studies described in this thesis. Suggested 
approaches for additional data will be presented according to the original results 
chapter they relate to. 
 
7.1. Chapter 3. Purification of calreticulin and pr eparation of monomeric CRT. 
This chapter describes the purification of purified full length human rCRT from the 
bacterium E. coli and the yeast Pichia pastoris using anion exchange chromatography 
followed by size exclusion chromatography.  Additionally, the CRT preparation from 
E. coli was treated using the antibiotic polymyxin B to neutralise any LPS activity as in 
the studies by (Bak et al., 2008).  
 
Suggested additional experiment: to confirm the neutralisation of LPS 
complexed to the E. coli CRT preparation by polymyxin B treatment and to 
assess whether any LPS was present on the Pichia pastoris CRT preparation. 
Rationale: LPS is the most predominant lipid on the outer layer of gram negative 
bacteria and is capable of triggering cellular responses (Kelley et al., 2013).  Although, 
(Bak et al., 2008 showed extracellular immune function of CRT in a bacterial 
preparation which was reported to have no endotoxin contamination following 
polymyxin B treatment, it was still was important to assess the levels of LPS in the 
CRT preparations purified. Since LPS is a bacterial protein it was assumed that it 
would not be present on the CRT protein expressed in the Pichia pastoris expression 
system. However, additional experiments could have been carried out to confirm both 
this and the effectiveness of the polymyxin B treatment to neutralise LPS in the E. coli 
preparation. 
Suggested methodology: Detected LPS levels could have been quantified using the 
Limulus Amebocyte Lysate (LAL) Endotoxin Detection Assay as described in (Pandya 




using a colourimetric endpoint that can be measured by reading the absorbance. 
Samples would be run in triplicate and a standard curve constructed with absorbance 
of standards on the x-axis and corresponding endotoxin concentration on the y-axis to 
allow quantification of endotoxin (EU/µg) in each sample. 
 
7.2. Chapter 4a. Examination of the conditions requ ired for binding of 
exogenous calreticulin to EOC cells. 
In Chapter 4a a series of studies were carried out to examine the effect of the ER 
stressors doxorubicin and thapsigargin on the binding of exogenous, fluorescently 
labelled CRT (FITC-CRT) to the surface of EOC cells. Since TUDCA has been 
reported to reduce ER stress (Vang et al., 2014) the CRT binding induced by 
doxorubicin and TUDCA was also examined in the presence of TUDCA to assess 
whether reversing ER stress could reduce CRT binding. Exogenous FITC-CRT 
binding was examined by flow cytometry and immunocytochemistry. A number of 
additional experimental controls and experimental approaches could have been either 
shown or included in these studies to reinforce the results. 
Suggested additional control: to investigate whether the observed FITC binding 
to the surface of EOC cells could be the result of free FITC in the experimental 
system. 
Rationale: The CRT-FITC preparation used in these studies was prepared as 
described in chapter 4a by conjugation of free FITC with CRT and subsequent 
purification of the conjugated protein by FPLC.  It was assumed that the binding of this 
highly purified FITC-CRT to the surface of ovarian cancer cells reflected direct binding 
of CRT-FITC to the cells. During the manufacture of the FITC-CRT all free FITC should 
have removed by gel filtration. However, to confirm that any remaining free FITC does 
not bind non-specifically to cells directly under experimental conditions, FITC without 
protein could be added to cells. This experiment was actually performed, but not 
included in Chapter 4a. The data are now shown in (Figure 7.1). 
Methodology: OVcar3 cells were incubated with 2µg/ml free FITC as the control or 




intensity of FITC and FITC-CRT bound to the cells was determined by flow cytometry. 
Unstained cells were examined for comparison. 
Results: It can be seen from figure 7.1 that binding of free FITC to OVcar3 cells was 
negligible. Although, there is a very slight shift in the fluorescence intensity of the FITC 
stained cells compared with unstained cells the FITC-CRT bound cells show a clear 
and distinct peak of fluorescence. The fact that the x-axis is a log scale and that the 
levels of free FITC used should be far in excess of any free FITC remaining after 
purification of the conjugated FITC-CRT suggest that the cell association of free FITC 







Figure 7.1. Free FITC does not bind to the surface of OVcar3 ovarian cancer 
cells .  OVcar3 cells were incubated with 2µg/ml free FITC or 2µg/ml FITC-CRT and 
fluorescence intensity of FITC and FITC-CRT bound to the cells was determined by 
flow cytometry. Unstained cells were examined for comparison. A representative 





Suggested additional control: Evaluation of any data from negative or positive 
controls in each individual experiment contributing to the averaged data set for 
each study; thus ensuring reliability of the averaged data.  
Rationale: In a negative control cells are not exposed to the experimental treatment 
but are exposed to the medium plus levels of the solvent in which any treatment is 
dissolved (vehicle) at equivalent levels to that present in the treatments. Ideally, no 
effect should be seen. A positive control, where included, should produce the expected 
effect. Both inform about the reliability of the data obtained and allow anomalous 
results to be identified.  
It was noted that in the representative graph shown in (Figure 4a.7 (c)) cells exposed 
to the negative control i.e. 0 µg/ml FITC-HAS, did demonstrate fluorescence and that 
inclusion of these data in the averaged graphs in Figure 4a.8 could influence the 
results obtained.  It was therefore important to re-examine all of the relevant primary 
data and controls to examine this possibility. 
Methodology: All of the negative controls in the individual repeats that contributed to 
the graphs in Figure 4a.8 were re-examined to investigate whether the data in (Figure 
4a.7 (c)) were anomalous or if there was a consistent fluorescent shift which could 
indicate an experimental error or artefact.  The graphs in (Figure 4a.8) were then 
redrawn with re-analysed data from experiments were the negative control did not 
show fluorescence. 
Results: 5 out of the 6 repeats for this experiment did not show a fluorescent shift in 
the negative control and a representative graph showing the flow cytometry data is 
shown in (Figure 7.2). 
The data shown originally in Figure 4a.8 have been recalculated excluding the data 
set where the 0µg/ml controls showed fluorescence and the results are shown in 




























Figure 7.2. Demonstration of FITC-CRT, FITC-HSA and  FITC-IgG binding to 
OVcar3 cancer cells by flow cytometry.  OVcar3 cells were treated with different 
concentrations (1-µg - 8µg/ml) of FITC protein or untreated (0, auto-fluorescence 
control) and analysed by flow cytometry (a)  Typical dot plot of the cells showing their 
size (forward scatter-FSC) and granularity (side scatter-SS). (b)-(d)Flow cytometry 
histograms of cells labelled with (b) CRT-FITC (c) HSA-FITC (positive control) (d) IgG-
FITC (negative control). Representative graphs from at least three independent 

































Figure 7.3.  Exogenous FITC-CRT binds to four cance r cell lines at all 
concentrations tested.  Cancer cells were incubated with increasing concentrations 
(0-8 µg/ml) of FITC-CRT, FITC-HSA (positive control) or FITC-IgG (negative control) 
for 30 min at 37°C in the dark. After incubation the amount of FITC-conjugated protein 
bound to cells was assessed by flow cytometry. (a), (b), (c), (d) and (e) cells treated 
with 0 (buffer alone, control), 1, 2, 4, 8 µg/ml FITC-CRT, HSA-FITC and IgG-FITC, 
respectively. Data are mean ± SD and analysed by one-way ANOVA and Tukey’s 
multiple comparison test ### p<0.001, n=5. Significance is between HSA and IgG 




Suggested additional experiment: to confirm that treatment of EOC cells with 
increasing concentrations of doxorubicin does induce enhanced surface 
exposure of phosphatidylserine (PS). 
Rationale: CRT has been reported to bind to PS exposed on the outer leaflet of the 
plasma membrane.  Therefore, it was assumed that the increased exogenous CRT 
binding induced by doxorubicin was the result of increased PS exposure.  This 
hypothesis could have been confirmed by assessing changes in externalised PS in 
response to doxorubicin treatment using annexin V which is known to bind to PS.   
Methodology: EOC would be treated with increasing concentrations of doxorubicin (0, 
2.5µM, 6.3µM, 12.5µM, 25µM) for 16 hours prior to incubation with fluorescently 
labelled annexin and analysis by flow cytometry. 
Results: these experiments were actually performed as part of the studies described 
in this thesis and a representative graph is shown in (Figure 7.4).  It can be seen that 
treatment of cancer cells with increasing concentrations of doxorubicin induces a 




































Figure 7.4. Doxorubicin (DX) induces externalisatio n of phosphatidylserine in 
A2780 ovarian cancer cells as assessed by annexin V  binding.  A2780 cells were 
treated with increasing concentrations of doxorubicin (0, 2.5µM, 6.3µM, 12.5µM, 
25µM) for 16 hours. Cell were then exposed to fluorescently labelled annexin V (5µl in 
100 µl of calcium binding buffer for 15min at 37 °C in the dark) and analysed by flow 




Note : DMSO or ethanol was included in all experiments at appropriate concentrations 
as a vehicle control. Doxorubicin was dissolved in dH2O and the stock was so highly 








Suggested additional experiment: to confirm that the ER stressors used in these 
studies i.e. doxorubicin and thapsigargin, do induce ER stress in the EOC cells 
studied. 
Rationale: both doxorubicin and thapsigargin have been reported in the literature to 
induce ER stress and thus it was assumed in this thesis that the process led to PS 
externalisation and enhanced CRT binding. However, in the studies described here 
ER stress was not confirmed in the cells used and therefore experiments could have 
been designed to study this. 
Methodology: ER stress could be examined in EOC cells treated ± doxorubicin or 
thapsigargin by assessment of activation of eukaryotic initiation factor 2 (eIF2α) and 
caspase 8 which are both activated downstream of ER stress and have been studied 
as ER stress markers (Oslowski and Urano, 2011) (Glab et al., 2017). Briefly, levels 
of activated i.e. phosphorylated, eIF2α could be assessed by western blotting with an 
appropriate anti-phospho antibody and levels of activated caspase 8 could be 




Suggested additional experiment: to examine whether enhanced exogenous 
CRT binding in response to the ER stressors doxorubicin and thapsigargin is 
specific to cancer cells. 
Rationale:  ICD, mediated by enhanced surface levels of CRT, has been reported to 
occur in cancer cells in response to chemotherapy such as doxorubicin via induction 
of ER stress.  The results presented in chapter 4a indicate that both doxorubicin and 
the ER stressor thapsigargin do induce cellular changes in EOC cells that result in 
enhanced surface binding of exogenous CRT.  The specificity of these results to 
cancer cells could have been tested by repeating these experiments in human non-
cancer cells, preferably primary cells, which better reflect normal in vivo cell 
physiology.   For instance, primary human endothelial cells from several sources are 
routinely cultured in the laboratories in Exeter.  The data presented in Figure 4b.2 




endothelial cells, but an investigation into whether doxorubicin treatment could lead to 
enhanced binding of exogenous CRT to these cells was not carried out. 
Methodology: Endothelial cells pre-treated ± doxorubicin or thapsigargin at 
concentrations indicated in Chapter 4 would be incubated with 2µg/ml CRT-FITC and 
the binding of the fluorescent protein to the endothelial cell surface assessed by 
immunocytochemistry and flow cytometry. 
 
Suggested additional experiment: to examine whether the observed effect of 
doxorubicin on exogenous CRT binding is specific to anthracyclines that induce 
ICD.  
Rationale: as previously mentioned doxorubicin is a member of the anthracycline class 
of anti-proliferative therapeutics and it has been reported to additionally induce ICD. 
Other anthracyclines such as idarubicin have also been reported to induce ICD (Garg 
et al., 2017).  Additional control experiments could therefore be carried out to examine 
not only whether the enhanced CRT binding observed occurs with other ICD inducing 
agents, but also whether an established chemotherapeutic that does not stimulate ICD 
induces the same effect e.g. mitomycin C.  
Methodology: EOC cells would be treated with increasing concentrations of idarubicin 
or mitomycin C, as indicated by the available literature and the known pharmacological 
levels, and binding of exogenous fluorescently labelled CRT would be investigated 
using flow cytometry and immunocytochemistry as previously described in Chapter 
4a.  Additionally, exposure of PS on the outer plasma membrane would be assessed 
as above using flow cytometry. 
These latter two additional studies could also additionally be carried out for the studies 
described in Chapter 4b which examined surface exposure of endogenous CRT in 







7.3. Chapter 4b. Examination of the conditions requ ired for surface exposure of 
translocated endogenous calreticulin in ovarian can cer cells  
In Chapter 4b studies were carried out to examine the effect of the ER stressors 
doxorubicin and thapsigargin on translocation of endogenous CRT to the cell surface 
of EOC cells. Again, since TUDCA has been reported to reduce ER stress (Vang et 
al., 2014), CRT translocation induced by doxorubicin and TUDCA was also examined 
in the presence of TUDCA to assess whether reversing ER stress could reduce CRT 
exposure. Levels of surface CRT were examined by flow cytometry and 
immunocytochemistry.  
 
Suggested additional control: inclusion of negative controls in the 
immunocytochemistry studies.  
Rationale: It is important to confirm that CRT labelling examined by 
immunocytochemistry is specific.  Therefore, controls should include cells treated with 
the fluorescent secondary antibody and the nuclear counterstain DAPI, but no primary 
antibody (but include vehicle or isotype control antibody only) to examine non-specific 
binding of the secondary antibody. Additional controls could include staining cells with 
DAPI only to confirm that this staining was successful. Cells could also be visualised 
by phase contrast microscopy before and after staining to confirm no loss of cells 
during the fixation and staining procedure. 
Methodology: Cells treated with doxorubicin or thapsigargin ± TUDCA should be fixed 
with 4% (w/v) paraformaldehyde and then sequentially incubated with primary 
antibody (anti-CRT) or vehicle (PBS) or isotype control antibody; fluorescently labelled 
secondary antibody alone or vehicle (PBS); DAPI,  as required, before examining 
using fluorescence microscopy. These vehicle only controls were carried out for the 
immunocytochemistry performed in this thesis, but not included in the data shown (e.g. 
Figures 4b.1, 4b.5 and 4b.8). 
Results: The data in (Figure 7.5) confirm that negative control cells which received 
vehicle alone and no primary antibody, in this case anti-CRT, did not show any non-

















Figure 7.5. No non-specific binding of secondary an tibody is observed in cells 
treated with vehicle in place of primary antibody p rior to staining with Cy5 
secondary antibody. SKov3 cells were treated ± 2.5 µM doxorubicin for 16 hours and 
then stained for exogenous CRT by immunocytochemistry. Cells were fixed with 4% 
(w/v) paraformaldehyde and then incubated firstly with either primary antibody (anti-
CRT) or PBS, followed by Cy5-labelled secondary antibody (or PBS) and then with 
DAPI. Fluorescence microscopy images were taken at 20 x magnification. Upper 
panels, cells treated with doxorubicin 2.5 µM; lower panels, untreated cells. Column 
A, cells received only vehicle plus DAPI; column B, cells received vehicle instead of 






It should also be noted that to ensure consistency in the collection of images of 
fluorescently labelled cells all cells were examined on a LEICA microscope and 
captured with LEICA software. Images were collected from randomly selected areas 
within each well and within each experiment microscope settings and image analysis 
settings were kept the same. 
 
7.4. Chapter 5.  Investigation into whether exogeno us CRT or cancer cells 
expressing surface CRT can induce maturation of DCs  and subsequent 
activation of T-cells. 
This chapter described a series of studies that investigated whether exogenous CRT 
or CRT expressed on the surface of EOC cells could induce maturation of iDCs to 
mDCs and whether the mDCs induced by these treatments could stimulate T-cell 
activation as assessed by T-cell proliferation. 
 
Suggested additional control: to include imDCs in the studies examining mDC 
activation of T-cell proliferation (Figure 5.1).  
Rationale: The studies described in this thesis examined the ability of mDCs (which 
had been stimulated to mature by various treatments) to induce T-cell proliferation.  
This experiment could have been improved by additionally including imDCs in the T-
cell proliferation assay.  This would have controlled for non-specific activation of T-
cells by cell types other than mature mDCs and also confirmed a differential effect of 
immature and mature DCs. 
Methodology: The experiments described in section 5.4.15 could be repeated, but 
additionally include imDCs as a control. Additionally, values for unstained cells should 
be included as a negative control for the CSFE staining.  























Figure 7.6. Mature DCs induce significantly more T- cell proliferation than imDCs.  
Immature DCs were incubated + 1µg/ml LPS to induce maturation. Either mDCs or 
the untreated iDCs were then co-cultured with CSFE -labelled T-cells in a 24-well plate 
in the presence of IL-2 (30 µg/ml) and T-cell proliferation was assessed after 5 days 
by  flow cytometry. Data are  mean + SD from 10 independent experiments, *p<0.05 









Suggested additional control: to examine the secretion of IL12/IL23 from iDCs 
incubated with untreated OVcar3 cells. 
Rationale: the data presented in Figure 5.27 show that imDCs incubated with OVcar3 
cells previously treated with increasing concentrations of doxorubicin secrete 
IL12/IL23 which is indicative of DC maturation (Khayrullina et al., 2008). An additional 
control that should have been included in this experiment would have been incubation 
of iDCs with OVcar3 cells which received no pre-treatment with doxorubicin. This 
would allow the specific effect of pre-treatment of OVcar3 cells with doxorubicin to be 
assessed.  This additional control was actually carried out, but not included in the data 
presented. 
 
Methodology: imDCs derived from THP-1 cells were co-incubated with OVcar3 ovarian 
cancer cells which had received no pre-treatment with doxorubicin for 4 days. Cell 
culture supernatants were collected and assessed for the content of IL-12/IL-23 using 
a commercially available ELISA kit.  
 
Results: incubation of iDCs with OVcar3 cells for 4 days did not significantly increase 
secretion of IL12/IL23 compared with iDCs alone.  iDCs incubated with OVcar3 cells 
pre-treated with 2.5 µM doxorubicin secreted significantly more IL12/IL23 than iDCs 



























Figure 7.7.  OVcar3 ovarian cancer  cells pre-treated with high concentrations of 
doxorubicin induce secretion of IL12/IL23 from THP- 1 derived imDCs during DC 
maturation . imDCs derived from THP-1 cells were co-incubated with IL4&GM-CSF 
(positive control for DC maturation), OVCar3 cells alone or OVcar3 cells pre-treated 
with increasing concentrations of doxorubicin (DX, 0.25,1, 2.5 µM).  After 4 days cell 
culture supernatants were collected and assessed for the content of IL-12/IL-23 using 
a commercially available ELISA kit. Data are mean + SD from three individual 
experiments with each determination performed in triplicate. *p<0.05 basal media 






Suggested additional experiment: to examine whether the observed ability of 
rCRT to induce imDC maturation could be due to the presence of LPS in the 
rCRT preparation. 
Rationale: Although it was assumed that the CRT expressed in Pichia pastoris was 
free of LPS because the expression system was a yeast, (Pandya et al., 2019) indicate 
that low levels of LPS are present in this preparation.  Since maturation of imDCs was 
induced by exogenous LPS, control experiments could be carried out to investigate 
whether the maturation of imDCs induced by rCRT could be due to the associated 
LPS. 
Methodology: the studies examining maturation of iDCs by CRT could be repeated in 
the presence or absence of polymyxin B at 10 µg/ml (plus polymyxin B alone as a 
control) as described by (Li et al., 2015). As discussed above polymyxin B neutralises 
LPS and this study would indicate whether the maturation of imDCs is due to LPS or 
genuinely due to CRT. However, polymyxin B is toxic to cells so results using 
polymyxin B must be interpreted with caution (Ahmed et al., 2017). 
 
Suggested additional experiment: to examine the secretion of interferon gamma 
(IFN-gamma) during maturation of DCs. 
Rationale: The experiments previously described in chapter 5 examined maturation of 
DCs by assessing expression of relevant surface markers and secretion of the 
cytokines IL12/23.  IFN-gamma has also been reported to be secreted during DC 
maturation (Pan et al., 2004); therefore, measurement of secreted IFN-gamma levels 
in the cell culture medium also be could carried out as an additional assessment to 
confirm maturation of DCs in the conditions studied. 
Methodology: Cell culture media would be collected from DCs matured for 4 days as 
described in section 5.4.11 and IFN-gamma levels would be measured by 
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